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Phytoestrogen containing extracts of Cyclopia, an indigenous South African fynbos plant used to 
prepare honeybush tea, may serve as a source of new estrogen analogues.  It would be of great benefit 
if these new analogues would not only prevent the development and progression of breast cancer 
which, globally, is responsible for the highest number of cancer associated deaths among females, but 
also have a reduced side-effect profile when compared to current treatments and, in addition, also 
alleviate menopause associated symptoms.   In this study three extracts, P104, SM6Met, and cup-of-
tea, from two species of Cyclopia, C. genistoides and C. subternata, were evaluated for their potential 
to modulate molecular targets involved in prevention and treatment of breast cancer.  We show that the 
phytoestrogenic extracts of Cyclopia antagonise estrogen-induced cell proliferation both in vitro as well 
as in vivo.  Furthermore, our study presents various molecular mechanisms whereby the Cyclopia 
extracts may be eliciting this effect.  Importantly, we show, for the first time, that the Cyclopia extracts 
behave as ERα antagonists and ERβ agonists which, with respect to the known role of the ER subtypes 
in breast cancer, where the ERα subtype is associated with the stimulation of cell proliferation and the 
occurrence of breast cancer, while ERβ ameliorates the action of ERα in breast cancer and could act as 
an inhibitor of breast cancer development, may be beneficial for the prevention or treatment of breast 
cancer.  In addition, we also show that the extracts of Cyclopia behave as selective estrogen receptor 
degraders by down-regulating ERα protein levels while stabilising ERβ protein levels, which not only 
provides a possible molecular explanation for the observed ERα antagonism and ERβ agonism, but, in 
addition, may be beneficial as higher ERα levels are associated with malignant breast cancer tumours, 
while higher ERβ levels are associated with benign tumours.  Furthermore, we show that the Cyclopia 
extracts affect the nuclear localization and distribution of both ER subtypes in a manner that provides 
an additional molecular explanation for the observed ERα antagonism and ERβ agonism.  Investigation 
of the molecular processes involved in the promotion and progression of breast cancer, such as the 
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distribution of cells between the phases of the cell cycle, cancer cell invasion, and the regulation of 
genes governing these processes provides evidence that the Cyclopia extracts are not as proliferative as 
estrogen.  In addition, Cyclopia extracts display anti-inflammatory properties, which may be beneficial 
as inflammation is an enabling characteristic in cancer development and progression. Furthermore, this 
study, for the first time, shows that the phytoestrogenic extracts of Cyclopia are absorbed, are not toxic, 
and display biological ERα antagonist activity in vivo by retarding uterine growth.  Thus, we propose 
that the Cyclopia extracts act as selective estrogen receptor subtype modulators with potential to be 
developed as a nutraceutical for the treatment or prevention of breast cancer.  
  




Fitoëstrogeen-bevattende ekstrakte van Cyclopia, ‘n inheemse Suid Afrikaanse fynbosplant wat 
gebruik word vir die voorbereiding van heuningbostee, mag as ‘n bron van nuwe estrogeen-analoë 
dien.  Dit sal baie voordelig wees indien hierdie nuwe analoë nie net die ontwikkeling en progressie 
van borskanker sal voorkom nie, aangesien borskanker wêreldwyd verantwoordelik is vir die grootste 
getal kankerverwante sterftes onder vroue, maar ook ‘n verminderde newe-effek profiel vertoon in 
vergelyking met huidige behandelings en ook, boonop, simptome wat met menopouse geassosieer 
word, sal verlig.  In hierdie studie is drie ekstrakte, P104, SM6Met, en cup-of-tea, vanaf twee spesies 
van Cyclopia, C. genistoides en C. subternata, geëvalueer vir hul potensiaal om die molekulêre teikens 
betrokke by die voorkoming en behandeling van borskanker te moduleer.  Ons wys dat die 
fitoëstrogeniese ekstrakte van Cyclopia antagoniseer estrogeen-geïnduseerde selproliferasie beide in 
vitro as ook in vivo.  Verder bied ons studie ook verkskeie molekulêre meganismes aan oor hoe die 
Cyclopia ekstrakte hierdie effek mag ontlok.  ‘n Belangrike bevinding is dat ons vir die eerste keer wys 
dat die Cyclopia ekstrakte hulself as ERα -antagoniste en ERβ-agoniste gedra wat, met betrekking tot 
die erkende rol van die ER-subtipes in borskanker, waar die ERα-subtipe geassosieer word met die 
stimulasie van selproliferasie en die gebeurtenis van borskanker, terwyl ERβ die aksie van ERα 
onderdruk en as ‘n inhibeerder van borskankerontwikkeling kan dien, voordelig mag wees vir die 
voorkoming of behandeling van borskanker.  Ons wys boonop ook dat die ekstrakte van Cyclopia 
hulself soos selektiewe estrogeen- reseptor-degradeerders gedra deurdat hul ERα-proteïnvlakke verlaag 
terwyl hul ERβ-proteïnvlakke stabiliseer.  Dit verksaf nie net ‘n moontlike molekulêre verduideliking 
vir die waargeneemde ERα-antagonisme en ERβ-agonisme nie, maar mag ook voordelig wees in 
borskanker aangesien hoër ERα-vlakke geasosieer word met kwaadaardige borskankertumors en hoër 
ERβ-vlakke met nie-kwaadaardige tumors.  Verder wys ons dat die Cyclopia ekstrakte die lokalisering 
en verspreiding van beide ER-subtipes in die selkern op so ‘n wyse beïnvloed dat dit ‘n addisionele 
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molekulêre verduideliking bied vir die ERα-antagonisme en ERβ-agonisme wat waargeneem is.  
Verdere ondersoek van die molekulêre prosesse betrokke by die promosie en progressie van 
borskanker, soos die verspreiding van selle tussen die fases van die selsiklus, die beweging van 
kankerselle na omliggende weefsels, en die regulering van gene wat hierdie prosesse beheer, verskaf 
bewyse dat die Cyclopia-ekstrakte nie so proliferatief is soos estrogeen nie.  Die ekstrakte van Cyclopia 
vertoon boonop ook anti-inflamatoriese eienskappe, wat voordelig mag wees aangesien inflammasie ‘n 
bydraende eienskap in kankerontwikkeling en -progressie is.  Verder wys hierdie studie vir die eerste 
keer dat die fitoëstrogeniese ekstrakte van Cyclopia geabsorbeer word, nie toksies is nie, en dat hulle 
biologiese ERα-antagonis aktiwiteit vertoon deurdat hulle uterus-groei vertraag in vivo.  Dus stel ons 
voor dat die Cyclopia-ekstrakte optree soos selektiewe-estrogeen-reseptor-subtipe-moduleerders met 
die potensiaal om ontwikkel te word as ‘n nutraseutiese middel vir die behandeling of voorkoming van 
borskanker. 
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Introduction to the dissertation 
  




Globally, a trend towards the use of traditional or alternative medicines is emerging: in Japan more 
than 50% of allopathic doctors prescribe traditional medicines, in the United Kingdom 7-48% of 
cancer patients have reported using botanical drugs after diagnosis, and in the United States the 
number of visits to alternative medicine providers exceed the number of visits to primary care 
physicians [1-3].  Traditional and alternative medicines encompass a variety of treatments, 
including traditional Chinese medicines, indigenous medicines, as well as herbal medicines [4].  
According to the World Health Organization (WHO), herbal medicines include herbs, herbal 
materials, herbal preparations and finished herbal products, that contain as active ingredients parts 
of plants, or other plant materials, or combinations thereof [4]. 
Traditionally, herbal medicines are prepared by either steeping or heating of the unprocessed plant 
material to produce an herbal tea [5].  The indigenous plant biome of South Africa has delivered 
various plants that are traditionally consumed as herbal teas, such as rooibos tea (Aspalathus 
linearis), honeybush tea (Cyclopia species), and bush tea (Athrixia phylicoides) [6].  However, only 
rooibos and honeybush tea, due to their sweet taste and aroma, have successfully moved into the 
commercial market [6].  With regards to the use of the South African herbal teas as alternative 
medicines, extracts of A. linearis, which include hot water extracts, as well as constituents of these 
extracts, have been shown to potentially have anti-obesity [7], anti-diabetic [8-11], anti-cancer [12-
14], as well as anti-oxidant [15,16] properties.  In addition, extracts of A. linearis has been shown to 
maintain normal glucocorticoid levels and may have applications in the management of stress 
related conditions and metabolic diseases [17].  Extracts and constituents of A. phylicoides have 
been shown to have anti-oxidant properties [18,19], which is comparable to that of A. linearis [18], 
and could potentially ameliorate metabolic disorders related to obesity and diabetes [20].  
Therefore, it becomes clear that herbal teas prepared from indigenous South African plants may 
have health promoting properties and have potential to be further developed as alternative 
medicines or nutraceuticals.  However, the focus of the current study will be on phytoestrogenic 




extracts of Cyclopia and their potential use as an alternative treatment for estrogen related disorders 
such as menopause associated side-effects as well as breast cancer development and progression.  
The current study expands on anecdotal findings that associates the consumption of honeybush tea 
with the stimulation of milk production in breast feeding women [21] and the alleviation of 
menopausal symptoms [22], as well as scientific findings that have shown that the plant material of 
several Cyclopia species contain various polyphenols with known phytoestrogenic properties [23].  
In addition, it has been shown that extracts of Cyclopia can bind to both subtypes of the estrogen 
receptor (ER) [22,24] and although they induce the proliferation of breast cancer cells, they do so 
with both a lower potency and efficacy than that of estrogen [25] and, in addition, antagonize 
estrogen induced breast cancer cell proliferation [24]. 
The remainder of this dissertation consists of five chapters:  Chapter 2 provides a literature 
overview, addressing the development and progression of cancer with the focus on breast cancer 
and the role of estrogen, the ER subtypes, and the signaling pathways under their control in breast 
cancer development and progression.  In addition, it provides an overview of current therapeutic 
strategies for the treatment or prevention of breast cancer.  Furthermore, the literature review 
includes a general overview of phytoestrogens and their potential application in the treatment or 
prevention of breast cancer.  Lastly, it includes a section about Cyclopia and highlights findings of a 
review article (Addendum A [23]), of which I am a contributing author, which are relevant to the 
current study.  The literature review aims to validate our decision of identifying the ER subtypes 
and the signaling pathways under their control as molecular targets for the treatment or prevention 
of breast cancer and to enlighten the reader about the potential of phytoestrogens and Cyclopia 
extracts specifically, for the development of a nutraceutical for the treatment or prevention of breast 
cancer.  Chapters 3 to 5, of which chapter 3 has been published in the Public Library of Science 
ONE (PloS One) (PLoS ONE 2013; 8(11): e79223. doi:10.1371/journal.pone.0079223), will each 
address one of our main aims and Chapter 6 is a final discussion about our combined findings.  In 
chapters 3 to 5 we address the following aims: 




 Investigate the possibility of ERα antagonism as well as ERβ agonism by three Cyclopia 
extracts, dried methanol extracts (DMEs) of both C. subternata and C. genistoides, as well as a 
water extract of C. subternata using both an in vitro transactivation and transrepression model 
where the ER subtypes are either co-expressed or individually.  In addition, we also investigate 
ERα antagonism, in vivo, by using the immature rat uterotrophic assay (Chapter 3). 
 Investigate the effect of the three Cyclopia extracts on the ER subtype protein levels as well as 
how treatment with these extracts modulate the ERα:ERβ ratio.  We will also evaluate how the 
Cyclopia extracts affect the nuclear localization and distribution of the ER subtypes (Chapter 
4). 
 Investigate how the Cyclopia extracts affect aspects of breast cancer promotion and progression 
in a breast cancer cell line, by evaluating how the Cyclopia extracts affect the distribution of 
cells between the phases of the cell cycle, the invasive potential of breast cancer cells, and the 
regulation of genes involved in breast cancer cancer promotion, progression, and survival 
(Chapter 5). 
In addition, for each of our aims, we will investigate an example from each of the major classes of 
phytoestrogens: genistein, a well-studied isoflavone, enterodiol, a lignin, and coumestrol, a 
coumestan [26,27].  Luteolin, an estrogenic polyphenol [23], will also be included as it was found to 
be present in all of the Cyclopia extracts, while E2 represents the major endogenous estrogen 
[28,29].  By including these compounds we would be able to compare the effect of the Cyclopia 
extracts to that of the known phytoestrogens, as well as E2, and, in addition, where possible, use 
literature findings regarding these compounds to try and elucidate the mechanism of action of the 
Cyclopia extracts. 
Furthermore, the results chapters, chapters 3 to 5, are written in manuscript format and each one 
contains an introduction, materials and methods, results, and discussion section and therefore some 
repetition between chapters will inevitably occur. 
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Menopause, which occurs naturally during midlife (42-58 years of age), signals the end of the 
fertile or reproductive phase of a woman’s life and is characterised by a decrease of up to 90% in 
the natural production of estrogen [1].  Menopause can be either a naturally occurring process 
linked to ageing [1-3] or can be brought on by the removal of the uterus and ovaries during a 
hysterectomy (surgical menopause) [4].  The onset of menopause, with the characterized decrease 
in estrogen production, is accompanied by a plethora of side effects that may affect the quality of 
life of an individual.  These side effects include, but are not limited to, vasomotor symptoms such as 
hot flushes, night sweats, sleeping problems, and vaginal dryness [2,4].  In addition, decreased 
estrogen production is also a major risk factor for osteoporosis [5]. 
Hormone replacement therapy (HRT) is traditionally prescribed to women undergoing menopausal 
transition to alleviate symptoms associated with menopause.  Women without a uterus 
(hysterectomy) are prescribed estrogen alone, while women with an intact uterus are prescribed 
estrogen in combination with progestins [6].  Although being very effective in alleviating 
menopausal symptoms, a number of side effects have been associated with the use of HRT, for 
example, an increased occurrence of vaginal bleeding [7], heart disease or strokes [8,9], and breast 
cancer [8,10]. 
Cancer is a disease that is the leading cause of mortality in economically developed countries and 
the second leading cause of death in developing countries [11].  Amongst women, breast cancer is 
the most frequently diagnosed cancer (23% globally and 29% in the United States) and is 
responsible for the highest number of cancer associated deaths (14% globally, 14% in the United 
States, and 15% in the European Union) [11-13].  Furthermore, breast cancer occurs most 
frequently in post-menopausal women, which is also the group who would be interested in using 
HRT [14,15].  Therefore, although globally there is a need to better understand the cause of cancer 
development and progression to prevent cancer development and/or develop efficient treatments 
once diagnosed if, in addition, these treatments could also alleviate symptoms associated with the 
menopausal transition they may be considered prophylactic regarding breast cancer development. 




For the purpose of this literature review, I will discuss the molecular mechanism(s) of cancer 
development and progression by focussing on breast cancer and elaborate on how knowledge of 
these mechanism(s) are currently, or in future may be, implemented for the development of 
treatments that may either prevent the development of breast cancer or inhibit, and possibly reverse, 
the progression thereof.  Furthermore, I will introduce the reader to Cyclopia, as the modulation of 
molecular targets involved in the prevention and treatment of breast cancer by the phytoestrogenic 
extracts of Cyclopia is the topic of my dissertation. 
2.1.  The development and progression of cancer with the focus on breast cancer. 
Exogenous estrogen in the form of HRT contributes to cumulative and excessive exposure to 
estrogens [16,17], which may be considered as one of the most important risk factors for developing 
breast cancer as it not only increases the exposure to carcinogenic estrogen metabolites [16-23], but, 
as increased estrogen driven proliferation reduces the amount of time allocated for DNA 
maintenance the resulting increased mutation frequency may contribute to the development of 
breast cancer [24,25].  Furthermore, although the incidence of breast cancer is higher in women 
using HRT [10,26,27], the occurrence thereof is not limited to this group.  Therefore, other risk 
factors that contribute towards excessive and cumulative estrogen exposure have to be considered.  
These factors include, but is not limited to, early menarche age [28-30], late onset of menopause 
[30-32], first full term pregnancy at a late age [30,31], and obesity [33,34]. 
Under normal physiological conditions the human cell will grow, divide and undergo apoptosis to 
sustain tissue structure and function.  Furthermore, this cycle of growth, division, and apoptosis is 
under strict regulation, which is exerted by the production and release of growth promoting, as well 
as, pro-and anti-apoptotic signals, and disruptions of this tight regulation can result in abnormal cell 
growth [35-37], that is the basis of cancer development and progression [38].  Cancer development 
is a long-term process and for several types of human cancer, including breast cancer, three steps of 
cancer formation may be distinguished: (1) initiation (genomic DNA damage), (2) promotion 
(initiated cells grow and divide to form an actively proliferating multi-cellular premalignant tumour 




cell population), and (3) progression (production of tumour cells with increased proliferative 
capacity, invasiveness, and metastatic potential) (Fig. 1) [39-42].  
 
Figure 1.  The development and progression of cancer.  Cancer development is a long-term process and 
for several types of human cancer there are three steps of cancer formation: (1) initiation, (2) promotion, and 
(3) progression.  Taken and adapted from Fimognari et al. [42] 
 
2.1.1.  Initiation 
Initiation (Fig. 1), an irreversible process, occurs when the genomic DNA of a normal cell 
undergoes damage that is either not repaired or repaired incorrectly [42,43].  The main cause of 
DNA damage is oxidative damage inflicted by reactive oxygen species (ROS) [43-45], which may 
be produced by exogenous (radiation, environmental agents, pharmaceuticals, or industrial 
chemicals) or endogenous (mitochondria, peroxisomes, or activation of inflammatory cells) sources 
[45-47].  If DNA damage occurs, followed by inadequate repair of the damage, the mutated 
damaged cell may undergo mitosis to generate various clones of the mutated cell [42].  With 
regards to breast cancer, specific metabolites of estrogens (estrone, E1, and estradiol, E2), sex 
hormones traditionally linked to the development of the female reproductive tract and secondary 
sex characteristics [48-50], may behave as endogenous chemical carcinogens [16-23].  The major 




metabolites of estrogens are catechol estrogens (CE) which, in the event of excessive CE formation, 
are oxidised to form catechol estrogen quinones (CE-Q) [18].  If insufficient inactivation of CE-Qs 
by glutathione (GSH) occurs, CE-Qs react with DNA to form stable and depurinating adducts 
(DNA covalently bonded to a carcinogen with release of a nucleic base), which results in apurinic 
sites in the DNA (Fig. 2) [18,20-22,51].  Inadequate repair of the apurinic sites in DNA is believed 
to generate mutations that may initiate estrogen induced cancers such as breast cancer [18,20-22].  
In addition, endogenous or exogenous estrogens increase cell division and consequently cell 
proliferation and this increased cell proliferation rate reduces the amount of time allocated to DNA 
maintenance resulting in an increased mutation frequency [24,25].  
 
Figure 2.  Major metabolic pathway in cancer initiation by estrogens.  Cathecol estrogen quinones react 
with DNA to form depurinating adducts which result in apurininc sites in the DNA.  CYP1B1, Cytochrome 
P450, family 1, subfamily B, polypeptide 1 ; CYP450, Cytochrome P450; DNA, Deoxyribonucleic acid.  
Figure taken from Cavalieri et al. [21]. 
Furthermore, defects in DNA maintenance, which includes detecting damage, repairing damaged 
DNA, and inactivating carcinogenic molecules before DNA damage occurs, may increase 
susceptibility to cancer initiation [35,52-54].  Defective DNA maintenance may be due to hereditary 
mutations in genes whose products are involved in DNA maintenance, thereby increasing an 




individual’s vulnerability to develop hereditary cancers [54].  For example, hereditary mutations of 
either the breast cancer (BRCA) 1 or the BRCA2 genes may increase the risk of developing breast 
or ovarian cancer [52,55,56] as the products of these genes are involved in the repair of double-
stranded DNA breaks [57]. 
To conclude, cancer initiation occurs upon DNA damage, which is either not repaired or repaired 
incorrectly, and can result from either excessive DNA damage or a defective DNA maintenance 
system. 
2.1.2.  Promotion 
In cancer, an initiated cell, may acquire mutations that confer survival and growth advantages to the 
cell that can drive clonal expansion via mitosis [42,58].  These initiated clones can survive 
indefinitely within normal tissues until re-stimulation/promotion [44] (Fig. 1).  Furthermore, altered 
gene expression which favours increased cell numbers is a hallmark of cancer promotion (Fig. 3, 
sustaining proliferative signalling) [35,45,58]. 
 
Figure 3.  The six hallmarks of cancer.  The hallmarks of cancer encompass six biological capabilities, 
resisting cell death, sustaining proliferative signalling, evading growth suppressors, activating invasion and 
metastasis, enabling replicative immortality, and inducing angiogenesis, acquired during the various steps of 
tumour development.  Taken from Hanahan et al. [35]. 




Various mutations have been identified that may contribute to the promotion of breast cancer.  With 
regards to estrogen synthesis, mutations in the gene that produces aromatase, an enzyme crucial for 
estrogen synthesis [59], have been identified in breast cancers [60-62].  These mutations increase 
aromatase enzyme levels and, consequently, the in situ overproduction of estrogen, which acts as a 
growth factor in breast cancer tissues, may contribute to the growth of breast tumours [61,63].  
Furthermore, estrogens exert their biological function at the target organ/tissue by binding to the 
estrogen receptor (ER), a member of the nuclear receptor family of transcription factors, which 
exists as two subtypes, ERα and ERβ [49,64-66].  The ER subtypes and their molecular mechanism 
of action will be discussed in detail in sections 2.2.1. and 2.2.2, but to clarify the significance of ER 
subtype mutations in breast cancer promotion it should be mentioned that the ERα subtype is 
associated with the stimulation of cell proliferation and the occurrence of breast cancer, while 
several studies have shown that ERβ ameliorates the action of ERα in breast cancer and could act as 
an inhibitor of breast cancer development [67-73].  An ERα gene mutation, Tyr537Asn mutation, 
has been identified that enables the transcription factor to activate its signalling pathway 
independently of ligand, thereby, sustaining proliferative signalling (Fig. 3), and this attribute may 
contribute to the hormone independent growth of tumours [74].  Also, amplification of the gene that 
encodes for ERα has been identified in proliferating breast cancers [75] and the elevation of 
receptor levels to create cells that are hyper-responsive to growth factors has been proposed as a 
mechanism of sustaining proliferative signalling [35].  Furthermore, a mutation in the ERβ gene 
that decreases ERβ expression has been identified and this decreased expression of ERβ may lead to 
an increased risk of breast cancer development [76].  Therefore, with regards to sustaining 
proliferative signalling in breast cancer, gene mutations that occur during initiation may influence 
growth factor production as well as their cognate receptors, thereby disrupting signalling pathways, 
resulting in the formation of actively proliferating tumour cells.  Furthermore, although not 
discussed, it is important to note that a plethora of mutations [37,38,77-81] have been identified that 
may contribute to the promotion of cancer cells and that these mutations not only sustain 




proliferative signalling (BRCA1 [82], cyclin D1 [38,78], CDK’s [38], Myc [38]) but can also 
impact other hallmarks of cancer, such as evading growth suppressors and resisting cell death (p53 
[37,38], Bcl-2 [37,38], Akt [38], PTEN [38] ) [35,37,81]. 
2.1.3.  Progression 
The final step in cancer development is progression (Fig. 1) and during this step the initiated cells 
that obtained hallmark capabilities, such as sustaining proliferative signalling, evading growth 
suppressors, and resisting cell death, during promotion will undergo further growth and division to 
generate new highly proliferative clones with invasive and metastatic potential [42].  Furthermore, 
progression encompasses the three remaining hallmarks of cancer, namely enabling replicative 
immortality, inducing angiogenesis, and activating invasion and metastasis (Fig. 3). 
Cell senescence in normal cells is an irreversible process where cells become non-proliferative 
while maintaining metabolic activity and, furthermore, is inevitably followed by cell death [35,83].  
Therefore senescence limits the replicative potential of a cell, thereby inhibiting uncontrolled 
proliferation.  Telomeres are repeated sequences located at the end of chromosomes that shorten 
after every cell division and at a certain telomere length cells become senescent followed by 
apoptosis [84].  Therefore, the length of telomeres is implicated in acquiring replicative immortality 
[35,85].  Telomerase, an enzyme that adds telomeric repeats to telomeres, is expressed in low levels 
in normal cells but in high functional levels in cancer cells [86,87].  In normal cells telomerase 
counters erosion of telomeres due to factors other than cell division, however, in cancer cells the 
enzyme maintains telomeric length and thereby the cell avoids senescence and apoptosis [35,85]. 
Furthermore, it has been shown that estrogen, as a physiological stimulus, can increase telomerase 
activity in MCF-7 breast cancer cells and human ovary epithelium cells via the ER, thus implicating 
estrogen and its cognate receptor in avoidance of senescence and apoptosis to allow breast cancer 
cells to acquire immortality [88,89]. 
The cancer cell, which through initiation, promotion, and progression, has evolved into a tumour of 
immortal hyper-proliferating cells, like normal cells, requires nutrients and oxygen and must 




remove carbon dioxide and metabolic waste [35,90].  The formation of new blood vessels or 
angiogenesis is employed by tumours to provide for these requirements [35,90,91].  Hypoxia, 
reduced oxygen availability, is a key signal for angiogenesis induction [91].  Studies have shown 
that nitric oxide (NO) production, and therefor hypoxia, is increased via estrogen activated ERα 
[92] and that angiogenesis may be inhibited by antiestrogens [93], establishing the role of estrogen 
and ERα in angiogenesis.  Furthermore, a marker of hypoxia, hypoxia-inducible factor 1 (HIF-1), is 
considered a key initiator of angiogenesis in tumours [94] and increases during breast cancer 
development.  HIF-1 is also associated with increased ER expression as estrogen stimulates a 
signalling pathway that may play a role in HIF-1 activation [94].  Therefore, estrogen en ERα may 
contribute to angiogenesis by either inducing hypoxia or by up-regulating initiators of angiogenesis 
and, thereby, play a role in sustaining developing tumours. 
Tumour invasion and metastasis, the sixth and final hallmark of cancer, is a process whereby cancer 
cells from a primary tumour invade surrounding tissues and migrate to distant sites, thereby 
spreading the cancer through the body [35,95,96].  This final step in cancer progression comprises 
several rate limiting steps:  (1) local invasion: invasion of adjacent tissues, (2) intravasation: cancer 
cells move into nearby blood and lymphatic vessels, (3) transit: cancer cells move through the 
lymphatic and blood systems, (4) extravasation: cancer cells move from lymphatic and blood 
vessels into distant tissues, (5) micrometastases: formation of small cancer nodules in distant 
organs, and (6) colonization: growth of macroscopic tumours in distant tissues [35,96,97].  
Furthermore, if any of these steps fail the entire process may be inhibited [97], an attribute which 
could be exploited for therapeutic purposes.  In breast cancer, metastasis at distant organs is the 
most common form of cancer re-occurrence and the foremost cause of fatalities [98,99], however, 
patients with ER positive tumours have a more favourable prognosis than patients with ER negative 
tumours [98].  Thus, with regards to breast cancer invasion and metastasis this suggests a protective 
role for the ERs.  Epithelial to mesenchymal transition (EMT) promotes cancer invasion during 
breast cancer progression and is characterized by a loss of cellular adhesion [100-102].  Nuclear 




factor-kappa B (NFκB), a pro-inflammatory transcription factor, is involved in the development of 
breast cancer [47,103,104].  NFκB consists of five subunits, NF-κB1, NF-κB2, RelA/p65, RelB and 
c-Rel [105], of which the RelB subunit has been shown to induce the expression of Bcl-2, an 
inhibitor of apoptosis that promotes cell survival and induces EMT in human mammary epithelial 
cells [105-107].  Furthermore, ERα inhibits RelB synthesis, thereby inhibiting Bc-l2 expresion and 
therefore, inhibiting EMT [108].  In addition, both ER subtypes have been shown to inhibit EMT by 
inducing expression of E-cadherin, an epithelial marker and adhesion molecule [100,109].   
Thus far I have discussed the development and progression of cancer, highlighting some of the 
situations where estrogens and their cognate receptors may influence breast cancer development and 
progression.  The steps of cancer development (Fig. 1), as well as the hallmark capabilities of 
cancer (Fig. 3), present several possible therapeutic targets for current breast cancer treatment as 
well as the development of new treatments.  Before I discuss these treatments, I will elaborate on 
the estrogens, the ER and its subtypes, ERα and ERβ, and how they may regulate signalling 
pathways that can contribute to breast cancer development and progression. 
2.2.  Estrogen and its molecular mechanism of action 
Estrogens are pleiotropic hormones [110] traditionally linked to the development of the female 
reproductive tract and secondary female sex characteristics [48-50,111] and can affect cell viability, 
cell proliferation, and gene expression [17,112,113].  Furthermore, estrogens also regulate 
cardiovascular physiology, bone integrity and neuronal growth [111].  In pre-menopausal women 
more than 95% of these estrogens are synthesised in and secreted by the ovary with the remainder 
being synthesised from steroid precursor molecules in tissues such as, for example, breast and 
adipose tissues [59,114,115].  In contrast, in post-menopausal women estrogens are predominantly 
produced by the peripheral conversion of steroid precursor molecules [116].  In brief, estrogen 
steroidogenesis (Fig. 4) entails the conversion of cholesterol to pregnenolone by the CYP11A1 
enzyme, where after pregnenolone is hydroxylated by CYP17A1 to form 17OH-pregnenolone, 
which in turn is converted to dehydroepiandrosterone (DHEA) by the same enzyme [117,118].  




DHEA is converted to either androstenedione by 3β-hydroxysteroid dehydrogenase/isomerase type 
2 (3βHSD2) or androstenediol by 17β-hydroxysteroid dehydrogenase/isomerase type 1 (17βHSD1) 
[117]. 
 
Figure 4.  Conventional pathway of estrogen steroidogenesis.  Cholesterol is converted to estrone and 
estradiol through a series of enzyme regulated reactions.  3βHSD, 3β-hydroxysteroid 
dehydrogenase/isomerase; 17βHSD, 17β-hydroxysteroid dehydrogenase/isomerase; b5, Cytochrome b5; 
CYP17A1, Cytochrome P450 17A1; CYP19A1, Cytochrome P450 19A1; POR, Cytochrome P450 reductase.  
Figure taken and adapted from Ghayee et al. [117]. 
Androstenedione can either be converted to testosterone by 17βHSD3 or E1 by CYP19A1 
(aromatase enzyme), whereas androstenediol is converted to testosterone by 3βHSD2, which in turn 
is converted to E2 by CYP19A1 [117-119].  The weak estrogen, E1, estrone, is converted to the 
potent and biologically active E2, estradiol, by 17βHSD1 [117].  Once synthesised/secreted the 
estrogens are transported to target organs by a plasma glycoprotein known as sex hormone binding 
globulin (SHBG) which, in turn, also regulates the availability of estrogens to the target organs 
[120-122].  At these target organs, such as the uterus, vagina, liver, bone, and breast [110,123-125], 
estrogens are released from SHBG, diffuse across the cell membrane and bind to mostly nuclear 
estrogen receptors (ERs) [64,126,127]. 
 




2.2.1.  Estrogen receptors 
Estrogen receptors form part of the nuclear receptor family of transcription factors, a family that 
shares a similar structural homology and represents the largest family of transcription factors 
[49,65].  Up until 1996 estrogens were thought to elicit their action through only one ER subtype 
(renamed ERα after discovery of second subtype) but this changed in 1996 with the discovery of a 
second subtype, ERβ [128,129].  These receptor subtypes are produced by different genes, located 




Figure 5.  Human estrogen receptors are comprised of two subtypes, ERα and ERβ.  (A) Schematic 
representation of the functional domain organization of the human ERs, (B) the percentage identity of the 
domains of human ERβ with human ERα, and (C) the amino acid sequences of the ERα and ERβ DNA 
binding domains (only divergent amino acids are indicated for ERβ).   A/B, N-terminal region, which 
contains AF-1; C, DNA binding domain; D, hinge region; E, ligand binding domain, which also contains 
AF-2; F, C-terminal region.  Adapted from Ruff et al. [130], Beck et al.[131], Enmark et al.[50] and Sanchez 
et al. [127]. 
Both receptor subtypes, shown in Fig. 5, consists of homologous regions known as domains and the 
three major domains are the ligand binding domain (LBD), the DNA binding domain (DBD), and 
the activation domains (AF) [49].   
These homologous domains have different functions that confer specificity for binding of the ER to 
the estrogen response element (ERE) in the promoter regions of estrogen responsive genes [65,132].  




The DBD (Fig. 5C) consists of approximately 70 amino acids that are folded into two zinc-finger 
motifs that are highly conserved between the receptor subtypes.  Furthermore, within these zinc-
finger motifs, two perpendicular α-helices extend from the base of the fingers, both of which have 
distinct functions [50,65].  The first helix interacts with DNA and conveys specificity, whereas the 
second finger has a dimer interface that directs subunit interactions for receptor dimerization 
[50,65,133-135].  The LBD (Fig. 5), which confers specificity for ligand binding and performs 
functions associated with ligand binding such as receptor release from heat shock proteins (HSPs), 
dimerization, interaction with co-activators as well as co-repressors, and transcriptional activation 
[65,127,130], is less conserved between the ER subtypes, a characteristic reflected by the diverse 
structures of ligands bound by these receptor subtypes [127].  Despite of the lower percentage 
homology of the LBD of the ER subtypes, 17β-estradiol (E2) has similar binding affinities for the 
two ER subtypes [50].  Furthermore, apart from the DBD and the LBD, each receptor subtype has 
an N-terminal domain which contains the transcription activation function 1 (AF1) [65,127] which, 
along with AF2 in the LBD, are associated with the recruitment of co-activators [50,136].  There is 
considerable variation between the ER subtype AF1 domains, which has a ligand-independent 
transactivation function, whereas AF2, the ligand dependent transactivation domain, is more 
conserved [137].  Variation in the in the AF1 domain may account for the high ligand independent 
transcriptional activity of the ERβ subtype [138].  The ERs also contain a flexible hinge region (Fig. 
5), which is less conserved between the ER subtypes, and this region contains nuclear localization 
signal information and plays a role in orientating the AF1 and AF2 domain for optimal E2-driven 
transactivation [137].   
Physiologically, while ERα is associated with the promotion of cell proliferation that contributes to 
the occurrence of breast and endometrial cancer, several studies have shown that ERβ inhibits ERα-
dependent cell proliferation and could prevent cancer development [67-73,139,140].  Furthermore, 
the subtypes stimulate the transcription of both common and distinct subsets of E2 target genes 
[69,110,141,142].  However, in many cases the degree of activation via ERβ is lower [50], despite 




the high ligand independent transcriptional activity of this subtype [138,143].  In addition, in breast 
cancer, higher ERα levels are associated with malignant tumours, while higher ERβ levels are 
associated with benign tumours [72,144].  Having discussed the synthesis of estrogen, as well as the 
receptors through which it elicits its function, the next section will elucidate the mechanisms 
whereby the ER elicits its function. 
2.2.2.  Molecular mechanisms of action of the estrogen receptor. 
Unliganded ERs are mainly located in the nucleus of target cells [65,126,127] in an inactive 
complex consisting of the ER, HSPs and immunophils [127,145,146].  Classically (Fig. 6-1), upon 
binding of E2 to the ER, the activated ER will dissociate from the chaperone complex (HSPs and 
immunophils), undergo a conformational change, dimerize, and bind to EREs in the promoter 
regions of target genes [17,49,65]. 
 
Figure 6.  Classic and alternative models of estrogen mediated transactivation.  Upon estrogen (E2) 
binding the ER can activate gene transcription via (1) classical DNA binding or (3) tethering to DNA bound 
transcription factors.  Furthermore, (2) unliganded phosphorylated ER can directly bind to DNA or (4) 
membrane bound-ERs can elicit a nongenomic effect.  Figure taken from Hall et al. [147].  GF, growth 
factor; R, receptor; ERE, estrogen response element; AP-1, activating protein-1. 
 




However, the ER can also activate gene transcription by implementing non-classical pathways (Fig. 
6-3) such as for activating protein-1 (AP-1), where the activated ER does not directly interact with 
the DNA in the promoter regions of AP-1 regulated genes, but tethers to the already bound 
transcription factors (c-Jun and c-Fos) and thereby influences transcription [148-151].  Furthermore, 
ER function may also be modulated by extracellular signals in the absence of E2 (Fig. 6-2) where 
the ER is activated via phosphorylation by, for example, signalling pathways initiated by epidermal 
growth factor (EGF) or insulin-like growth factor (IGF-1) [147,152,153].  Lastly, membrane bound-
ERs (Fig. 6-4) have been identified and it has been shown that they are G protein-linked and can 
elicit a range of signal transduction events like, for example, the induction of cell proliferation and 
the inhibition of apoptosis [147,154-157].  In addition, the intracellular ER may also be localised at 
the cell membrane and activate signal transduction pathways such as the MAP-kinase pathways 
[156,158]. 
The two ER subtypes, ERα and ERβ, introduce another level of complexity to the molecular 
mechanism of estrogen action via the ERs.  These subtypes may dimerize to form ERα/α 
homodimers, ERβ/β homodimers, or ERα/β heterodimers [159-161].  All three dimer pairs can bind 
to DNA and are transcriptionally active, but with varying degrees of activity [143,162,163].  It is 
presumed that ERα/α homodimers increase cell proliferation and thereby contribute to cancer 
development, whereas the ERβ/β homodimer has an opposing protective effect [69,162-164].  
Furthermore, it has been suggested that the ERα/β heterodimer activates genes that are distinct from 
those activated by either homodimer and that the heterodimer has a growth inhibitory effect on 
breast epithelial cells [160,162,165].  Therefore, dimerization, both homo- and heterodimerization, 
is an important characteristic of the ERs that may impact the development and progression of breast 
cancer. 
In a previous section it was mentioned that NFκB, a pro-inflammatory transcription factor, is 
involved in the development of breast cancer [47,103,104] and therefore, it is important to state that 
liganded ER not only activates gene transcription but can also repress it.  For transrepression, 




specifically the repression of NFκB driven genes, various mechanisms of ER mediated 
transrepression have been described [166].  The ER may bind to NFκB and thereby prevent DNA 
binding of the transcription factor [167,168],  ligand bound ER present at promoter regions may 
recruit co-repressors [169,170], ligand bound ERα and activated NFκB may compete for co-
activator recruitment [171,172], or ERα, through a non-genomic pathway, may inhibit translocation 
of activated NFκB to the nucleus [173].  Furthermore, it has also been suggested that the ER may 
inhibit production of interleukin-6 (IL-6), a pro-inflammatory cytokine, not only by transrepression 
of NFκB, but also by transrepression of CCAAT/enhancer-binding protein beta (C/EBPβ) activity 
via a protein-protein interaction [174].  In addition, ERα may inhibit matrix metalloproteinase-1 
(MMP-1) transcription by tethering to AP-1 sites in the promoter region of the MMP1 gene [175].  
Although ERα has been shown to inhibit transcription by tethering to an AP-1 site, estrogen may 
also activate transcription from some AP-1 sites via ERα, whereas it inhibits this activation via 
ERβ, while, in contrast, antiestrogens may activate transcription from these AP-1 sites via ERβ 
[176].  Therefore, these findings further illustrate the complexity of estrogen signalling via the ER. 
To conclude, estrogens are sex hormones traditionally linked to female reproductive development 
and exert their function via the ER, which exists as two subtypes, ERα and ERβ.  Furthermore the 
ERs may activate or repress the transcription of genes by various mechanisms.  Also, earlier we 
discussed how estrogens may contribute towards the development and progression of breast cancer.  
Therefore, in the following section we will discuss how estrogen and its cognate receptors are 
targeted for the treatment of breast cancer at a molecular level. 
2.3.  Treatment of breast cancer at the molecular level. 
Currently, endocrine responsive breast cancer, both ER positive and hormone dependent [177], 
which accounts for approximately 75% of breast cancers, is treated by the administration of 
adjuvant endocrine therapy (ET) in the form of aromatase inhibitors (AIs), ovarian function 
suppression, or the selective estrogen receptor modulators (SERMs), like tamoxifen [116,178-180].  
Blocking of estrogen production by AIs is an established therapeutic option for post-menopausal 




women where estrogens are mainly produced from the peripheral conversion of androgens by 
aromatase [116,181-183], however, this is not an effective therapeutic option for pre-menopausal 
breast cancer patients as pre-menopausal estrogen levels cannot be efficiently reduced [184,185].  
Aromatase inhibitors inhibit the CYP19A1 aromatase enzyme (Fig. 4) that coverts androgens to E1 
and E2 with the goal of reducing the circulating levels of estrogens [181].    Current AIs may be 
divided into two groups, the steroidal, type 1, and non-steroidal, type 2, AIs [116,182,186].  The 
steroidal AIs have a steroidal structure similar to that of the substrate of the aromatase enzyme 
which, upon binding, is converted to an intermediate that covalently binds to the enzyme, thereby 
irreversibly inactivating the aromatase enzyme [116,186].  In contrast, the non-steroidal AIs prevent 
androgen binding by non-covalently binding to the aromatase enzyme and saturating the binding 
sites [116].  Furthermore, although AIs are successfully used for the treatment of endocrine 
responsive breast cancers and are mostly associated with only mild side effects such as hot flashes 
[187-189], joint pain [187,190], vaginal dryness [189] and headaches [187], their use is hampered 
by a significant increase in the occurrence of osteoporosis [116,187,191] and AI resistance in a 
considerable number of patients [116,192].  In addition, the use of AIs is not an effective 
therapeutic option for pre-menopausal breast cancer patients as AIs alone cannot efficiently reduce 
pre-menopausal estrogen levels [184,185].  Thus, for these patients complete ablation of ovarian 
function by either surgical oophorectomy [193,194], radiation induced ablation [195], the use of 
luteinizing hormone- or gonadotropin hormone-releasing hormone (LHRH or GnRH) agonists 
[185,195,196], or chemotherapy [197] is an option [183,184].  Furthermore, although both the 
above mentioned treatments, with estrogen levels as a target, is effective for the treatment of breast 
cancer it is accompanied by undesirable side-effects such as adverse menopausal symptoms and the 
increased occurrence of osteoporosis.  Therefore, the development of breast cancer therapies is on-
going and another possible target for these therapies is the ERs. 
The search for new and improved breast cancer therapies that target the ERs heralded the era of the 
SERMs with selective ER modulation being described for the first time in 1987 [198].  SERMs are 




compounds that, like estrogen, can interact with the ER but have tissue specific activities that differ 
from that of estrogen [198-202].  Ideally, a SERM would act as an ER antagonist in the breast, 
thereby antagonizing the proliferative effect of E2 via the ER, and act as an ER agonist in the bone, 
thereby preventing osteoporosis associated with decreased levels of estrogen.  Several SERMs have 
been developed with the following proposed molecular mechanisms of antagonist action: SERMs 
may act as antagonists by binding to the ER with a higher affinity than E2 and block the binding of 
E2, they may block the binding of co-activators, or SERMs may induce the recruitment of co-
repressors. [203-205].  Not much is known regarding the molecular mechanism of SERM agonism 
[203], although it has been suggested that they may block the binding of co-repressors [205] or 
activate cell surface signalling pathways that result in ligand-independent activation of ERs 
[147,199,206,207]. 
Tamoxifen, a first generation SERM and one of the most commonly used ETs for breast cancer 
treatment, fulfills the requirement of being an ER antagonist in breast tissue but only increases bone 
mineral density in postmenopausal, not pre-menopausal, women with breast cancer [202,208,209].  
However, not only has tamoxifen usage been linked to an increased risk of venous 
thromboembolism and occurrence of hot flashes, but it also acts as an agonist in the endometrium 
and thereby stimulates endometrial growth and endometrial hyperplasia, a risk factor for 
endometrial cancer [199,210-213].  The adverse tamoxifen associated side-effects instigated the 
development of further generations of SERMs.  The second generation SERM, raloxifene, is an 
improvement from tamoxifen as it is an antagonist in both the breast and the endometrium, while 
being an agonist in bone tissue [209,214-216], however it does increase the risk of venous 
thromboembolic diseases [199,210].  Third generation SERMs, such as lasoxifene and 
bazedoxifene, are currently in development, however, the focus of the research endeavor has shifted 
to osteoporosis treatment with protection against breast cancer as a beneficial side effect 
[198,201,217]. 




SERMs bind to the ER and affect estrogen signaling thus modulating breast cancer development 
and progression, however, the down-regulation of ER protein levels could also attenuate the effect 
of excessive estrogen levels.  The prospect of down-regulating ER levels for therapeutic purposes 
instigated the development of selective estrogens receptor down-regulators (SERDs).  Natural 
estrogens down-regulate protein levels of both of the ER subtypes by enhancing ER ubiquination 
for consequent ubiquitin-proteasome pathway mediated degradation [218-225].  However, the ideal 
SERD would only down-regulate ERα levels, associated with cell proliferation and cancer 
development, while stabilizing, or up-regulating, ERβ levels, which inhibits ERα-dependent cell 
proliferation.  Fulvestrant, also known as Faslodex or ICI 182,780, is a complete ER antagonist that 
down-regulates ERα levels [218,226] while stabilizing ERβ protein levels [218].  Furthermore, 
fulvestrant has been shown to inhibit the growth of breast tumour xenografts [227,228].  During 
clinical trials, fulvestrant treatment presented undesirable, yet minor, side effects such as headaches, 
hot flushes, nausea, and disturbance of menses [229].  However, the poor bioavailability as well as 
length of time required to achieve a useful therapeutic concentration in target tissues, weighs 
against fulvestrant as an ideal breast cancer treatment [227,230].  GW5638/DPC974, an orally 
active non-steroidal tamoxifen derivative and SERD [227,230], also down-regulates ERα levels 
[230,231].  Further development of GW5638/DPC974 was discontinued but afore mentioned 
findings merits further investigation regarding SERDs. 
All of the discussed treatments (AIs, SERMs, and SERDs) display beneficial properties for the 
prevention and treatment of breast cancer, although, through either targeting estrogen synthesis or 
the ER, undesirable side-effects are still a problem.  Interestingly many of these side-effects are also 
side-effects that are associated with the depletion of estrogen during menopause, such as hot 
flushes, night sweats, sleeping problems, vaginal dryness [2,4] as well as an increased risk of 
osteoporosis [5].  Therefore, it may be beneficial to find a treatment that not only inhibits breast 
cancer development and progression, but also alleviates menopause associated side effects.  It could 
be postulated that to achieve this goal you would require a therapeutic agent that could mimic the 




beneficial effects of estrogen in some contexts, while inhibiting estrogen associated proliferation in 
the breast and uterus.  Clearly this would argue against an agent that is a complete anti-estrogen or 
results in blocking estrogen synthesis. 
Figure 7 delineates the beneficial as well as unfavourable characteristics of current HRT and the 
current SERMs, tamoxifen and raloxifene, while highlighting the properties of an ideal SERM. 
Previously I discussed the opposing roles of the ER subtypes in breast cancer development, where 
ERα is proliferative and ERβ is anti-proliferative.  These opposing characteristics of the ER 
subtypes has guided the search for an effective therapeutic compound that could alleviate 
menopausal symptoms while preventing breast cancer development and progression towards 
compounds that target the ER subtypes.  These compounds would not be SERMS, but rather 
selective estrogen receptor subtype modulators (SERSMs).  The ideal SERSM would be an ERα 
selective antagonist [232], while selectively activating ERβ transcriptional pathways 
[139,140,233,234], would down-regulate ERα protein levels while stabilizing ERβ protein levels 
[232,235] and would display anti-inflammatory properties by inhibiting transcription of pro-
inflammatory genes to prevent the occurrence of post-menopausal osteoporosis [139,236].  
Advances towards finding the elusive ideal SERSM have been made and several subtype specific 
compounds have been identified, for example methyl-piperidino-pyrazole (MPP) (ERα specific 
antagonist) [237,238], diarylpropionitrile (DPN) (ERβ specific agonist) [239], ERB-041 (ERβ 
specific agonist) [240,241], liquiritigenin (ERβ specific agonist) [234], which was isolated from the 
plant extract MF101 (ERβ specific agonist) [233] and the R, R enantiomer of 5,11-cis-diethyl-
5,6,11,12-tetrahydrochrysene-2,8-diol (THC, ERα agonist and ERβ antagonist) [242]. 





Figure 7.  Development towards finding the ideal selective estrogen receptor modulator (SERM).  A 
summary of the good and bad effects of current hormone replacement therapy (HRT), the benefits and 
shortfalls of the known SERMs, tamoxifen (T) and raloxifene (R), and the characteristics of an ideal SERM.  
CHD, coronary heart disease; DVT, deep vein thrombosis; MSK, musculoskeletal side effects.  Figure taken 
from Jordan, V.C., 2004 [243]. 
The isolation of a highly specific ERβ agonist, liquiritigenin, from a plant extract, MF101, which 
itself is an ERβ agonist, raises the question of whether the ideal SERSM may be found in plant 
material?  This question guides us towards phytoestrogens, plant compounds that are referred to as 
natural SERMs and which may be both estrogenic as well as anti-estrogenic [244-247].  Despite 
conflicting evidence regarding doses of phytoestrogens and breast cancer risk [248,249], findings 
regarding the subtype specificity of phytoestrogens [250-252] have generally pointed the search in 
the direction of phytoestrogens and focused attention on phytoestrogen rich food sources as a 
possible source of the ideal SERSM.  Furthermore, reluctance among concerned users regarding the 
use of “unnatural” substances, has led to a search for safer and more “natural” products as an 
alternative to synthetic drugs [253,254]. 




2.4.  Phytoestrogens 
The occurrence of breast cancer in Asia is much lower compared to that of Western countries [255-
257].  However, in countries like Japan the occurrence of breast cancer is increasing and one of the 
proposed contributing factors is the change to a more “Western” diet consisting of more food from 
animal origin [256].  Furthermore, the low incidence of hormone dependent cancers, such as breast 
cancer, among these populations has been proposed to be the result of diets rich in, for example, 
soybean products, which contain phytoestrogens [255,258].  These differences in breast cancer 
occurrence focused attention on phytoestrogens and their use as chemo-preventive substances. 
As previously mentioned, phytoestrogens are non-steroidal compounds from plant origin with the 
ability to have estrogenic or anti-estrogenic properties [259].  Phytoestrogens have a 2-
phenylnaphthalene-type chemical structure similar to that of estrogen (Fig. 8) and may bind to both 
of the estrogen receptor subtypes [260].  Phytoestrogens may be divided into three major classes, 
the isoflavones, coumestans, and lignans [259,261].  The isoflavones, genistein, daidzein, and 
glycitein, are the major phytoestrogens that may be obtained via dietary intake and their main 
sources are legumes and soy products [261,262], while coumestans, like coumestrol, are found in 
bean sprouts and clover [262]. Furthermore, the lignans, enterodiol and enterolactone, are referred 
to as mammalian lignans as they are produced by the gut microflora in the colon from plant lignan 
precursors, found in, for example, linseed, wheat, and bran [262-265]. 
The isoflavone, genistein, is well studied and can bind to both ER subtypes although it generally 
has a higher affinity for ERβ [250-252,266].  Furthermore, genistein exerts an estrogenic effect 
through both of the ER subtypes and can recruit co-regulators for the transcription of ERα and ERβ 
selective genes [131,250,267].  Also, genistein inhibits proliferation of ER positive MCF-7 cells, a 
human breast cancer cell line, both in the presence [252,268] and absence [269] of E2 and this effect 
is mediated via the ER [252,269].  In addition, perinatal exposure of rats to physiologically relevant 
concentrations of genistein provides protection against chemically induced mammary cancer 




development [270] and, furthermore, this early exposure to genistein promotes the differentiation of 
mammary cells which, in adulthood, may suppress the formation of breast cancer [270-272].   
 
Figure 8.  Structures of examples of the major classes of phytoestrogens.  Structures of genistein 
(isoflavone), coumestrol (coumestan), and enterolactone (lignan) compared to the endogenous estrogen 
(estradiol), a synthetic estrogen (diethylstilbesterol), and a SERM (tamoxifen, a synthetic estrogen).  
Structures taken from Duncan et al. [259] and Kshirsagar et al. [273]. 
  
Genistein has also been shown to inhibit angiogenesis, have anti-oxidant properties, and decreases 
rat ovarian and rat uterine aromatase activity and therefore, may inhibit both cancer initiation as 
well as progression [259,261,274-276].  With regards to menopause and HRT, isoflavones attenuate 
bone loss in perimenopausal women [277] and may reduce hot flashes [278,279].  Although 
genistein has many positive attributes regarding breast cancer there are cautionary findings, such as, 
that neonatal exposure to genistein in the physiological range induces uterine adenocarcinoma 
[280], that low concentrations of genistein induces MCF-7 cell proliferation [281], that genistein 




can inhibit MCF-7 cell apoptosis [282], and that exposure to genistein after the development of an 
estrogen dependent tumor will promote tumor growth [281]. 
The mammalian lignans, enterodiol and enterolactone, inhibit MCF-7 cell proliferation more 
pronouncedly than in ER negative breast cancer cells [283], decrease breast cancer cell viability in 
the presence of E2 [284], and reduce MCF-7 tumor xenograft growth and angiogenesis in mice 
[285].  Furthermore, both of the lignans can inhibit estrogen production via the aromatase and 
17βHSD pathway and consequently reduce cell proliferation [286]. In addition, enterolactone has a 
low binding affininty for both of the ER subtypes [266], but can transactivate estrogen dependent 
gene transcription, albeit with a low potency [266,284].  Therefore the mammalian lignans, 
produced from plant pre-cursors, show potential as chemo-preventative as well as chemotherapeutic 
compounds. 
Coumestrol, the major coumestan [262,287], is not as well studied but has been shown to bind to 
the ER [288,289], have higher estrogenic potency than genistein [290], transactivate gene 
transcription through both ER subtypes with stronger activation through ERβ [267], induce MCF-7 
cell growth [282,291,292], and inhibit breast cancer cell invasion without affecting cell viability 
[293].  Therefore, although coumestrol can inhibit breast cancer cell invasion and thus inhibit the 
progression of breast cancer, caution is advised for use with estrogen dependent tumors.  However, 
the use of phytoestrogenic coumestrol as an alternative to traditional HRT is a possibility that may 
still be explored. 
Phytoestrogens may be referred to as natural SERMs as they have been shown to bind to the ER and 
have tissue specific estrogenic and anti-estrogenic properties [244,294].  For example, genistein has 
been shown be anti-estrogenic in breast tissue and cells [252,269,270] and estrogenic in bone tissue 
[294] and the uterus [295].  In addition phytoestrogens have also been shown to have selective ER 
subtype modulating properties.  Genistein can bind to both ER subtypes but displays a higher 
affinity for ERβ [250-252], whereas genistein as well as coumestrol, although not being ER subtype 
selective, display stronger transactivation of gene transcription via ERβ than via ERα [252,267].  In 




addition, the phytoestrogen, liquiritigenin as well as the plant extract, MF101, are ERβ specific 
agonists [233,234].  Taken together these findings suggest that an ER subtype specific modulator 
may be found in phytoestrogen containing plant material. 
In conclusion, phytoestrogens generally show potential to be developed for the treatment of 
menopause associated side effects as well as for breast cancer chemo-prevention.  However, 
contradictory findings regarding the treatment of hormone sensitive cancers highlights the 
importance of further research, especially research that will determine the optimal time of treatment 
during the development and progression of cancer.  Despite these contradictory findings, the 
general ER subtype specificity of phytoestrogens marks phytoestrogen rich food sources as an 
attractive target for finding the elusive ideal SERSM.  One such source may be Cyclopia. 
2.5.  Cyclopia 
Cyclopia (family: Fabaceae; tribe Podalyrieae), is an indigenous fynbos plant (Fig. 9) from the 
Western Cape province of South Africa [296,297].  Traditionally, the “fermented” (oxidized) form 
of Cyclopia, has been consumed as a fragrant, caffeine free honeybush tea beverage with the 
“unfermented” form being introduced to the commercial market more recently [252,297,298].  
Anecdotal evidence associates the consumption of honeybush tea with being an appetite enhancer, a 
stimulator of milk production in breast feeding women, a treatment for a spastic colon, and it is 
believed to provide relief to arthritis sufferers [297].  Furthermore anecdotal findings suggest that 
honeybush tea alleviates menopausal symptoms [251].  These anecdotal findings instigated research 
into the beneficial health properties of Cyclopia, as well as, into identifying the compounds within 
Cyclopia that elicit these effects. 
Previous studies have shown that extracts of various Cyclopia species increased the antioxidant 
status of the liver in rats [299], inhibited tumour promotion in mouse skin [300], inhibited aflatoxin 
B1 (AFB1) induced mutagenesis [301], provided protection against fumonisin B1 (FB1)-induced 
cancer in rat livers [302], inhibited esophageal cancer development in rats [303], and displayed anti-
obesity characteristics by inducing lipolysis [304] and inhibiting adipogenesis [305].  The current 




study, however, will focus on the phytoestrogenic properties of Cyclopia and the modulation of 
molecular targets involved in the prevention and treatment of breast cancer by the extracts of 
Cyclopia.  Therefore I will limit my discussion to the phytoestrogenic properties of Cyclopia 
extracts and the polyphenols they contain.  
Studies investigating the chemical composition of Cyclopia have shown that phenolic compounds 
with estrogenic activity, for example luteolin, eriodictyol, naringenin, and formononetin, are present 
in various species of Cyclopia [252,298,306-309].  Louw et al. (Addendum A, [308]) summarizes 
the known polyphenol content of Cyclopia and highlights the polyphenols present in the shoots and 
leaves of Cyclopia that have been shown to have phytoestrogenic properties.  Furthermore it 
provides an overview of the potential uses of phytoestrogens and, in addition, states the importance 
of the standardisation of both the levels of active compounds as well as the activity levels (potency 




Figure 9.  The Cyclopia plant.  The shoots of two of the Cyclopia species, C. subternata (left) and C. 
genistoides (right).  The yellow flowers are distinctive of the Cyclopia species.  Photos taken from Louw et 
al. [308]. 




For the benefit of the reader I will briefly highlight certain points from Louw et al. (Addendum A, 
[308]) regarding the phytoestrogenic extracts of C. genistoides and C. subternata as they are 
relevant to this study. 
P104, a dried methanol extract (DME) of C. genistoides, has been shown to bind with a lower 
affinity than E2 to both of the ER subtypes [251,252], but with a higher affinity for ERα [252].  
However, although having a higher affinity for ERα, P104 could only transactivate an ERE-
containing promoter reporter construct via ERβ with an efficacy similar to that of E2 but with a 
lower potency [252].  Furthermore, P104 induced MCF-7BUS cell proliferation with a lower 
potency than that of E2, an effect shown to be mediated via the ER, and, in addition, P104 
antagonized E2-induced MCF-7BUS cell proliferation [252].  SM6Met, a DME of C. subternata, 
like P104, has been shown to bind to the ER with a lower affinity than E2 [298] and transactivated 
an ERE-containing promoter reporter construct with a lower potency, but not efficacy, than that of 
E2 [298].  SM6Met also induced MCF-7BUS cell proliferation with a lower potency than that of E2 
[298].  The water extract of C. subternata, cup-of-tea, has also been shown to induce MCF-7BUS 
cell proliferation with both a lower potency and efficacy than that of E2 [298].  These findings 
warrant further investigation into how the phytoestrogenic extracts of Cyclopia would modulate the 
molecular targets involved in the prevention and treatment of breast cancer. 
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3.1.  Introduction  
Hormone replacement therapy (HRT), estrogens alone or in combination with progestins, is 
traditionally prescribed to women undergoing menopausal transition to alleviate symptoms 
associated with menopause [1], such as hot flashes, night sweats, sleeping problems, vaginal 
dryness, and osteoporosis [2-4].  However, a number of side effects have been associated with the 
use of HRT, for example, an increased occurrence of breast cancer [5,6], vaginal bleeding [7], and 
heart disease or strokes [6,8].  These side effects have led to reluctance among concerned 
consumers to use HRT and instigated a search for new estrogen analogues with an improved risk 
profile.  Furthermore, it would be of great value if these analogues should also display chemo-
preventative properties in breast tissue [9,10]. 
 Estrogens elicit their biological effects by binding to transcription factors called estrogen receptors 
(ERs) in the target organ/tissue (uterus, ovary, vagina, liver, bone, and breast) [11-13].  The ER 
exists as two subtypes, namely ERα and ERβ [14].  Current estrogens in HRT activate both 
subtypes of ER in all tissues [14-19].  This attribute is beneficial in bone [18,20,21] and for hot 
flashes [18,21], but detrimental in the breast [6,21,22] and uterus [21,23] as it increases the risk of 
tumourigenesis.  In contrast, the selective estrogen receptor modulators (SERMs), although not ER 
subtype specific [24,25], act as agonists in certain tissues, such as bone [26-28], and as antagonists 
in others, such as breast [9,10,29].  Although, the well-known SERMs, raloxifene and tamoxifen 
[30], have been shown to  decrease the risk of  breast cancer [18,31,32] and increase bone mineral 
density [26-28,33], they have also been linked to an increased risk of venous thromboembolism and 
occurrence of hot flashes, and can stimulate endometrial growth [28,34-36].  SERMs are thus not 
considered as suitable alternatives for HRT.   
Physiologically, while ERα is associated with the promotion of cell proliferation that contributes to 
the occurrence of breast and endometrial cancer, several studies have shown that ERβ inhibits ERα-
dependent cell proliferation and could prevent cancer development [15,22,37-43].  17β-estradiol 
(E2) has similar binding affinities for the two ER subtypes [44], and the subtypes stimulate the 




transcription of both common and distinct subsets of E2 target genes [13,17,39,45].  However, in 
many cases the degree of activation via ERβ is lower [44], despite the high ligand independent 
transcriptional activity of this subtype [46,47].  In light of the above, it has been suggested that the 
development of ER subtype specific ligands may herald the arrival of a new generation of estrogen 
analogues that may present a novel treatment for post-menopausal symptoms, which in addition, 
may prevent or decrease the occurrence of breast cancer [44,48,49].  An ideal or “designer” 
estrogen analogue or selective estrogen receptor subtype modulator (SERSM) has been postulated 
that would have the following attributes:  act as an ERα selective antagonist [50], down-regulate 
ERα protein levels [50,51], selectively activate ERβ transcriptional pathways [15,19,24,43], and 
display anti-inflammatory properties by inhibiting transcription of pro-inflammatory genes to 
prevent the occurrence of post-menopausal osteoporosis [15,52].  Current examples of subtype 
specific ligands are, methyl-piperidino-pyrazole (MPP) (ERα antagonist) [53,54], 
diarylpropionitrile (DPN) (ERβ agonist) [55], ERB-041 (ERβ agonist) [56,57], liquiritigenin (ERβ 
agonist) [19], isolated from the plant extract MF101 (ERβ agonist) [24].  Phytoestrogens have been 
referred to as natural SERMs and can be both estrogenic as well as antiestrogenic [58-60].  
Furthermore, although evidence in the literature shows that phytoestrogens can bind to both ER 
subtypes, they generally have a higher affinity for the ERβ subtype [61-63] as well as a higher 
transcriptional potency and efficacy via ERβ [63].  Despite conflicting evidence regarding doses of 
phytoestrogens and breast cancer risk [64,65], generally,  findings have pointed the search in the 
direction of phytoestrogens and focused attention on phytoestrogen rich food sources as a possible 
source of the ideal SERSM. 
One such source may be Cyclopia (family: Fabaceae), an indigenous fynbos plant from the Western 
Cape province of South Africa [66,67].  Traditionally, the “fermented” (oxidized) form of Cyclopia, 
has been consumed as a fragrant, caffeine free honeybush tea beverage with the “unfermented” 
form being introduced to the commercial market more recently [63,67,68].  Studies that investigated 
the chemical composition of Cyclopia have shown that phenolic compounds with estrogenic 




activity, for example luteolin, eriodictyol, naringenin, and formononetin, are present in various 
species of Cyclopia [63,68-72].  Furthermore, although dried methanol extracts (DMEs) from plant 
material of two species of Cyclopia, C. genistoides and C. subternata, have been shown to bind to 
the ERs and are able to transactivate an ERE-containing promoter reporter construct [62,63,68], 
only the extract from C. genistoides was investigated for ER subtype specificity and found to 
transactivate only through ERβ, despite binding to both subtypes [62,63].  In addition, studies by 
Verhoog et al. [63] and Mfenyana et al. [68] showed that although extracts of Cyclopia are able to 
induce proliferation of the ERα and ERβ positive MCF-7 BUS cells, they antagonise E2 induced 
cell proliferation. 
The current study was prompted by the findings of Verhoog et al. [62,63] that the Cyclopia extract, 
P104, although binding to both receptors and with a much higher affinity for ERα, was able to 
activate an ERE-containing promoter reporter construct only via ERβ.  As the possibility of ERα 
antagonism by Cyclopia extracts had not been addressed in previous studies it appeared essential to 
evaluate ERα antagonism while also re-evaluating ERβ agonism.  The combination of ERα 
antagonism and ERβ agonism may be especially relevant for the chemoprevention of breast cancer 
as ER antagonism serves as the basis of current chemo-preventative agents [29,31,32,73,74], while 
ERβ specific agonists have recently been identified as having potential for the chemoprevention of 
breast cancer [19,22].  In addition, this combination might be advantageous for the treatment of 
menopausal symptoms as an ERβ agonist has been shown to alleviate both hot flashes and the surge 
of inflammation related diseases during menopause [24,52], while an ERα antagonist would not 
result in hyperplasia of the uterus, commonly associated with ERα agonists [15,52].  Thus, in this 
study, we evaluate the potential of several extracts of Cyclopia to act as ERα antagonists and ERβ 
agonists and demonstrate that all extracts display ERα antagonism, while two also display ERβ 
agonism.  In addition, all extracts antagonise E2-induced MCF-7BUS cell proliferation, one extract 
displays anti-inflammatory activity, and the two tested extracts do not stimulate uterine growth. 
These results suggest that the Cyclopia extracts, which display ERα antagonism and ERβ agonism, 




have positive attributes that could possibly be further exploited for the development of safer drugs 
for the treatment or prevention of osteoporosis or pre-menopausal symptoms. 
3.2.  Material and methods 
3.2.1.  Ethics statement 
Animal care and experimental procedures were conducted with strict adherence to the accepted 
standards for the use of animals in research and teaching as reflected in the South African National 
Standards 10386: 2008.  Stellenbosch University ethics committee approved this study (ethical 
approval reference: 11NB_LOU01). 
3.2.2.  Test Compounds 
17β-Estradiol (E2), genistein, luteolin, enterodiol, phorbol 12-myristate 13-acetate (PMA) and 
fulvestrant (ICI 182,780) were obtained from Sigma-Aldrich
®
, South Africa, and coumestrol was 
obtained from Fluka™ Analytical, Sigma-Aldrich
®
, South Africa.  The Cyclopia extracts used for 
in vitro studies, P104 [62], SM6Met [68] and cup-of-tea [68], were previously prepared, while for 
in vivo studies new SM6Met and cup-of-tea extracts were prepared as previously described [68].  
E2, genistein, luteolin, enterodiol, coumestrol and Cyclopia extract stock solutions were prepared in 
dimethylsulfoxide (DMSO). 
3.2.3.  High-performance liquid chromatography (HPLC) analysis of C. subternata extracts 
The newly prepared SM6Met and cup-of-tea extracts were analyzed using HPLC.  Extracts and 
stock solutions of standards were prepared in DMSO and aliquots frozen at -20°C until needed for 
analysis. For experimental analysis ascorbic acid was added to defrosted standards and extracts to a 
final concentration of 9.8 mg/ml. The mixtures were then filtered using Millex-HV syringe filters 
(Millipore) with a 0.22 µm pore size.  
Analyses were performed on an Agilent 1200 HPLC consisting of an in line degasser, diode-array 
detection (DAD), column oven, autosampler and quaternary pump, controlled by Chemstation 
software (Agilent Technologies, Santa Clara, CA). The HPLC method previously described by De 




Beer et al. [75] was used to quantify the major phenolic compounds in C. subternata extracts: A 
Gemini-NX C18 (150 × 4.6 mm; 3 μm; 110 Å) column was used in conjunction with 2% acetic acid 
(A) and acetonitrile (B) as mobile phases. Injection volumes ranged from 10-20 µl for standards and 
5-50 µl for the extracts. Separation was performed at a flow rate of 1 ml/min with the following 
mobile phase gradient: 0-2 min (8% B), 2-27 min (8-38% B), 27-28 min (38-50% B), 28-29 min 
(50% B), 29-30 min (50-8% B), 30-40 min (8% B); at a temperature of 30°C. 
The dihyrochalcones, flavanones and benzophenones were quantified at 288 nm, whereas the 
xanthones, flavones and phenolic acids were quantified at 320 nm. A calibration curve consisting of 
seven points was set up for all the available standards (mangiferin (Sigma-Aldrich®, South Africa), 
isomangiferin (Chemos GmbH, Germany), luteolin (Extrasynthese, France), eriocitrin 
(Extrasynthese, France), hesperidin (Sigma-Aldrich®, South Africa), protocatechuic acid (Fluka™ 
Analytical, Sigma-Aldrich
®
, South Africa)) and also standards needed to calculate equivalent values 
(aspalathin (kind gift from Prof. Gelderblom, PROMEC unit, Medical Research Council, 
Tygerberg, South Africa), apigenin (Fluka™ Analytical, Sigma-Aldrich®, South Africa), and 
nothofagin (kind gift from Prof. Gelderblom, PROMEC unit, Medical Research Council, 
Tygerberg, South Africa)). Iriflophenone-3-C-β-glucoside and iriflophenone-di-O,C-hexoside was 
quantified using iriflophenone-3-C-glucoside isolated from C. genistoides (personal communication 
from Dr. D. de Beer). Scolymoside and vicenin-2 were expressed as luteolin and apigenin 
equivalents, respectively, as no authentic reference standards were available for these compounds. 
Also phloretin-3',5'-di-C-glucoside and 3-hydroxyphloretin-3',5'-di-C-hexoside were expressed in 
terms of nothofagin (3-hydroxyphloretin-3'-C-glucoside) and aspalathin (3-hydroxyphloretin-5'-C-
glucoside)  equivalents, respectively. 
3.2.4.  Cell Culture 
COS-1, African green monkey kidney fibroblast cells (ATCC, United States of America), and 
MCF-7BUS human breast cancer cells [76] (a kind gift from A. Soto, Tufts University, Boston, 
Massachusetts, United States of America) were maintained in high glucose (4.5 g/L) Dulbecco’s 




modified eagle’s medium (DMEM) (Sigma-Aldrich
®
) supplemented with 10% FCS (Highveld 
Biologicals, South Africa), 100 IU/ml penicillin and 100 µg/ml streptomycin (Gibco, Invitrogen™, 
South Africa), 2mM glutamine (Merck), 44mM sodium-bicarbonate (Gibco), 1mM sodiumpyruvate 
(Gibco, Invitrogen Corporation), and 0.1mM non-essential amino acids (Gibco).  All cells were 
maintained in a humidified cell incubator, set at 97% relative humidity and 5% CO2 at 37˚C.  For 
the cell proliferation assays (MTT assay) MCF-7BUS cells were withdrawn from 100 IU/ml 
penicillin and 100µg/ml streptomycin for seven days prior to use. 
3.2.5.  MTT assay  
On day one MCF-7BUS cells were seeded into 96-well tissue culture plates at a concentration of 
2500 cells/well and allowed 24 hours to settle.  The next day cells were washed with 200 µl/well 
pre-warmed PBS and the medium was changed to DMEM without phenol red supplemented with 
5% charcoal treated FCS (Highveld Biologicals, South Africa) and incubated for 24 hours.  After 
incubation the cells were treated for 48 hours with increasing concentrations test compounds and 
Cyclopia extracts in the presence or absence of 10
-9
M E2 where after the colorimetric MTT (3-(4,5- 
dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide) assay, adapted from Verhoog et al. [63] and 
Mfenyana et al. [68], was performed. Briefly, the MTT assay entails that 4 hours before the end of 
the incubation period the assay medium is changed to 150 µl DMEM without phenol red, but 
supplemented with 5% charcoal stripped FCS, and 50 µL of MTT (methylthiazolyldiphenyl-
tetrazolium ) (Sigma-Aldrich
®
) solution (5 mg/ml) is added to each well.  Cells are then incubated 
for four hours at 37°C, the medium removed, and 200 µL of solubilisation solution (DMSO) added 
to each well.  The plate is then covered with foil, shaken at room temperature for 5 min, and the 
absorbance read at 550 nm on a BioTek
®
 PowerWave 340 spectrophotometer. All assays included a 
negative solvent control, which consisted of 0.1% (v/v) DMSO only.  Results are expressed as fold 
induction relative to solvent. 
 




3.2.6.  Promoter reporter studies 
MCF-7BUS and COS-1 cells were seeded in sterile 10 cm tissue culture plates at a concentration of 
2 x 10
6
 cells/plate and allowed 24 hours to settle.  On day two the cells were rinsed once with sterile 
phosphate buffered saline (PBS) (pre-warmed to 37˚C), medium changed to DMEM without phenol 
red supplemented with 10% charcoal treated FCS and 1% penicillin and streptomycin mixture, and 
cells were transfected.  
3.2.6.1.  Plasmids 
Human (h) ERα (pSG5-hERα [77]) and ERβ (pSG5-hERβ [78]) expression plasmids were kind 
gifts from F. Gannon (European Molecular Biology Laboratory, Heidelberg, Germany).    The ERE-
containing promoter reporter construct (ERE.vit2.luc) was a kind gift from K. Korach, National 
Institute of Environmental Health Science, U.S. [79] and the NFκB-containing promoter reporter 
construct (p(IL6κB)350hu.IL6Pluc+ [80]) was a kind gift from G. Haegeman, University of Ghent, 
Ghent, Belgium.  pGL2-Basic (Promega Corporation, Madison, Wisconsin, U.S.A.) was used as an 
empty vector. 
3.2.6.2.  Transactivation 
To test transactivation through ERα COS-1 cells were transfected with 150 ng hERα and 6000 ng of 
an ERE-containing promoter reporter construct.  To test transactivation through ERβ COS-1 cells 
were transfected with 150 ng hERβ, 3000 ng of an ERE-containing promoter reporter construct, and 
3000 ng empty vector.  MCF-7 BUS cells (which contain endogenous hERα and hERβ) were 
transfected with 3000 ng of an ERE-containing promoter reporter construct and 3000 ng empty 
vector.  The amount of promoter reporter construct for each test model that was selected was 
determined by the highest E2 induction achieved (Figure S1). 
3.2.6.3.  Transrepression 
To test transrepression through ERα COS-1 cells were transfected with 150 ng hERα, 1500 ng of an 
NFκB-containing promoter reporter construct and 4500 ng empty vector.  To test transrepression 
through ERβ COS-1 cells were transfected with 150 ng hERβ, 4500 ng of an NFκB-containing 




promoter reporter construct and 1500 ng empty vector.  MCF-7BUS cells (which contain 
endogenous hERα and hERβ) were transfected with 6000 ng of an NFκB-containing promoter 
reporter construct.  The amount of promoter reporter construct for each test model that was selected 
was determined by the most effective E2 repression of PMA induction achieved (Figure. S2) 
All transfections were performed using FuGENE
TM
 6 transfection reagent (Roche Applied Science, 
South Africa) as described by the manufacturer.  Cells were left for 24 hours, replated in sterile 24-
well tissue culture plates at a concentration of 5 x 10
4 
cells/well and allowed 24 hours to settle.  
Cells were treated for 24 hours with test compounds and Cyclopia extracts and lysed overnight with 
50 µl lysis buffer [0.2% (vol/vol) Triton, 10% (vol/vol) glycerol, 2.8% (vol/vol) Tris-phosphate-
EDTA, and 1.44 mM EDTA] per well at -20 ˚C.  Luciferase activity was determined using the 
luciferase assay kit (Promega Corporation, Anatech, South Africa) according to the manufacturer’s 
instructions and normalized for protein content (Bradford assay [81]).  Results are expressed as fold 
induction relative to solvent. 
3.2.7.  Western Blot 
Cell lysates from COS-1 cells transfected with either ERα (150 ng hERα/10 cm plate) or ERβ (150 
ng hERβ/10 cm plate) and MCF-7BUS cells were prepared by adding lysis buffer A (10mM Hepes 
pH 7.5 (Gibco, Invitrogen Corporation), 1.5mM MgCl2, 10mM KCl, 0.1% NP-40 (Roche Applied 
Science) and Complete Mini protease inhibitor cocktail (Roche Applied Science), shaking on ice for 
15 min and frozen overnight at -20˚C. 
On thawing, lysate were transferred to 1.5ml Eppendorf tubes on ice, centrifuged for 10 min at 
12 000 x g at 4˚C and the cleared lysate was transferred to 1.5ml Eppendorf tubes on ice, alliquoted 
and stored at -20˚C until assayed.  Lysates (20µl) were separated on a 10% SDS-PAGE gel. 
Following electrophoresis, proteins were electro-blotted and transferred to a Hybond-ECL 
nitrocellulose membrane (Amersham Biosciences, South Africa), which was probed for ERα 
(diluted 1:500), ERβ (1:250) and GAPDH (1:500). Proteins were visualized using HRP labeled anti-
rabbit antibody for ERα (1:2500) and ERβ (1:1000), or HRP labeled anti-mouse antibody for 




GAPDH (1:5000), and ECL Western blotting detection reagents (Pierce
®
, Thermo Fisher Scientific 
Inc., U.S.A.) and medical x-ray film (Axim (PTY) LTD., South Africa).  All antibodies, primary 
[ERα (HC-20), cat# sc-543, ERβ (H-150), cat# sc-8974, and GAPDH (0411), cat# sc-47724] and 
secondary (anti-rabbit, cat# sc-2005, and anti-mouse, cat# sc-2030), were purchased from Santa 
Cruz Biotechnology, Inc., U.S.A.   
3.2.8.  Animal care 
Immature female Wistar rats were obtained from the Stellenbosch University, South Africa, 
breeding unit and were received as weanlings on postnatal day 18.  The animals had free access to 
standard rat feed (Pure Harvest Rat Feed, Afresh Vention (PTY) Ltd, South Africa) and drinking 
water.  The animals were housed in a 12 hour light-dark cycle at a constant temperature of 20 °C in 
EHRET individually ventilated cages (EHRET, Emmedingen, Germany).  The animals were 
allowed at least 24 hours to acclimatize before the onset of experimental procedures.   
3.2.9.  Immature rat uterotrophic assay 
The immature rat uterotrophic assay was performed according to methods previously described by 
Kanno et al. [82] and de Lima et al. [83].  Immature Wistar rats (21 days) were randomly assigned 
to groups (n=10) and treated daily with E2, genistein, Cyclopia extracts, or vehicle control (sterile 
PBS) by oral gavage for three consecutive days.  The dose volume was 200 μl/day.  The test 
compounds were suspended in sterile PBS and the solution was kept homogenous by stirring before 
administration.  General health, vaginal opening, and body weight was monitored daily and 
recorded.  On day four, approximately 24 hours after last dose, animals were weighed and sacrificed 
by administration of a high dose of Isoflurane (2-chloro-2-(difluoromethoxy)-1,1 1-trifluoro-
ethane), (Safeline pharamceuticals Pty (Ltd)).  Livers were removed and weighed.  Uteri were 
removed, cleaned of excess fat, photographed, weighed, pierced to remove luminal fluids, and 
blotted uterine weights were obtained immediately.  
 




3.2.10.  Evaluation/Monitoring of vaginal opening of Wistar rats for extended period 
Immature Wistar rats (21 days) were randomly assigned to groups (n=10) and treated daily with E2, 
Cyclopia extracts, or vehicle control (sterile PBS) by oral gavage for 30 consecutive days.  The dose 
volume had to be increased gradually from 200 μl/day to 400 μl/day as animals increased in body 
weight.  The test compounds were suspended in sterile PBS and the solution was kept homogenous 
by stirring before administration.  General health, vaginal opening, and body weight was monitored 
daily and recorded.  On day 30 animals were weighed and sacrificed by administration of a high 
dose of Isoflurane. 
3.2.11.  Data manipulation and statistical analysis 
The GraphPad Prism® version 5.10 for Windows (GraphPad Software) was used for graphical 
representations and statistical analysis.  One-way ANOVA and Dunnett’s post-test comparing all 
columns to the solvent control were used for statistical analysis and significance is displayed on the 
graphs.  For all experiments the error bars represent the SEM of at least two independent 
experimental repeats, except for in vivo studies where the error bars represent the SEM of the 
number of animals used. 
3.3.  Results 
 3.3.1.  HPLC analyses of extracts of Cyclopia 
New SM6Met and cup-of-tea extracts were prepared from the same harvesting of C. subternata 
previously used to prepare these extracts [68].  HPLC analysis was performed on these newly 
prepared SM6Met and cup-of-tea extracts (Table 1).  Prior HPLC results of previously prepared 
P104 [63]  and SM6Met [68] extracts are also shown in Table 1.  The results indicate the presence 
of the xanthones, mangiferin and isomangiferin, the flavones, scolymoside, luteolin, and vicenin-2, 
the flavanones, eriocitin and hesperidin, the dihydrochalcones, phloretin-3,5-di-C-glucoside and 
aspalathin, the benzophenones, iriflophenone-3-C-β-glucoside and iriflophenone-di-O,C-hexoside, 
and the phenolic carboxylic acid, protocatechuic acid. P104, a DME from C. genistoides, contained 




more mangiferin and isomangiferin than SM6Met, a DME from C. subternata, while, the cup-of-tea 
extract from the same species contained the least. 
Table 1.   Major polyphenols present in previously and newly prepared extracts of Cyclopia as determined 
by HPLC. 
 Extract 
 Previously prepared Newly prepared 
Polyphenol [% of dry extract 









Mangiferin 3.606 1.850 1.899 1.000 
Isomangiferin 5.094 0.750 0.645 0.420 







 1.289 0.876 
Vicenin-2 (apigenin-6,8-di-C-
glucoside) 





 1.250 0.846 0.600 
Hesperidin (hesperitin-7-O-
rutinoside) 
nt 1.870 2.049 0.935 
Phloretin-3’,5’-di-C-glucoside nt 1.270
d
 1.278 0.939 
3-Hydroxyphloretin-3',5'-di-C-
hexoside 
nt nt 0.700 0.582 
Iriflophenone-3-C-β-glucoside nt nt 0.669 0.590 
Iriflophenone-di-O,C-hexoside nt nt 0.958 0.896 






Previously “Unknown 1” was quantified as luteolin equivalents as it appeared to be a flavone. 
d
Previously “Unknown 2” was quantified as hesperidin equivalents as it appeared to be a flavanone. 
Luteolin was present in all of the extracts, albeit at small amounts, with the P104 extract containing 
the largest amount, followed by the SM6Met extracts, and with the cup-of-tea extract containing the 
least.  The luteolin rutinoside, scolymoside, was not evaluated in P104.  The DMEs of C. subternata 
contained more scolymoside, eriocitrin, hesperidin, and phloretin-3,5-di-C-glucoside than the cup-
of-tea extract.  The newly prepared DME, SM6Met, contained higher amounts than the cup-of-tea 
extract of compounds not previously tested for, namely, iriflophenone-3-C-β-glucoside, 
iriflophenone-di-O,C-hexoside, 3-hydroxyphloretin-3',5'-di-C-hexoside, vicenin-2, and 
protocatechuic acid.  In general the DMEs contained higher concentrations of the polyphenols 
quantified (Table 1) than the water extract. 




3.3.2.  Methanol extracts of Cyclopia act as agonists of ERβ, while all extracts antagonize E2-
induced activation via ERα. 
To evaluate ERα antagonism while also re-evaluating ERβ agonism COS-1 cells were transiently 
transfected with either ERα (Figs. 1 A, C) or ERβ (Figs. 1 B, D) and an ERE-containing promoter 
reporter construct.  Agonism was tested in the absence (Figs. 1 A, B) and antagonism in the 
presence (Figs. 1 C, D) of 10
-9
 M E2.  Three Cyclopia extracts, from two species, C. genistoides and 
C. subternata, were tested.  Two were methanol extracts, P104 and SM6Met, and one was a water 
extract, cup-of-tea.  In addition we investigated an example from each of the major classes of 
phytoestrogens: genistein, a well-studied isoflavone, enterodiol, a lignin, and coumestrol, a 
coumestan [84,85].  Luteolin, an estrogenic polyphenol [71], was also included as it was found be 
present in all of the Cyclopia extracts (Table 1), while E2 represents the major endogenous estrogen 
[86,87]. 
E2 induced ERα mediated transactivation in a dose dependent manner with significant induction at 
two concentrations of E2, 10
-9 
M (2.7 x 10
-4
 μg/ml) (2.5 ± 0.5 fold) and 9.8 µg/ml (3.6 x 10
-5
 M) 
(3.9 ± 0.7 fold), but not at the lowest concentration of 10
-11
 M (2.7 x 10
-6
 µg/ml) (Fig. 1A).  The 
same trend was seen for ERβ (2.5 ± 0.5 fold at 10
-9
 M and 2.7 ± 0.4 fold at 9.8μg/ml) (Fig. 1B), 
although at the highest concentration of E2 higher induction was observed via ERα than via ERβ 
(3.9 ± 0.7 vs. 2.7 ± 0.4 fold).  Although the 9.8 μg/ml E2 represents a supra-physiological 
concentration the 10
-11
 M and 10
-9
 M E2 concentrations reflect the pre- and post-menopausal levels 
of E2 respectively [88]. At the concentration of 9.8 µg/ml, genistein (3.6 x 10
-5
 M), luteolin (3.4 x 
10
-5
 M), and coumestrol (3.7 x 10
-5
 M) significantly activated gene transcription through both of the 
ER subtypes (Figs. 1A, B).  Enterodiol, however, could not significantly activate gene transcription 
through either of the subtypes at the concentration of 9.8 µg/ml (3.2 x 10
-5
 M) (Figs. 1A, B).  None 
of the Cyclopia extracts were able to induce activation through ERα (Fig. 1A), but both the 
methanol extracts, P104 and SM6Met, were able to significantly activate transcription through ERβ 
(2.4 ± 0.4 and 2.5 ± 0.3 fold, respectively). 
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Figure 1. Evaluation of ER subtype specific agonism and antagonism of transactivation of an ERE-
containing promoter reporter construct in COS-1 cells.  COS-1 cells were transfected with either (A and 
C) pSG5-hERα or (B and D) pSG5-hERβ and ERE.vit2.luc and treated for 24 hours with a series of test 
compounds or extracts.  To test agonism cells were treated with test compounds or extracts alone, (A and B), 
while, to test for antagonism cells were treated with test compounds or extracts in the presence of 10
-9
M E2 
(C and D).  Statistical analysis was done using One-way ANOVA with Dunnett’s post-test comparing all 
columns to the solvent control (*, P<0.05; **, P<0.01; ***, P<0.001).  The dotted line through the bars 
represents the values for solvent control.  Mean ± SEM is of four independent experiments done in triplicate. 
To address antagonism, transactivation in the presence of 10
-9
 M E2 was evaluated (Fig. 1C and D).  
The phenolic compounds, genistein, luteolin, and coumestrol were not antagonists but had an 
additive effect on E2-induced activation via both receptor subtypes (Figs. 1C and D), confirming 
their agonism through both subtypes (Fig. 1A and B).  Enterodiol in contrast, however, only 
displays ERα antagonism (0.7 ± 0.1 fold vs. E2 activation set as 1) (Fig. 1C).  All of the Cyclopia 
extracts significantly antagonized ERα mediated E2-induction (P104, 0.7 ± 0.1, SM6Met, 0.7 ± 0.1, 




and cup-of-tea, 0.6 ± 0.1 fold), however, only P104 had an additive effect on the E2-induced 
activation through ERβ (Fig. 1D).  In conclusion, the methanol extracts of Cyclopia are ERβ 
agonists and all extracts are ERα antagonists. 
3.3.3.  In MCF-7BUS cells expressing both ER subtypes all extracts of Cyclopia transactivate an 
ERE-driven promoter reporter construct. 
Most tissues affected by menopause and/or implicated in HRT side effects, such as uterus, bone, 
and breast, contain both ER subtypes [89].  Thus, having shown that methanol extracts of Cyclopia 
are ERβ agonists and all extracts are ERα antagonists in a system where the ER subtypes were 
evaluated separately, we were interested in investigating the transactivation potential of Cyclopia 
extracts in a system where both subtypes are present.  
MCF-7BUS cells, containing both ERα and ERβ (Fig. 2A), were transfected with an ERE-
containing promoter reporter construct and both agonism (Fig. 2B) and antagonism (Fig. 2C) were 
tested.  Although strong transactivation was seen with E2, none of the polyphenols on their own 
were able to significantly activate gene transcription in this system where both ER subtypes are 
present (Fig. 2B), despite the fact that these polyphenols transactivate when the ER subtypes 
function in isolation (Fig. 1A and B).  Furthermore, most of the polyphenols, excluding coumestrol, 
antagonized E2 induction when both ER subtypes are together (Fig. 2C), whereas when the subtypes 
were expressed separately only enterodiol showed ERα antagonism (Fig. 1C).  In contrast to the 
polyphenols, the extracts of Cyclopia, P104 (3.4 ± 0.5 fold), cup-of-tea (3.4 ± 0.5 fold) and, 
SM6Met (3.5 ± 0.6 fold), were able to activate transcription to a similar extent as 10
-9
 M E2 (3.8 ± 
0.3 fold) (Fig. 2B).  These results, together with the fact that the Cyclopia extracts did not 
antagonize E2 induction (Fig. 2C), suggests that when both ER subtypes are co-expressed the 
Cyclopia extracts act as agonists, whereas when the ER subtypes are expressed separately they only 
act as agonists through ERβ and antagonize ERα induction.  










































































































































































































Figure 2.  Evaluation of transactivation of an ERE-containing promoter reporter construct in MCF-
7BUS cells expressing both ERα and ERβ.  MCF-7BUS cells, with endogenous ERα and ERβ (A), were 
transfected with ERE.vit2.luc and treated for 24 hours with a series of test compounds or extracts.  To test 
agonism cells were treated with test compounds or extracts alone (B), while, to test for antagonism cells were 
treated with test compounds or extracts in the presence of 10
-9
M E2 (C).  Statistical analysis was done using 
One-way ANOVA with Dunnett’s post-test comparing all columns to the solvent control (*, P<0.05; **, 
P<0.01; ***, P<0.001).  The dotted line through the bars represents the values for solvent control.  Mean ± 
SEM is of three independent experiments done in triplicate. 
3.3.4.  An extract of C. genistoides represses NFκB activation via ERα and ERβ whereas the 
extracts of C. subternata are ERβ antagonists. 
The decline in estrogen levels during menopause leads to a surge in the occurrence of inflammatory 
disorders [52,90-92].  Furthermore, NFκB, a pro-inflammatory transcription factor, is involved in 
the development of breast cancer [93-95].  Taking this into account we wanted to evaluate the 
ability of Cyclopia extracts to repress the activation of an NFκB-containing promoter reporter 
construct by transfecting COS-1 cells with said construct and either ERα (Figs. 3A, C, E)  or ERβ 
(Figs. 3B, D, F).   
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Figure 3.  Evaluation of ER subtype specific agonism and antagonism of an NFκB-containing 
promoter reporter construct in COS-1 cells.    COS-1 cells were transfected with either (A, C, and E) 
pSG5-hERα or (B, D, and F) pSG5-hERβ and p(IL6kB)350hu.IL6Pluc+ and treated for 24 hours with a 
series of test compounds or extracts. To test agonism cells were treated with test compounds or extracts 
alone, (A and B), while, to test antagonism cells were treated with test compounds or extracts in the presence 
of 10
-9
 M E2 (C and D).  To ascribe the observed effect to the ER we treated cells with P104 and SM6Met in 
the absence or presence of the ER antagonist ICI 182,870 (E and F).  Statistical analysis was done using 
One-way ANOVA with Dunnett’s post-test comparing all columns to either (A, B, E, and F) 10ng/ml PMA 
or (C and D) 10ng/ml PMA + 10
-9
M E2 (*, P<0.05; **, P<0.01; ***, P<0.001).  The dotted lines through the 
bars represent the values for either (A, B, E, and F) solvent control, 10ng/ml PMA, or 10ng/ml PMA + 10
-9
M 
E2 or (C and D) 10ng/ml PMA + 10
-9
M E2.  Mean ± SEM is of three independent experiments done in 
triplicate. 
In addition, this system would provide information concerning the behavior of Cyclopia extracts in 
a transrepression model.  Agonism was tested in the absence (Figs. 3A, B) and antagonism (Figs. 
3C, D) in the presence of 10
-9
 M E2.   
PMA (phorbol 12-myristate 13-acetate, an activator of NFκB driven gene expression [96,97]) 
activation of the NFκB-containing construct was repressed by E2 via both receptor subtypes (Fig. 
3A and B) with a more pronounced repression through ERα (38.6% vs. 27.2%).  Like E2, all of the 
polyphenols, as well as P104 (C. genistoides extract), acted as ERα agonists by repressing PMA 
activation (genistein 52.1%, luteolin 50.6%, enterodiol 57.4%, coumestrol 61.8%, and P104 59.2%) 
(Fig. 3A).  Furthermore, genistein (34.8% repression) and P104 (40.7% repression), like E2, also 
displayed significant ERβ agonism (Fig. 3B).  Therefore, in our transrepression model P104 is not 
an ERβ selective agonist, but displays agonism via both subtypes.  The water extract of C. 
subternata, cup-of-tea, was unable to repress PMA induction through either ERα or ERβ (Figs 3A, 
B) while the methanol extract, SM6Met, also unable to repress PMA induction through either 
subtype, significantly added to the activation observed with PMA alone via ERα (5.1 ± 0.5 vs. 3.5 ± 
0.5) (Fig. 3A, B). 
Antagonism was evaluated in the presence of 10
-9
 M E2 and only genistein (Fig. 3C) had a 
significant effect via ERα by antagonizing E2 repression of PMA activation.  The polyphenols, 
luteolin, enterodiol, and coumestrol, but not genistein, however, antagonized E2 repression of PMA 




activation via ERβ (Fig. 3D).  Although none of the extracts displayed significant antagonism of 
ERα, the extracts of C. subternata displayed ERβ antagonism (Fig. 3D). 
The result for SM6Met in Fig. 3A prompted us to investigate whether this effect was via ERα or if 
SM6Met is able to activate the NFκB-containing construct through another mechanism of action.  
Therefore, we repeated the experiment, for both receptor subtypes, with SM6Met, as well as P104, 
in the presence and absence of an ER antagonist, ICI 182,780 (Figs. 3E, F).  The observed 
repression of PMA activation by E2 and P104 via ERα and ERβ is abolished by ICI (Fig. 3E, F) and 
thus, the observed repression is indeed via the ER.  SM6Met, like ICI, increases PMA activation 
through ERα (Fig. 3E) and both have no significant effect on PMA activation via ERβ (Fig. 3F).  
Furthermore, the increased transactivation observed with SM6Met in Fig. 3A may be attributed to 
residual E2 remaining after stripping of FCS, as suggested by others [22], which would further 
support the contention that SM6Met is behaving as an ERα antagonist.  In conclusion then the 
results suggest that for our transrepression model the methanol extract of C. genistoides (P104) is 
behaving like an ERα and ERβ agonist, while the methanol extract of C. subternata  (SM6Met) is 
an ERα antagonist in the absence of E2, and an ERβ antagonist in the presence of E2. 
3.3.5.  In MCF-7BUS cells expressing both ER subtypes all extracts are agonists, while the water 
extract of C. subternata also displays antagonistic activity. 
As we have shown that P104 is an ER agonist and SM6Met is an ER antagonist in a transrepression 
model where the ER subtypes function in isolation (Fig. 3), we wanted to test the effect of these 
extracts in a model where both subtypes are present as most tissues affected by menopause and/or 
implicated in HRT side effects contain both subtypes. 
MCF-7BUS cells were transfected with an NFκB-containing promoter reporter construct and both 
agonism (Fig. 4A) and antagonism (Fig.4 B) evaluated.  Strong repression was observed with E2, 
the polyphenols, and P104 when both subtypes are present (Fig. 4A), which correlates with what 
was observed previously for ERα alone (Fig. 3A).  However, for ERβ alone (Fig. 3B), significant 
repression was previously seen only with E2, genistein, and P104 but not with luteolin, enterodiol, 




and coumestrol.  Unlike previous results, SM6Met behaved differently when subtypes were co-









































































































































































































Figure 4.  Evaluation of transrepression of an NFκB-containing promoter reporter construct in MCF-
7BUS cells expressing both ERα and ERβ.  MCF-7BUS cells were transfected with 
p(IL6kB)350hu.IL6Pluc+ and treated for 24 hours with a series of test compounds or extracts. To test 
agonism cells were treated with test compounds or extracts alone, (A), while, to test for antagonism cells 
were treated with test compounds or extracts in the presence of 10
-9
M E2 (B).  Statistical analysis was done 
using One-way ANOVA with Dunnett’s post-test comparing all columns to either (A) 10ng/ml PMA or (B) 
10ng/ml PMA + 10
-9
M E2 (*, P<0.05; **, P<0.01; ***, P<0.001).  The dotted lines through the bars 
represent the values for either (A) solvent control, 10ng/ml PMA, or 10ng/ml PMA + 10
-9
M E2 or (B) 
10ng/ml PMA + 10
-9
M E2.  Mean ± SEM is of three independent experiments done in triplicate. 
It displayed agonism when subtypes are expressed together (Fig. 4A) while displaying antagonism 
when expressed separately (Fig. 3A and D).  Similarly, where no agonist activity via either subtype 
alone was observed previously, the cup-of-tea extract was able to change its behavior when both 
subtypes are present by displaying ER agonism. Furthermore, antagonism in the presence of both 
subtypes was only seen with the cup-of-tea extract (Fig. 4B), while the subtype specific antagonism 
of genistein, luteolin, enterodiol, coumestrol, and SM6Met (Figs. 3C, D) is abrogated in the 
presence of both subtypes.  Taken together, in a transrepression model, the DME of C. genistoides, 
P104, is an ER agonist in all models (Figs. 3A, B, and 4A), the DME of C. subternata, SM6Met, is 
an ERβ antagonist in the presence of E2 (Fig. 3D), an ERα antagonist in the absence of E2 (Fig. 3A, 
E), and an agonist in the presence of both ER subtypes (Fig. 4A), while the water extract of C. 




subternata, cup-of-tea, is an ERβ antagonist (Fig. 3D) and an ER agonist/antagonist (Figs. 4A, B) in 
the presence of both subtypes.  This differential behavior of the Cyclopia extracts in the 
transrepression model contrasts to similar behavior by the extracts in the transactivation model 
where all extracts displayed antagonism through ERα (Fig. 1) alone, while displaying agonism to 
ERβ (Fig. 1) alone or when both subtypes are expressed (Fig. 2). 
3.3.6.  Cyclopia extracts weakly induce proliferation of breast cancer cells but antagonizes E2-
induced breast cancer cell proliferation. 
Having shown that Cyclopia extracts can modulate both transactivation and transrepression  in the 
presence of both ER subtypes and when the subtypes are expressed alone, we wanted to re-evaluate 
agonism of P104 [63], SM6Met and cup-of-tea [68] (Fig. 5) and antagonism of P104 [63] (Fig. 6) 
and for the first time evaluate antagonism of SM6Met and cup-of-tea (Fig. 6) on MCF-7BUS breast 
cancer cell proliferation.  Cell proliferation in MCF-7BUS cells constitutes an integrated model 
where not only the ER subtypes are co-expressed, but both transactivation and transrepression of 
endogenous genes contribute towards the final phenotype, whether it is proliferative or anti-
proliferative [39,98-100].  
The MTT cell proliferation assay using MCF-7BUS cells was used to address agonism (Fig.5A-H).  
Estrogen induced cell proliferation at a wide range of concentrations (10
-6
 M to 10
-10
 M) with the 
highest efficacy (2.1 ± 0.1 fold) observed at 10
-9
 M E2 (2.7 x 10
-4
 μg/ml) (Fig. 5A).  Like E2, all of 
the polyphenols were also able to induce cell proliferation, but not to the same extent as E2, with a 
maximum efficacy of: genistein, 1.5 ± 0.1 fold at 10
-9
 M (2.7 x 10
-4
 μg/ml) (Fig. 5B), luteolin, 1.5 ± 
0.1 fold at 10
-5 
M (2.7 μg/ml) (Fig. 5C), coumestrol, 1.6 ± 0.1 fold at 10
-6
 M (3.0 x 10
-1
 μg/ml) (Fig. 
5D), and enterodiol, 1.3 ± 0.1 fold at 10
-9
 M (3.0 x 10
-4
 μg/ml) (Fig. 5E).  Similarly, all three 
extracts of Cyclopia induced proliferation of cells with a lower efficacy than E2 with maximum 
efficacies of 1.5 ± 0.2 (significantly different from E2), 1.3 ± 0.03 (significantly different from E2), 
and 1.7 ± 0.2 (not significantly different from E2) fold for 9.8 μg/ml of P104, cup-of-tea and 
SM6Met, respectively (Figs. 5F-H).   














































































































































































































































































































EC50 = 2.59 x 10
-6g/ml EC50 = 1.96 x 10
-5g/ml
EC50 = 8.97 x 10
-5g/ml EC50 = 5.45 x 10
-4g/ml #
EC50 = 2.64 x 10
-5g/ml EC50 = 6.00 x 10
-4g/ml #
EC50 = 1.20 x 10
-4g/mlEC50 = 5.00 x 10
-1g/ml ###
 
Figure 5.  Evaluation of agonism of proliferation, a more complex endpoint encompassing both 
transactivation and transrepression in MCF-7BUS cells expressing both ERα and ERβ.  MCF-7 BUS 
cells were treated with increasing concentrations of (A) E2, (B-E) polyphenols, and (F-H) Cyclopia extracts 
for 48 hours.  After treatment the amount of living cells was determined using a MTT assay.  Statistical 
analysis was done using One-way ANOVA with Dunnett’s post-test comparing all columns to the solvent 
control (*, P<0.05; **, P<0.01; ***, P<0.001) or to E2 for EC50 values (#, P<0.05; ##, P<0.01; ###, 
P<0.001).  The dotted line through the bars represents the values for solvent control.  Mean ± SEM is of two 
independent experiments done in six replicates, except (A) where mean ±SEM is of three independent 
experiments done in six replicates. 
The potencies, depicted by EC50 values on graphs (Figs. 5A-H), of the polyphenols, as well as of 
the  Cyclopia extracts, were lower than that of E2 with coumestrol, P104, and SM6Met significantly 




lower and may be listed in order of decreasing potency as follow:  E2 > genistein > enterodiol > 





























































































































































































































































Figure 6.  Evaluation of antagonism of proliferation, a more complex endpoint encompassing both 
transactivation and transrepression in MCF-7BUS cells expressing both ERα and ERβ.    MCF-7 BUS 
cells were treated with increasing concentrations of (A-D) polyphenols and (E-G) Cyclopia extracts for 48 
hours in the presence of 10
-9
M E2.  After treatment the amount of living cells was determined using a MTT 
assay.  Statistical analysis was done using One-way ANOVA with Dunnett’s post-test comparing all columns 
to the solvent control (*, P<0.05; **, P<0.01; ***, P<0.001).  The dotted line through the bars represents the 
values for solvent control.  Mean ± SEM is of two independent experiments done in six replicates. 
 




To address antagonism (Fig. 6A-G), increasing concentrations of the polyphenols and Cyclopia 
extracts were tested in the presence of 10
-9
 M E2 (highest efficacy, Fig. 5A).  Genistein (Fig. 6A) 
and enterodiol (Fig. 6D), significantly repressed E2-induced cell proliferation (23.3% at 10
-5
 M 
(2.70 μg/ml) and 24.5% at 10
-5
 M (3.02 μg/ml), respectively).  Although, luteolin (Fig. 6B) and 
coumestrol (Fig. 6C) displayed no significant antagonism, coumestrol did have a significant 
additive effect (1.3 ± 0.1 fold) at 10
-9
 M (2.96 x 10
-4
 μg/ml), suggesting agonism.  Similarly, 
genistein, an antagonist at high concentrations, also had a significant additive effect (1.2 ± 0.1 fold) 
at the lower concentration of 10
-8
 M (2.70 x 10
-3
 μg/ml) (Fig 6A).  All extracts of Cyclopia were 
able to antagonize E2-induced cell proliferation, with P104 repressing 19.8% at 9.8 x 10
-1
 μg/ml, 
SM6Met 16.8% 9.8 x 10
-4
 μg/ml, and cup-of-tea 15.6% repression at 9.8 x 10
-4
 μg/ml (Figs. 6E, F, 
G).  Taken together, these results show that although all extracts of Cyclopia induced cell 
proliferation, the P104 and cup-of-tea extracts did so at a significantly lower efficacy and the 
methanol extracts at a significantly lower potency than E2, and that all extracts could antagonize E2-
induced cell proliferation. 
3.3.7.  SM6Met does not stimulate the growth of rat uteri, antagonizes E2-induced uterine 
proliferation, and delays vaginal opening. 
For the in vivo studies only extracts from C. subternata was used as P104 plant material was not 
available in bulk.  The immature rat uterotrophic assay is used to determine the ability of test 
compounds to stimulate ERα induced uterine growth as ERβ is not highly expressed in the uterus 
[56,101] and also allows for the detection of antiestrogens [102].  Rats were administered E2, 
genistein, and the two C. subternata extracts, SM6Met and cup-of-tea, via oral gavage and the 
effects on uterine growth were evaluated (Fig. 7A, B, and Fig. S3).  Estrogen, as well as genistein, 
induced uterine growth (2.5 ± 0.2 and 2.0 ± 0.2 fold, respectively) (Fig. 7).  In contrast, the extracts 
significantly reduced uterine weight relative to solvent (Fig. 7 and Fig. S3).  SM6Met also 
significantly repressed E2-induced uterine growth by 33.0%, a result that is similar, but less 




pronounced, than that seen with ICI 182,780 (59.7% repression) (Fig. 7) suggesting that the extracts 
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Figure 7.   Evaluation of the in vivo effect of E2, genistein and SM6Met on immature rat uterine 
growth.  Immature female wistar rats were treated with 100µg/kg body weight E2, in the presence and 
absence of 2000mg/kg body weight SM6Met or 10mg/kg body weight ICI 182,780, 100mg/kg body weight 
genistein, 2000mg/kg body weight SM6Met, and 10mg/kg body weight ICI 182,780 for three consecutive 
days.  Animals were sacrificed on day four, (A) uteri were photographed, and (B) wet uterine/final body 
weight was determined.  One-way ANOVA with Dunnett’s post-test comparing all columns to either solvent 
control (*, P<0.05; **, P<0.01; ***, P<0.001) or E2 (#, P<0.05; ##, P<0.01; ###, P<0.001).  The dotted lines 
through the bars represent the values for solvent control or E2.  Mean ± SEM is of at least five animals/group. 
We also addressed body weight changes and toxicity (Fig. S4) and found that E2 significantly 
increased body weight, whereas genistein significantly decreased body weight.  The extracts of 
Cyclopia and ICI 182,780, however, did not lead to significant weight gain or loss as compared to 
solvent, except for the animals treated with the highest concentrations (2000mg/kg BW) of SM6Met 
and cup-of-tea extracts which gained significantly less weight than the solvent treated animals. With 
regards to toxicity, none of the treated animals showed any significant changes in liver weight, 























































Figure 8.  Evaluation of the effect of E2 and SM6Met on the timing of vaginal opening.  Immature 
female wistar rats were treated for 30 consecutive days with 100μg/kg body weight E2 and 2000mg/kg body 
weight SM6Met and the day of vaginal opening was determined.  One-way ANOVA with Dunnett’s post-
test comparing all columns to solvent control (*, P<0.05; **, P<0.01; ***, P<0.001).  The dotted line through 
the bars represents the values for solvent control.  Mean ± SEM is of at least eight animals/group.. 
Furthermore, as another marker of estrogenic activity, albeit a less sensitive marker [102], we also 
evaluated time of vaginal opening over an extended period of daily treatments (Fig. 8).  Estrogen 
led to premature vaginal opening when compared to solvent (4.2 ± 0.4 vs. 14.3 ± 1.2 days).  This 




correlates with the observed increase in uterine weight in Figure 7.  The significantly delayed 
vaginal opening of SM6Met treated animals (19.0 ± 1.3 days) also correlates with uterine weight 
results in displaying antiestrogenic behavior.  The significant delay in vaginal opening was 
observed for all three of the concentrations of SM6Met, however, although the cup-of-tea extract 
showed a similar trend, it was not significant (Fig. S5). 
To summarize, for the first time we show that the C. subternata extracts are absorbed when 
administered orally and elicit a biological effect in vivo.  Specifically, Cyclopia extracts, in contrast 
to E2 and genistein, did not induce uterine growth and SM6Met antagonized E2-induced uterine 
growth.  Furthermore, the extracts also delayed vaginal opening in contrast to E2.  These results 
suggest that the Cyclopia extracts display ERα antagonism in vivo by retarding uterine growth 
[56,101]. 
3.4.  Discussion 
HRT in the form of estrogens provides relief from the plethora of menopause associated symptoms 
[1].  Although these estrogens provide relief from menopausal symptoms, they introduced new 
HRT associated risks, including an increased occurrence of breast cancer, heart disease, strokes, and 
endometrial cancer [1,5,6,8].  These risks, and the associated reluctance of usage, instigated the 
search for a new generation of estrogen analogues that would provide the benefits of estrogens 
without the associated risks.  In addition, it would be of great value if these new analogues display 
chemo-preventative properties in breast and endometrial tissues [9,10,29]. 
The search for new estrogen analogues heralded the era of the SERMs.  These SERMs would 
selectively modulate estrogen receptors in different tissues, acting as antagonists in the breast and 
uterus (chemo-preventative) and as agonists in the bone (osteoporosis prevention).  Tamoxifen, a 
first generation SERM, provided the desired protective effect in the breast [31,32] and raloxifene, a 
second generation SERM, had protective properties in breast and bone tissues [26,27,103].  
However, as these SERMS have been linked to the increased occurrence of hot flashes and 
stimulated endometrial growth (tamoxifen), the search continues [28,34,35].  Third generation 




SERMs, such as lasoxifene and bazedoxifene, are currently in development, but the focus has 
shifted to osteoporosis treatment with protection against breast cancer as a beneficial side effect 
[104-106]. 
Although SERM development continues there is increased interest in SERSMs, analogues that can 
differentially modulate specific ER subtypes.  This was brought on by studies that have shown that 
ERβ inhibits ERα dependent cell proliferation and could prevent cancer development [15,22,37,40-
43].  Phytoestrogens have been shown to be both estrogenic as well as antiestrogenic and while they 
can bind to both ER subtypes, they generally have a higher affinity for ERβ as well as a higher 
transcriptional potency and efficacy via ERβ [61-63].  Thus, phytoestrogen rich food sources have 
become important potential resources of SERSMS. 
The current study evaluated previously described extracts of Cyclopia, a source of phytoestrogens, 
for ER agonism and/or antagonism (summarized in Table S1).  Specifically, we evaluated the effect 
of Cyclopia extracts on transactivation and transrepression in a model where ERα and ERβ were 
expressed separately.  This allows for the evaluation of the modulation of ER subtype specific 
activity in two transcriptional models: a classical ERE transactivation model and an NFκB 
transrepression model.  In the transactivation model the methanol extracts, P104 and SM6Met were 
ERβ agonists, while all extracts antagonized ERα.    In the transrepression model, however, the 
behavior of the Cyclopia extracts became more complex.  P104, which displayed opposite effects 
via the subtypes in the transactivation model, acted as an agonist for both subtypes in the 
transrepression model.  The extracts of C. subternata, however, did not elicit such uniform effects 
in the transrepression model.  SM6Met, a methanol extract, acting as an ERα antagonist and ERβ 
agonist regarding transactivation, displayed antagonism towards ERα, in the absence of E2, and 
towards ERβ, in the presence of E2.  Similar antagonism towards ERα in the absence of E2 has also 
been seen for the plant extract MF101 regarding IL6 mRNA expression [24]. The water extract, 
cup-of-tea, also changed its behavior, acting as an ERβ antagonist for transrepression as opposed to 
an ERα antagonist for transactivation.  These behavioral changes were not exclusive to the Cyclopia 




extracts as the polyphenols also displayed these characteristics.  Luteolin, for example, displayed 
ER agonism through both subtypes in the transactivation model but was an ERα agonist and an ERβ 
antagonist in the transrepression model.  The occurrence of mixed agonism and antagonism towards 
ER subtypes has also been observed for the xenoestrogen, Bisphenol A (BPA) [107].   
As the current experiments were performed in the same cell line we have to look towards 
differences between the mechanisms of transactivation and transrepression for clarification of these 
results.  Classically, transactivation is a product of ER dimer binding directly to the DNA sequence, 
however, tethering to DNA bound transcription factors (TFs) in the promoter region of affected 
genes has also been described [108-111].  Binding of the ER to DNA, whether it is direct or 
indirect, initiates the recruitment of co-activators, which then modulates transcription [112].  
Regarding transrepression, specifically the repression of NFκB driven genes, various mechanisms 
of ER mediated transrepression have been described [109].  The ER can bind to NFκB and thereby 
prevent DNA binding of the transcription factor [113,114],  ligand bound ER present at promoter 
regions can recruit co-repressors [115,116], ligand bound ERα and activated NFκB can compete for 
co-activator recruitment [117,118], or ERα, through a non-genomic pathway, inhibits translocation 
of activated NFκB to the nucleus [119].  We can use this knowledge of the mechanism of action and 
combine it with what we know about SERMs and ER subtypes specific ligands to postulate a 
mechanism of action of Cyclopia agonism and antagonism.  For the SERMs, three mechanisms of 
antagonism have been proposed [18].  SERMs can bind to the ER with a higher affinity than E2 and 
block the binding of E2, they can block the binding of co-activators, or SERMs can induce the 
recruitment of co-repressors. [18,120,121].  Not much is known regarding the mechanism of SERM 
agonism [18], although it has been suggested that they can block the binding of co-repressors [121].  
In addition, MF101 and liquiritigenin, both ERβ selective agonists, although being able to bind to 
ERα, cannot recruit co-activators to ERα, and MF101 cannot promote the interaction of ERα with 
regulatory elements [15,24].  Furthermore, it has been suggested that SERMs may activate cell 
surface signaling pathways that results in ligand-independent activation of ERs [29,122,123]. 




Therefore, with regards to transactivation, we may postulate that the extracts of Cyclopia cannot 
transactivate via ERα as they are unable to recruit the necessary co-activators, while for ERβ, P104 
and SM6Met are able to do so.  It is also possible that the extracts of Cyclopia cannot induce ERα 
interaction with regulatory elements.  The observed ERα antagonism of E2-induced transactivation 
may be due to the extracts binding to ERα and either inhibiting E2 binding, inhibiting the 
recruitment of co-activators or stimulating the recruitment of co-repressors.  In our transrepression 
model P104 behaves like E2 and could be exerting its function by any of the NFκB repression 
models discussed earlier.  However, SM6Met displays ERα antagonism in the absence of E2 and this 
antagonism is lost in the presence of E2.  Therefore, it is possible that SM6Met is unable to recruit 
co-repressors in the absence of E2 and is unable to inhibit the E2-induced recruitment of co-
repressors.  Furthermore, antagonism of ERβ in the transrepression model by SM6Met and cup-of-
tea may be due to the recruitment of co-activators to ERβ. 
Next we evaluated agonism and antagonism of Cyclopia extracts in a more complex environment 
where the ER subtypes are co-expressed.  We used the MCF-7BUS cells, a breast carcinoma cell 
line, not only because it co-expresses the subtypes (Fig. 2A), but also to evaluate the activity of the 
extracts in breast tissue cells.  With regards to transactivation, all extracts of Cyclopia were agonists 
and are likely exerting this agonism through ERβ as they were ERβ agonists and ERα antagonists in 
COS-1 cells.  Also, previously we discussed the possibility that the extracts may be unable to 
recruit co-activators to ERα or induce ERα-regulatory element interactions, which supports the idea 
that the Cyclopia extracts are mediating their transactivative effects in MCF-7BUS cells via ERβ. 
Interestingly, the polyphenols, genistein and luteolin, having displayed ER agonism in COS-1 cells, 
in an environment where both ER subtypes are present displayed only weak agonism, which may be 
attributed to the fact that lower concentrations were used in MCF-7BUS cells. However, when both 
subtypes are present these polyphenols display antagonism, which was not apparent when the 
subtypes were expressed separately.  When both ER subtypes are expressed in the transrepression 
model, all the polyphenols as well as the Cyclopia extracts acted as agonists, while the water extract 




of C. subternata also displayed ER antagonism.  The ER agonism of P104 in the transrepression 
model is thus not a cell type selective effect as it is seen in both the COS-1 (kidney) and MCF-
7BUS (breast) cells.  The ER antagonism of cup-of-tea in MCF-7BUS cells is likely mediated via 
ERβ as ERβ antagonism was observed in COS-1 cells transfected with ERβ, but not in cells 
transfected with ERα.  However, the SM6Met extract, which displayed antagonism for ERα and 
ERβ in COS-1 cells, changes its behavior in the MCF-7BUS cells and acts as an ER agonist in the 
transrepression model.  Furthermore, a similar switch in behavior is observed with the polyphenols 
as the subtype specific antagonism is abrogated in the presence of both ER subtypes.  These 
observed behavioral changes of the Cyclopia extracts as well as the polyphenols in different tissues 
have also been observed for the SERM, tamoxifen [18].  Ball et al. [18] found that tamoxifen 
differentially regulated ER regulated genes in different cell lines and ascribed this phenomenon to 
the presence, or lack of, co-regulators in different tissues.  Therefore, the differential effect of 
Cyclopia extracts as well as the polyphenols in cells from different tissues might be due to changes 
in the co-regulator environment. 
As MCF-7BUS cells express both ER subtypes, we also have to consider the possibility of ERα/β 
heterodimer formation and the biological relevance thereof as opposed to homodimer formation in 
COS-1 cells expressing the ER subtypes in isolation.  Using two phytoestrogens that are ERα/β 
heterodimer selective, cosmosiin and angolensin, it was shown that heterodimer formation, in the 
presence of these ligands, leads to higher activation of an ERE-promoter reporter construct than 
homodimers and furthermore that heterodimer formation has a growth inhibitory effect in breast 
and prostate epithelial cells [124].    Previous studies by Powell et al. [46] showed that the ERβ 
selective agonist, liquiritigenin, which can bind to both ER subtypes, induces an ERα conformation 
that prefers heterodimerization with ERβ, as opposed to forming ERα homodimers.  Therefore, we 
cannot exclude heterodimer formation as an explanation for the strong agonist effect of the 
Cyclopia extracts in the transactivation model in MCF-7BUS cells. 




Having evaluated the agonist and antagonist activity of Cyclopia extracts in a system where the ER 
subtypes were expressed separately and together, in a transactivation and a transrepression model, 
we increased the level of complexity by evaluating the effect of the extracts on MCF-7BUS cell 
proliferation, a system where the final cell phenotype is a product of not only the two ER subtypes 
but also of an integrated transactivation and transrepression system [39,98-100].  Although the 
Cyclopia extracts, like E2, induced cell proliferation it was with either a significantly lower potency 
(P104 and SM6Met) or lower efficacy (P104 and cup-of-tea) than E2.  Furthermore, in the presence 
of E2, all of the Cyclopia extracts displayed antagonistic properties.  Similarly, the polyphenols also 
induced cell proliferation with either lower efficacies or potencies than E2 and some (genistein and 
enterodiol) also displayed antagonism.  Previously, the agonist activity seen in the transactivation 
model in MCF-7BUS cells was ascribed to ERβ activation and this is probably translating into weak 
induction of MCF-7BUS cell proliferation.  Furthermore, liquiritigenin, an ERβ selective agonist, 
although not able to induce significant MCF-7 cell growth in a mouse xenograft model [19,24], was 
able to induce proliferation of the ERα and ERβ positive [125] osteoblast-like murine MC3T3-E1 
cells [126].  The antagonism of E2-induced cell proliferation by extracts of Cyclopia could be 
attributed to ERα antagonism (observed in the transactivation model in COS-1 cells), ER mediated 
repression of proliferation inducing genes (ER transrepression observed in MCF-7BUS 
transrepression model), ERβ-mediated transcription (observed in the transactivation model in COS-
1 cells) of anti-proliferative and anti-apoptotic genes [39,127], or they might favor the formation of 
ERα/β heterodimers, which has been suggested to have growth inhibitory effects in breast epithelial 
cells [124].   
Furthermore, we also evaluated the estrogenic and antiestrogenic properties of the Cyclopia extracts 
in an in vivo model, an immature rat uterotrophic assay.  For the first time we show in vivo 
biological activity of the phytoestrogenic extracts of Cyclopia.  SM6Met and cup-of-tea, unlike E2 
and genistein, did not increase uterine weight and SM6Met, like the ER antagonist ICI 182,780, 
antagonized E2-induced uterine growth.  The ERα subtype is the major subtype expressed in the 




uterus with very low levels of ERβ expressed [56,101].  Powell et al. [46] show that although ERβ 
homodimers and ERα/ERβ heterodimers are favored, genistein is capable of inducing ERα 
homodimers and activating ERα-induced transcription.  Therefore, we can assume that the increase 
in uterine growth induced by genistein in the uterotrophic assay is a product of increased ERα 
homodimerization and hence, increased ERα mediated transcription.  The ERβ selective agonists, 
liquiritigenin and ERB-041, in contrast, do not induce uterine growth [19,128].  Thus, the findings 
regarding ERβ selective agonists combined with the low levels of ERβ in the uterus excludes ERβ 
as the subtype eliciting the effect of Cyclopia extracts in the uterus.  It is thus likely that the effect 
of Cyclopia extracts is due to ERα antagonism, as seen in the transactivation model in COS-1 cells, 
or that upon binding to the ER, the Cyclopia extracts induce a change in conformation that inhibits 
co-activator recruitment or activates co-repressor recruitment.  The inability of the Cyclopia 
extracts to induce uterine growth, in contrast to MCF-7BUS cell proliferation, might also be 
attributed to either the differences in the concentration of co-regulators or the differences in co-
regulator recruitment in the breast and uterus [129,130]. 
Having established ER agonist and/or antagonist activity of Cyclopia extracts, we look towards 
HPLC data, from the current and previous studies, to identify the polyphenol(s) responsible for the 
observed effects.  The xanthones, mangiferin and isomangiferin, were identified in all Cyclopia 
extracts, but as mangiferin has no estrogenic potential, while isomangiferin has not previously been 
tested for estrogenicity [71], it is unlikely that the observed ER agonist/antagonist effects of 
Cyclopia can be ascribed to these polyphenols.  However, mangiferin has been shown to inhibit the 
proliferation of breast cancer cells via ER independent mechanisms [131] and therefore, as 
mangiferin is present in all extracts at relatively high amounts it cannot be excluded as the 
polyphenol antagonizing E2-induced MCF-7BUS cell proliferation.  Of the remaining polyphenols 
identified in the extracts the only aglycone present is the flavone, luteolin.  In vitro, luteolin binds to 
both of the ER subtypes, is an ERα and ERβ agonist, induces MCF-7BUS cell proliferation, and 
antagonizes E2-induced MCF-7BUS cell proliferation [62,63,71,132-134].  Therefore, with regards 




to the Cyclopia extracts, the ERβ agonism observed in the transactivation model, the induction of 
MCF-7BUS cell proliferation, and the antagonism of E2-induced cell proliferation may be ascribed 
to the presence luteolin in the extracts, however, the observed ERα antagonism in the 
transactivation model cannot.   Although luteolin is present in all extracts, the concentration is low.  
However, the 7-O-rutinoside of luteolin, scolymoside, is present in substantial amounts in all of the 
C. subternata extracts (presence was not evaluated in P104).  This rutinoside of luteolin has not 
previously been tested for estrogenicity [71], however, as glycosides may be hydrolyzed by 
intestinal β-glucosidases [135,136], the bioavailability of the aglycone, luteolin, and hence 
phytoestogenicity of the extracts may increase upon hydrolysis of scolymoside.  Furthermore, 
luteolin has been shown to have anti-tumor characteristics and can sensitize breast cancer cells to 
anti-tumor drugs such as tamoxifen [137] and therefore, the presence of luteolin, as well as 
scolymoside, in Cyclopia extracts can be seen as positive regarding chemoprevention as well as 
breast cancer treatment. Generally, the glycosides of polyphenols either display reduced estrogenic 
activity compared to the aglycones or have not been evaluated for estrogenicity [71].  Thus, if the 
hydrolysis of glycosides present in the Cyclopia extracts is considered, it allows us to evaluate the 
phytoestrogenicity of the aglycones alongside their glycosides: apigenin (aglycone of vicenin-2), 
eriodictyol (eriocitrin), hesperitin (hesperidin), phloretin (phloretin-3,5-di-C-glucoside), 
hydroxyphloretin (3-hydroxyphloretin-3’,5’-di-C-hexoside), and iriflophenone (iriflophenone-2-C-
β-glucoside and iriflophenone-di-O,C-hexoside).  However, as β-glucosidases are produced by 
intestinal flora [138,139], consideration of glycoside metabolism will not help to identify the 
polyphenols responsible for in vitro results but may only be relevant for interpretation of in vivo 
results.  For example, as luteolin and apigenin have been shown to significantly increase uterine 
weight, either in the presence or absence of estrogens [140,141], the effect elicited by Cyclopia 
extracts in vivo cannot be ascribed to luteolin, scolymoside, or vicenin-2.  The effect of the other 
identified polyphenols has not been evaluated in vivo and therefore we cannot definitively attribute 
the in vivo effect of the Cyclopia extracts to any of these polyphenols.  Of the glycosides, ericotrin 




and hesperidin have been tested for phytoestrogenicity in vitro [71].  However, hesperidin does not 
bind to the ER [62] or activate an ERE-containing promoter reporter construct [133].  Eriocitrin, 
however, has been shown to bind to only ERβ [62], but no work has been done to elucidate the 
estrogenic effect elicited by this polyphenol.  The dihydrochalcone, 3-hydroxyphloretin-3',5'-di-C-
hexoside, has previously been identified in Cyclopia [75].  3-Hydroxyphloretin-3',5'-di-C-hexoside 
has not been tested for estrogenicity, but aspalathin, a monoglucoside, has been shown to inhibit the 
proliferation of liver cells [142], however, due to the presence of unique drug metabolizing enzymes 
in the liver, the possibility of aspalathin metabolites eliciting this effect cannot be excluded nor can 
the results be extrapolated to breast cancer cells.  The phytoestrogenicity of the remaining 
glycosides and aglycones, as well as protocatechuic acid, has not been tested [71].  In summary, 
none of the compounds identified in the Cyclopia extracts can account for the observed ERα 
antagonism, some (luteolin and eriocitrin) may explain the observed ERβ agonism and others 
(mangiferin and aspalathin) should not be excluded as possible effectors of ER-independent effects 
on proliferation. Therefore, thus far, we cannot with certainty ascribe the effects observed with 
Cyclopia extracts in this study to any of the individual constituents of our extracts.  Although, 
further research regarding the polyphenol content, bioavailability, and estrogenic activity of our 
extracts is required to identify the compound causing the observed effects, we cannot exclude the 
possibility that a mixture of polyphenols is required to elicit the effects observed with Cyclopia 
extracts. 
Physiologically, our results may be assessed both in terms of treatment of menopausal symptoms 
(hot flashes, osteoporosis, and increased inflammation [2-4,52,90-92]) and prevention of estrogen 
replacement associated side effects (breast cancer and uterine proliferation [5,6,52]).  With regards 
to menopausal symptoms, the ERβ agonist MF101 [24], has been shown in clinical trials to reduce 
hot flashes and thus, the ERβ agonism of the Cyclopia extracts may be considered as a positive 
attribute.  Furthermore, with regards to the postmenopausal surge in inflammatory disorders the fact 
that the Cyclopia extracts displayed agonism in the transrepression model in MCF-7BUS cells may 




also be considered as a positive attribute for the treatment of postmenopausal inflammatory 
disorders.  With respect to the known roles of ER subtypes in breast cancer [15,22,37-43], the fact 
that extracts of Cyclopia antagonize ERα, while being ERβ agonists, may be beneficial.  In 
addition, the extracts were able to antagonize the proliferation of breast cancer cells in the presence 
of E2 at lower concentrations than that required for breast cancer cell proliferation.  Furthermore, 
not only do the Cyclopia extracts show potential as protectors against breast cancer development 
and inflammatory disorders, they also do this without promoting uterine growth, a negative SERM 
associated side effect [35,143]. 
Although Cyclopia extracts show potential to be developed as SERSMs, further work, which is 
ongoing, is needed to clarify their mechanism of action.  This includes, but is not limited to, directly 
comparing the Cyclopia extracts with the known SERMs tamoxifen and raloxifene, investigating 
the effect of Cyclopia extracts on ER subtype levels, ER homo- or heterodimerization, induction or 
inhibition of co-regulator recruitment, and the modulation of cancer development and progression 
in a rat breast cancer model.  In addition, further work is needed to identify the polyphenol(s) 
responsible for eliciting the observed effects and the possibility that distinct polyphenols present in 
Cyclopia, rather than an individual polyphenol, may be causing the observed ERα agonism and ERβ 
antagonism cannot be excluded.  
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Figure S1.  Determination of ERE-containing promoter reporter construct concentration.  (A & B) 
COS-1 cells, transfected with equal amounts of (A) ERα and (B) ERβ, and (C) MCF-7BUS cells were 
transfected with increasing amounts of the ERE-containing promoter reporter construct (ERE.vit2.luc) and 
treated with either solvent or E2 to determine at which concentration of the ERE-containing promoter 
reporter construct the highest induction of E2 is observed.  The dotted line through the bars represents the 
values for solvent control.  Fold induction is indicated in boxes above the E2 columns.  Mean ± SEM is of 
one experiment done with three to four repeats. 
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Figure S2.  Determination of NFκB-containing promoter reporter construct concentration.  (A & B) 
COS-1 cells, transfected with equal amounts of (A) ERα and (B) ERβ, and (C) MCF-7BUS cells were 
transfected with increasing amounts of the NFκB-containing promoter reporter construct 
(p(IL6kB)350hu.IL6Pluc+) and treated with either solvent, PMA or PMA + E2 to determine at which 
concentration of the NFκB-containing promoter reporter construct the highest repression by E2 of PMA 
induction is observed.  The dotted lines through the bars represent the values for either solvent control or 
10ng/ml PMA.  Percentage repression, where applicable, is indicated in boxes above the PMA + E2 columns.  
Mean ± SEM is of one experiment done with three repeats. 























































































































































































































Figure S3. The effect of the SM6Met and cup-of-tea extracts on immature rat uterine growth.  
Immature female wistar rats were treated with 2000, 200, and 20mg/kg body weight SM6Met and cup-of-tea 
for three consecutive days.  Animals were sacrificed on day four, (A) uteri were photographed and (B) wet 
and (C) blotted uterine/final body weight was determined.  One-way ANOVA with Dunnett’s post-test 
comparing all columns to solvent control (*, P<0.05; **, P<0.01; ***, P<0.001).  The dotted line through the 
bars represents the values for solvent control.  Mean ± SEM is of at least eight animals/group. 
 























































































































































































































































































































Figure S4.  The effect of E2, genistein, extracts of Cyclopia, and ICI on body and liver weight. Immature 
female wistar rats were treated for three consecutive days with 100µg/kg body weight (BW) E2, in the 
presence and absence of 2000mg/kg BW SM6Met or 10mg/kg BW ICI 182,780, 100mg/kg BW genistein, 
2000, 200, or 20mg/kg BW SM6Met, 2000, 200, or 20mg/kg BW cup-of-tea, and 10mg/kg BW ICI 182,780 
for three consecutive days.  Animal were sacrificed on day four and changes in (A) body and (B) liver 
weights were determined.  One-way ANOVA with Dunnett’s post-test comparing all columns to solvent 
control (*, P<0.05; **, P<0.01; ***, P<0.001).  The dotted line through the bars represents the values for 
solvent control (A and B) and 100µg/kg BW E2 (A).  Mean ± SEM is of at least five animals/group 
 
 



































































































Figure S5. The effect of different concentration of the SM6Met and cup-of-tea extracts on the onset of 
vaginal opening.  Immature female wistar rats were treated for 30 consecutive days with the SM6Met and 
cup-of-tea extracts and the day of vaginal opening was determined.  One-way ANOVA with Dunnett’s post-
test comparing all columns to solvent control (*, P<0.05; **, P<0.01; ***, P<0.001).  The dotted line through 
the bars represents the values for solvent control.  Mean ± SEM is of at least eight animals/group  




Table S1.  Summary of ER agonism and antagonism of Cyclopia extracts. 
Extract Type of 
extract 










    ERβ ERα Fig. 1 
   Transactivation:  MCF-7BUS cells + ERE-promoter reporter 
construct. 
ER nt Fig. 2 






 Fig. 3 
   Transrepression:  MCF-7BUS cells + NFκB-promoter reporter 
construct. 
ER - Fig. 4 
   Cell proliferation:  MCF-7BUS cells ER ER [1] 
    ER ER Figs. 5, 6 
SM6Met Methanol C. subternata Transactivation:  ERα and ERβ expressing T47D-KBluc cells 
stably transfected with ERE-promoter reporter construct. 
ER nt [2] 
   Transactivation:  COS-1 + hERα/hERβ & ERE-promoter 
reporter construct. 
ERβ ERα Fig. 1 
   Transactivation:  MCF-7BUS + ERE-promoter reporter 
construct. 
ER - Fig. 2 







   Transrepression:  MCF-7BUS cells + NFκB-promoter reporter 
construct. 
ER - Fig. 4 
   Cell proliferation:  MCF-7BUS cells ER nt [2] 
    ER ER Figs. 5, 6 
   Immature rat uterotrophic assay - ERα Fig. 7 
   Vaginal opening - ERα
f
 Fig. 8 
Cup-of-tea Water C. subternata Transactivation:  COS-1 cells + hERα/hERβ & ERE-promoter 
reporter construct. 
- ERα Fig. 1 
   Transactivation:  MCF-7BUS cells + ERE-promoter reporter 
construct. 
ER - Fig. 2 
   Transrepression:  COS-1 cells + hERα/hERβ & NFκB-promoter 
reporter construct. 
- ERβ & 
weak ERα 
Fig. 3 
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   Transrepression:  MCF-7BUS + NFκB-promoter reporter 
construct. 
ER ER Fig. 4 
   Cell proliferation:  MCF-7BUS cells ER nt [2] 
    Weak 
ER 
ER Figs. 5,6 
   Immature rat uterotrophic assay - ERα Sfig. 1 
   Vaginal opening - Weak ERα Sfig. 3 
a
Tested in the absence of E2. 
b
Tested in the presence of 10
-9
 M  E2. 
c
nt = not tested 
d
- = no effect 
e
Tested in the absence of exogenous estrogens. 
f
Tested in the presence of endogenous estrogens. 
1. Verhoog NJ, Joubert E, Louw A. (2007) Evaluation of the phytoestrogenic activity of Cyclopia genistoides (honeybush) methanol extracts and relevant 
polyphenols. J Agric Food Chem 55: 4371-4381. 
2. Mfenyana C, DeBeer D, Joubert E, Louw A. (2008) Selective extraction of Cyclopia for enhanced in vitro phytoestrogenicity and benchmarking against 
commercial phytoestrogen extracts. J Steroid Biochem Mol Biol 112: 74-86 
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Phytoestrogenic extracts of Cyclopia differentially targets 









4.1.  Introduction 
Estrogens are sex hormones traditionally linked to the development of the female reproductive tract and 
secondary sex characteristics [1-3] and can affect cell viability, cell proliferation, and gene expression 
[4,5].  Estrogens exert their biological function by binding to the estrogen receptor (ER), a member of 
the nuclear receptor family of transcription factors, in the target organ/tissue [2,6,7].  The ER exists as 
two subtypes, namely ERα and ERβ [8].  
Classically, upon estrogen binding, the ER undergoes a conformational change, dimerizes and binds to 
specific estrogen response elements (EREs), found in the promoter regions of estrogen responsive 
genes [2,4,5], however, tethering to DNA bound transcription factors (TFs) in the promoter region of 
affected genes has also been described [9-12].  The ER, even in the absence of ligand, is located 
primarily in the nucleus of the cell [13-16].  However, it has been shown that unliganded ERα shuttles 
from the nucleus to the cytoplasm [13].  Upon ligand activation both of the ER subtypes localize in the 
nucleus and form ordered clusters, which is indicative of areas of active transcription [16-18].  It has, 
however, been shown that different ER ligands can differentially affect both maximal nuclear 
localization and rate of nuclear localization [13,18].  Furthermore, different ER ligands have also been 
shown to result in dissimilar patterns of ER distribution within the nucleus, which correlates with 
different transcriptional outcomes [18,19]. 
The two ER subtypes, with opposing functions in breast cancer development and progression, adds to 
the complexity of ER signalling.  Specifically, it has been shown that ERα is associated with cell 
proliferation and the occurrence of breast cancer, whereas several studies have shown that ERβ acts as 
an antagonist of ERα in breast cancer and could act as an inhibitor of breast cancer development [20-
26].   Furthermore, although the two subtypes are co-expressed in approximately 60% of breast cancer 
tumours [27-29], higher ERα levels are associated with malignant tumours, while higher ERβ levels are 





associated with benign tumours [25,30].  In addition, it has been suggested that tissue specific 
responses to ER agonists and antagonists may depend more on the relative levels of each subtype rather 
than absolute levels [31-33].  These findings suggest that evaluating the effects of treatment on the ratio 
of ERα:ERβ would be more useful than evaluating effects on the subtypes separately.   
Although the ER subtypes complicate the understanding of ER signalling, it introduces an opportunity 
for novel drug development with the specific subtype protein levels as therapeutic targets.  Advances 
towards the targeting of ER protein levels have been made.  For example, the full ER antagonist, 
fulvestrant (ICI 182,780), a selective estrogen receptor degrader (SERD), promotes the degradation of 
ERα [34,35] while stabilizing ERβ protein levels [34].  Furthermore, fulvestrant inhibited the growth of 
breast tumour xenografts [36,37].  Unfortunately, during clinical trials, fulvestrant treatment caused 
undesirable side effects such as headaches, hot flushes, nausea, and disturbance of menses [38].  
Although these are seen as minor side effects, the poor bioavailability, as well as length of time that it 
takes to achieve a useful therapeutic concentration in target tissues, eliminates fulvestrant in the search 
for the ideal breast cancer treatment [36,39].  GW5638/DPC974, an orally active non-steroidal 
tamoxifen derivative and SERD [36,39], also down-regulates ERα levels [39,40].  Although further 
development of GW5638/DPC974 was discontinued, afore mentioned findings merits further 
investigation regarding SERDs and the modulation of ER subtype specific regulation of physiological 
processes. 
Extracts of Cyclopia (family: Fabaceae), an indigenous fynbos plant from the Western Cape province 
of South Africa [41,42], have previously been shown to bind to the ER and transactivate an ERE-
containing promoter reporter construct [43-45].  Furthermore, in Chapter 3 we showed that these 
extracts elicit ER subtype specific responses by acting as ERα antagonists and ERβ agonists.  
Collectively these findings suggested that the Cyclopia extracts may be worthwhile candidates to 





investigate for SERD activity, specifically, the ability of SERDs to down-regulate ERα [34,35,39,40] 
levels while stabilizing ERβ [35].  Therefore, in the MCF-7BUS cells, a human breast cancer cell line 
expressing both ERα and ERβ, we investigated the modulation by Cyclopia extracts of not only the ER 
subtypes levels individually, but also how these changes modified the ERα:ERβ ratio after treatment.  
As estrogen signalling is a product not only of estrogen binding to the ER, which is determined by the 
ER levels, but also ER nuclear localization [2,6,7,16,18], we in addition, using COS-1 cells transiently 
transfected with fluorescently tagged ER subtypes, investigated whether the Cyclopia extracts would 
alter the extent and rate of nuclear localization of the ER subtypes as well as nuclear distribution. 
4.2.  Material and methods 
4.2.1.  Test Compounds 
17β-Estradiol (E2), genistein, luteolin, enterodiol, and fulvestrant (ICI 182,780) were obtained from 
Sigma-Aldrich
®
, South Africa, and coumestrol was obtained from Fluka™ Analytical, Sigma-Aldrich
®
, 
South Africa.  The Cyclopia extracts, P104 [44], SM6Met [45] and cup-of-tea [45], were previously 
prepared.  E2, genistein, luteolin, enterodiol, coumestrol, ICI 182,780, and Cyclopia extract stock 
solutions were prepared in dimethylsulfoxide (DMSO). 
4.2.2.  Cell Culture 
COS-1, African green monkey kidney fibroblast cells (ATCC, United States of America), and MCF-
7BUS human breast cancer cells [46] (a kind gift from A. Soto, Tufts University, Boston, 
Massachusetts, United States of America) were maintained in high glucose (4.5 g/L) Dulbecco’s 
modified eagle’s medium (DMEM) (Sigma-Aldrich
®
) supplemented with 10% FCS (Highveld 
Biologicals, South Africa), 100 IU/ml penicillin and 100 µg/ml streptomycin (Gibco, Invitrogen™, 
South Africa), 2mM glutamine (Merck), 44mM sodium-bicarbonate (Gibco), 1mM sodiumpyruvate 





(Gibco), and 0.1mM non-essential amino acids (Gibco).  All cells were maintained in a humidified cell 
incubator, set at 97% relative humidity and 5% CO2 at 37˚C. 
4.2.3.  Western Blot 
MCF-7BUS cells were seeded into sterile 6-well tissue culture plates at a concentration of 2.5 x 10
5
 
cells/well and allowed 24 hours to settle.  On day two the cells were rinsed once with sterile phosphate 
buffered saline (PBS) (pre-warmed to 37˚C), medium changed to DMEM without phenol red 
supplemented with 10% charcoal treated FCS and 1% penicillin and streptomycin mixture, and treated 
for 24 hours with E2, polyphenols and Cyclopia extracts (concentrations used indicated in figures) 
where after cells were placed on ice and washed once with ice cold PBS.   
COS-1 cells were seeded in sterile 10 cm tissue culture plates at a concentration of 2 x 10
6
 cells/plate 
and allowed 24 hours to settle.  On day two the cells were rinsed once with sterile phosphate buffered 
saline (PBS) (pre-warmed to 37˚C), medium changed to DMEM without phenol red supplemented with 
10% charcoal treated FCS and 1% penicillin and streptomycin mixture.  Cells were transfected with 
either ERα (30, 150 or 300 ng hERα/10 cm plate) or ERβ (30, 150, or 300 ng hERβ/10 cm plate) using 
FuGENE
TM
 6 transfection reagent (Roche Applied Science, South Africa) as described by the 
manufacturer.  Empty vector (pGL2-Basic from Promega) was used to adjust all transfection conditions 
to a constant amount of total DNA/condition (300 ng).  Human (h) ERα (pSG5-hERα [47]) and ERβ 
(pSG5-hERβ [48]) expression plasmids were kind gifts from F. Gannon (European Molecular Biology 
Laboratory, Heidelberg, Germany).  Cells were left for 24 hours, replated into sterile 6-well tissue 
culture plates at a concentration of 2.5 x 10
5
 cells/well and allowed 24 hours to settle where after cells 
were placed on ice and washed once with ice cold PBS. 
Cell lysates from washed COS-1 and MCF-7BUS cells were prepared by adding lysis buffer A (10mM 
Hepes pH 7.5 (Gibco), 1.5mM MgCl2, 10mM KCl, 0.1% NP-40 (Roche Applied Science) and 





Complete Mini protease inhibitor cocktail (Roche Applied Science), shaking on ice for 15 min and 
freezing overnight at -20˚C.  On thawing, lysates were transferred to 1.5ml Eppendorf tubes on ice, 
centrifuged for 10 min at 12 000 x g at 4˚C and the cleared lysates were transferred to 1.5ml Eppendorf 
tubes on ice, alliquoted and stored at -20˚C until assayed.  Lysates (20µl) were separated on a 10% 
SDS-PAGE gel. Following electrophoresis, proteins were electro-blotted and transferred to a Hybond-
ECL nitrocellulose membrane (Amersham Biosciences, South Africa), which was probed for ERα 
(diluted 1:500), ERβ (1:250) and GAPDH (1:500). Proteins were visualized using HRP labelled anti-
rabbit antibody for ERα (1:2500) and ERβ (1:1000), or HRP labelled anti-mouse antibody for GAPDH 
(1:5000), and ECL Western blotting detection reagents (Pierce
®
, Thermo Fisher Scientific Inc., U.S.A.) 
and medical x-ray film (Axim (PTY) LTD., South Africa).  All antibodies, primary and secondary, 
were purchased from Santa Cruz Biotechnology, Inc., U.S.A.  To determine relative ERα and ERβ 
levels the x-ray film bands of ERα, ERβ and GAPDH were quantified using UN-SCAN-IT software 
and results expressed as the intensity of the ERα or ERβ band relative to the GAPDH band. 
4.2.4.  Whole-cell binding assays 
COS-1 cells transfected with ERα and ERβ for Western blot analysis were also replated for whole-cell 
binding assays into sterile 24-well tissue culture plates at a concentration of 5 x 10
4 
cells/well.  Cells 
were allowed 24 hours to settle and washed three times with 500 μl PBS (pre-heated at 37°C) to 
remove any endogenous estrogen-like compounds present in the culture medium. 
To determine the estrogen receptor subtype affinity (Kd) for E2, DMEM containing 10 or 20 nM 
radiolabelled estradiol (
3
H-E2, specific activity = 100 Ci/mmol, American Radiolabeled Chemicals, 
Inc., St. Louis, Missouri, USA) in the absence or presence of increasing amounts of unlabeled E2 were 
added to cells, which were incubated at 37 ˚C.  After four hours plates were placed on ice, the medium 
aspirated and the cells washed three times with ice cold bovine serum albumin-PBS (0.2%) for 15 





minutes at 4˚C.  One hundred microliters of lysis buffer (0.2% (v/v) Triton, 10% (v/v) glycerol, 2.8% 
(v/v) Tris-phosphate-EDTA and 1.44 mM EDTA) was added to each well where after the plates were 
shaken at room temperature for 15 min and frozen overnight at -20˚C.  On thawing of samples, 5 µl of 
lysate from each well was used for protein determination using the Bradford method [49].  The 
remaining lysate was transferred to scintillation vials to which 1.5 ml of scintillation fluid (Quickszint 
FLOW 2, Zinsser Analytic, South Africa) had been added.  Radioactivity of the assay samples was 
determined using a Perkin Elmer Tri-Carb
®
 B2810TR liquid scintillation analyser and Quantasmart™ 
software (Separation Scientific, South Africa).  As homologous competitive binding was used, the Kd 
may be directly determined from the IC50 value for each concentration of 
3
H-E2 using the following 
formula:  IC50 = [
3
H-E2] + Kd.  The Kd for the three concentrations of transfected ER of both subtypes 
was determined by using the global fit model of GraphPad Prism
®
 version 5.10 for Windows 
(GraphPad Software).  A global fit model defines a family of curves and it is useful as it allows sharing 
of parameters between data sets and for each shared parameter the program will find one (global) best-
fit value that is applicable to all data sets. To fit one transfected concentration (30, 150, or 300 ng) of a 
specific ER subtype data, the program was instructed to fit one value for receptor number (Bmax) and 
one value for receptor affinity (Kd) that applied to both concentrations of 
3
H-E2 (10 and 20 nM) data 
sets.  Furthermore, to determine the specific estrogen binding for the three concentrations of transfected 
ER of both subtypes, DMEM containing either 10 nM 
3
H-E2 or 10 nM 
3
H-E2 and a 1000 fold 
unlabelled E2 were added to appropriate wells.  Cells were incubated at 37 ˚C for four hours where after 
cells were lysed and the protein concentration and radioactivity determined as described above.  
Specific binding was calculated as total binding (10 nM 
3
H-E2) – non-specific binding (10 nM 
3
H-E2 + 
1000 fold unlabelled E2).  The use of specific binding values is usefull as it corrects for the binding of 
3
H-E2 to any sites other than the ER.  Furthermore, the obtained specific binding (cpm/mg protein) and 





previously determined Kd values were also used to determine the concentration in fmol ER/mg protein 
of expressed receptor from the transfected ER using the following equations: 
Convert cpm to dpm: 
                                                dpm = cpm x (100/Counting Efficiency)              [1] 
(CE was 37.2% in our system)                          
Convert dpm to Ci: (1 Ci = 2.22 x 10
12 
dpm): 
                                                      Ci = dpm (Equation 1)/ 2.22 x 10
12
                                            [2] 
Convert Ci value to fmol using specific activity (SA) of ligand in Ci/mmol:  
SA for 
3
H-E2 = 100 Ci/mmol 
                                               Fmol (10
-12
 mol) = ((Ci (Equation 2)/SA)) . 10
12                                        
[3] 
And thus 
                                     fmol/mg protein = fmol (Equation 3) /mg protein = Ymax                           [4] 
The Ymax (Equation 4) in fmol/g protein, Kd, and [Ligand] values in nM are now known and therefore 
Bmax may be calculated in fmol/mg protein (Equation 5). 
 
                                                Bmax = (Ymax ([Ligand] + Kd))                                                         [5] 
[Ligand] 
 
4.2.5.  Quantification of MCF-7BUS Western Blots 
To obtain quantitative ER subtype protein values from the qualitative Western blots the three standard 
ERα/ERβ concentrations, from the same transfection as used for whole cell binding of which the 
expressed protein values, in fmol/mg protein, are known, were separated on a 10% SDS-PAGE gel 
along with the treated MCF-7BUS lysates.  ER proteins were visualized using appropriate anti-bodies 
as described above and the bands were quantified using UN-SCAN-IT software to obtain pixel values, 





which represents the ERα or ERβ band intensity relative to the intensity of the GAPDH band.  The 
pixel values of the three standard ERα/ERβ concentrations were plotted against the known ERα/ERβ 
expressed values in fmol/mg protein to generate a standard curve.  Using this standard curve and the 
pixel values of treated MCF-7BUS samples, quantitative protein values were determined, which was 
used to determine the ERα:ERβ ratio in treated MCF-7BUS cells. 
4.2.6.  Live cell nuclear import 
COS-1 cells were seeded into eight chamber tissue culture plates on day one at a concentration of 2 x 
10
4
 cells/chamber and allowed to settle for 24 hours.  On day two the cells were rinsed once with sterile 
phosphate buffered saline (PBS) (pre-warmed to 37˚C) and medium changed to  high glucose (4.5 g/L) 
DMEM without phenol red supplemented with 10% charcoal treated FCS and 1% penicillin and 
streptomycin mixture.  COS-1 cells were transfected with either 200 ng/chamber pCMX-ERα-YFP or 
200 ng/chamber pCMX-YFP-ERβ and 600 ng/chamber of the pCMX-pL2 empty vector for a total 
DNA concentration of 800 ng/chamber using FuGENE
TM 
6 transfection reagent as described by the 
manufacturer.  The pCMX-ERα-YFP, pCMX-YFP-ERβ and pCMX-pL2 plasmid constructs were kind 
gifts from Dr. Wei Xu, McArdle Laboratory for Cancer Research, University of Wisconsin [27].  The 
medium was changed 24 hours after transfection and cells were incubated for an additional 24 hours to 
allow expression of constructs.  Cells were analysed at the Stellenbosch University’s central analytical 
facility imaging unit in the temperature-controlled chamber (37 ˚C) of an Olympus Cell system 
attached to an IX-81 inverted fluorescence microscope equipped with an F-view-II cooled CCD camera 
and a 150W Xenon lamp as light source, which is part of the MT20 excitation source. An Olympus 
Plan Apo N 60X/1.4 oil objective, an YFP filter set and the Cell
®
 imaging software were used for 
image acquisition and analysis.  Cells were induced with E2, polyphenols and Cyclopia extracts 
(concentrations used indicated in figures) and YFP images were taken every minute over a 30 min 





period.  Nuclear import was quantified as the increase in YFP fluorescence in the nucleus (within a 
region of interest) over the period of stimulation.  Fluorescence in the nucleus of solvent treated control 
cells was subtracted from all time points (baseline correction) and a one phase exponential association 
curve was fit to the data. The generated half time (t1/2) represents the time it takes to achieve 50% of 
maximal YFP nuclear accumulation. 
To determine nuclear YFP-ER distribution cells with clear nuclear distribution was chosen at time 
points 0, 15, and 30 minutes.  As long a line as possible was drawn through the nuclei of selected cells 
avoiding nucleoli and the Cell
®
 imaging software was used to quantify YFP fluorescence intensity 
along this line.  GraphPad Prism
®
 software was used to quantify the coefficient of variation (CV) of 
YFP fluorescence intensity along the drawn line.  A lower CV indicates a more random nuclear 
distribution, while a higher CV value is indicative of a more ordered nuclear distribution [50]. 
4.2.7.  Data manipulation and statistical analysis 
The GraphPad Prism
®
 version 5.10 for Windows (GraphPad Software) was used for graphical 
representations and statistical analysis.  One-way ANOVA and Dunnett’s post-test comparing all 
columns to the solvent control were used for statistical analysis and significance is displayed on the 
graphs.  For all experiments the error bars represent the SEM of at least two independent experimental 
repeats. 
4.3.  Results 
4.3.1.  The Cyclopia extracts down-regulated ERα, while up-regulating ERβ in the human breast 
cancer cell line, MCF-7BUS 
Estrogens exert their biological function through the ER, which exists as two subtypes, ERα and ERβ 
[2,6-8].   













































































































































































































































































































































































































































































































































Figure 1.  In MCF-7BUS cells the Cyclopia extracts down-regulated ERα protein levels and up-regulated 
ERβ levels.  Clear lysates of MCF-7BUS cells treated with either E2, polyphenols, or Cyclopia extracts in the   
absence (A, B & C) or presence (D, E & F) of 10
-9
M E2 were subjected to Western blotting and probed with 
subtype specific ERα- (A, B, D & E) and ERβ (A, C, D & F) antibodies.  (A & D) Representative blots of 
independent experiments that were quantified with UNSCAN-IT software (B, C, E & F).  Statistical analysis was 
done using One-way ANOVA with Dunnett’s post-test comparing all columns to the either solvent control (B & 
C) or 10
-9
M E2 (E & F) (*, P<0.05; **, P<0.01; ***, P<0.001).  The dotted line through the bars represents the 
values for solvent control (B & C) or 10
-9
M E2 (E & F).  Mean ± SEM is of three (B, C & E) or two (F) 
independent experiments. 
ERα is associated with cell proliferation and the occurrence of breast cancer, while several studies have 
shown that ERβ acts as an antagonist of ERα in breast cancer and could act as an inhibitor of breast 
cancer development [20-26].  Furthermore, higher ERα levels are associated with malignant tumours, 
while higher ERβ levels are associated with benign tumours [25,30].  Therefore, we evaluated the 
effect of Cyclopia extracts on the ER subtype levels in MCF-7BUS, which express both subtypes 
(Chapter 3). 
Western blots indicate that ERα protein levels were significantly down-regulated (by 77%) by 10
-9
M E2 
when compared to solvent treated cells (Figs. 1A&B).  The methanol extracts of Cyclopia, P104 and 
SM6Met, like E2, also significantly down-regulated ERα protein levels, by 68% and 33%, respectively 
of solvent values. The water extract, cup-of-tea, also down-regulated ERα protein levels (by 20%), 
however, values did not reach significance.  In contrast, the polyphenols had no significant effect on 
ERα protein levels.  E2 had no significant effect on ERβ protein levels (5% down-regulation) unlike all 
of the Cyclopia extracts, which significantly up-regulated ERβ protein levels (P104 by 160%, cup-of-
tea by 229%, and SM6Met by 217%) (Figs. 1A&C).  All of the polyphenols, like the Cyclopia extracts, 
up-regulated ERβ protein levels although the luteolin values did not reach significance. 
We also evaluated the effect of Cyclopia extracts on ERα and ERβ protein levels in the presence of 10
-
9
M E2 (concentration reflects pre-menopausal E2 levels [51] and was found to induce highest MCF-
7BUS cell proliferation in Chapter 3).  All of the extracts of Cyclopia, in the presence of 10
-9
M E2 were 





able to down-regulate, although not significantly, ERα levels further than E2 alone (P104 by 37%, cup-
of-tea by 47%, and SM6Met by 41% relative to E2 alone) (Figs. 1D&E), which correlates with the 
findings that Cyclopia extracts on their own possessed the ability to down-regulate ERα (Fig. 1B).  The 
polyphenols, genistein and luteolin, like the Cyclopia extracts, also down-regulated ERα protein levels 
in the presence of 10
-9
M E2.  However, ERβ levels in the presence of E2 were up-regulated by all of the 
Cyclopia extracts and most of the polyphenols, except luteolin, although the values did not reach 
significance (Figs. 1 D&F). 
In conclusion, the Cyclopia extracts down-regulated ERα protein levels in MCF-7BUS cells, both in 
the absence (Fig. 1B) and presence (Fig. 1E) of E2, while all of the Cyclopia extracts stabilized ERβ 
protein levels in both the absence (Fig. 1C) and presence (Fig. 1F) of E2.  Considering the known roles 
of the ER subtypes in breast cancer [20-26] these results may be seen as positive attributes of the 
Cyclopia extracts in terms of breast cancer prevention or treatment.  However, as several studies have 
suggested that the ERα:ERβ ratio rather than the absolute subtype levels may be important in breast 
cancer [31-33] we next set out to evaluate the effects of the Cyclopia extracts on this ratio. 
4.3.2.  Combining Western blotting with whole cell binding allows for the quantification of ER subtype 
protein levels. 
Western blotting is a technique most suited to evaluating relative changes in concentrations of specific 
proteins like ERα and ERβ, however, as ERα and ERβ specific antibodies may have different affinities 
for their cognate proteins, Western blotting alone would not be adequate to evaluate the modulation of 
the ERα:ERβ ratio.   To overcome this we reassessed results obtained with Western blotting, which 
could illustrate subtype specific modulation of ER levels by treatments, using a standard curve where 
pixels obtained from Western blots are correlated with ER concentration in fmol/mg protein as 
determined with whole cell binding using radiolabelled E2 (Fig. 2). 





First, towards determining expressed ER concentration in fmol/mg protein, we determined the Kd 
(binding affinity) values for all three concentrations (30, 150, and 300ng) of transfected ERα (Fig. 3A) 
and ERβ (Fig. 3B) in COS-1 cells.   
COS-1 cells + ER or ER
standards (30, 150, and 300ng)
Treated MCF-7BUS cells
Western blot Whole cell binding
to determine








Figure 2.  The sequence of experimental procedures to quantify relative ERα and ERβ protein levels in 
MCF-7BUS cells after treatment.  COS-1 cells were transiently transfected with 30, 150, and 300 ng ERα or 
ERβ.  The transfected cell were subjected to Western blotting as well as whole cell binding to determine the ER 
subtype concentrations in both pixels and fmol/mg protein.  From these values a standard curve was generated, 
which was used to determine relative ER subtype concentrations in MCF-7BUS cells treated with polyphenol 
and Cyclopia extracts in the absence or presence of 10
-9
M E2. 
The Kd value was determined for each concentration of ER subtype, as it has been shown that 
increasing concentrations of steroid receptor results in co-operative ligand binding, which may 
influence the binding affinity of the ligand [52-54].   
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Figure 3.  Combining Western blotting with whole cell binding for the quantitative quantification of ER 
subtype protein levels.  The binding affinity of E2 for (A) ERα and (B) ERβ at 30, 150, and 300 ng transfected 
ER was determined using competitive whole cell binding.  Clear lysates of treated MCF-7BUS and untreated 
COS-1 cells (COS-1 cells transfected with either 30ng, 150ng, or 300ng pSG5-hERα or 30ng, 150ng, and 300ng 
pSG5-hERβ) were subjected to Western blotting and probed with subtype specific ERα- and ERβ antibodies, 
quantified with UNSCAN-IT software, and standard curves were generated plotting relative (C) pSG5-hERα or 
(D) pSG5-hERβ protein band intensities, in pixel concentration, against either ng transfected ER or fmol 
expressed ER/mg protein.  Expressed ER protein levels (fmol ER/mg protein) were calculated using 
experimentally determined Kd values as well as a published Kd values [55].  Mean ± SEM is of two to three 
independent experiments. Figures (C) and (D) are representative standard curves of 6 independent experiments 
as standard curves are generated after each Western blot. 
Our Kd values indeed decreased, indicating increased affinity, within increasing concentrations of 
transfected ER, which supports the findings that higher ER concentrations display co-operative ligand 
binding.  However, our Kd values were in the μM range whereas most published Kd values for ER are 
in the nM range [52,54-56].  Although unlikely, the difference between the experimentally determined 
Kd values and the published Kd values may be ascribed to the presence of tritiated E2 binders other 
than the ER, which, in future, should be evaluated by performing whole cell binding studies in 
untransfected COS-1 cells.  To evaluate the influence of this difference we used both our 
experimentally determined Kd values as well as published Kd values (ERα = 0.05 nM and ERβ = 0.09 
nM) [55]) to calculate the concentration of ERα and ERβ.  As Table 1 shows the difference in Kd 
values had little effect on the calculation of ER concentration in fmol/mg protein. 
Having established the Kd values for each concentration of transfected ER we determined the 
concentration of expressed ER in fmol/mg protein using the equations described in the materials and 
methods section of this chapter.  Western blots were performed on lysates of COS-1 cells transfected 
with the three standard ER concentrations used to determine the Kd values.  Linear standard curves 
were generated by plotting the band intensities, in pixels, of the Western blots obtained with the three 
ER standards against the ng transfected ER, as well as the calculated fmol expressed ER/mg protein for 
ERα (Fig. 3C) and ERβ (Fig. 3D).  Furthermore, we also plotted ng transfected ER against fmol 





expressed ER/mg protein.  The correlation between pixels and fmol expressed ER/mg protein was 
excellent (r
2
 varying between 0.98 and 1.00), however, the correlation between pixels and ng 
transfected ER and ng transfected ER and fmol expressed ER/mg protein was less good (r
2
 varying 
between 0.80 and 0.91).  This may be due to the fmol/mg protein values not linearly increasing as more 
ER is transfected into the COS-1 cells and therefore, the doubling of ng transfected ER (150ng to 
300ng) is not reflected by a doubling of fmol/mg protein expressed.  We would thus expect that 
calculation of the ERα:ERβ ratio using ng transfected ER would be higher than the ratio calculated 
using fmol expressed ER/mg protein.  We used both ng transfected ER as well as fmol expressed 
ER/mg protein to calculate the ERα:ERβ ratios, however, as the correlation between pixels and fmol 
expressed ER/mg protein is higher we would accord more weight to ERα:ERβ ratios calculated in this 
manner. 
4.3.3.  Cyclopia extracts decreased the ERα:ERβ ratio in MCF-7BUS cells. 
The co-expression of ERα and ERβ has been shown to inhibit the proliferative effect of ERα [20-26].  
Also, cells expressing higher levels of ERα compared to ERβ show ERα dependent increases in growth 
while growth is inhibited in cells expressing equal amounts of ERα and ERβ.  Therefore, it has been 
suggested that the ratio of ERα:ERβ in the same tumour cell is an important to predictor of the 
physiological effect of treatments [32,57,58].  We thus propose that treatments that increase the relative 
amount of ERβ compared to ERα would be favourable for breast cancer treatment and/or prevention 
and wanted to evaluate the modulation of the ERα:ERβ ratio in MCF-7BUS cells treated with Cyclopia 
extracts. 
Western blots were performed on lysates from treated MCF-7BUS cells together with lysate standards 
prepared in COS-1 cell for which fmol expressed ER/mg protein had been established using whole-cell 
binding (Fig. 2).  Standard curves were established for each ER subtype (Fig. 3C & D) and used to 





correlate band intensity (pixels) of lysates from the treated MCF-7BUS cells with ng transfected ER as 
well as fmol expressed ER/mg protein.   
Table 1.  The modulation of relative ERα:ERβ levels by polyphenols and Cyclopia extracts in both the 
absence and presence of E2 in MCF-7BUS cells.  MCF-7BUS cells were treated with polyphenols and 
Cyclopia extracts in the absence (A) or presence (B) of 10
-9
M E2.  Standard curves, generated as explained in the 
materials and methods section, were used determine relative ERα:ERβ levels after 24 hour treatment period.  
Statistical analysis was done using One-way ANOVA with Dunnett’s post-test comparing all columns to the 






, p<0.001) or  10
-9
M E2 (A&B) treated cells (*, P<0.05; **, P<0.01; 
***, P<0.001).  Mean ± SEM is of two to three independent experiments. 
 ERα : ERβ Ratio 
(ng Transfected 
receptor) 
ERα : ERβ Ratio 
(fmol/mg protein 
Experimental Kd) 





M E2 1 : 49.59 ± 10.48    1 : 24.11 ± 3.76 1 : 24.96 ± 4.01 
+ 10
-9
M Genistein 1 : 33.11 ± 23.30  1 : 19.05 ± 13.90 1 : 18.95 ± 18.83 
+ 10
-9
M Luteolin 1 : 9.59 ± 6.36 1 : 5.12 ± 3.24 1 : 5.10 ± 3.22 
+ 10
-9
M Enterodiol 1 : 124.50 ± 122.60 1 : 72.65 ± 71.68 1 : 72.28 ± 71.32 
+ 10
-9
M Coumestrol 1 : 45.13 ± 39.44 1 : 26.19 ± 23.21 1 : 26.06 ± 23.09 
+ 9.8µg/ml P104 1 : 45.66 ± 20.80 1 : 25.93 ± 12.90 1 : 25.80 ± 12.83 
+ 9.8µg/ml Cup of Tea 1 : 47.16 ± 35.47 1 : 27.20 ± 21.07 1 : 27.06 ± 20.96 




 ERα : ERβ Ratio  
(ng Transfected 
receptor) 
ERα : ERβ Ratio  
(fmol/mg protein  
Experimental K d) 
ERα : ERβ Ratio  
(fmol/mg protein  
Literature K d) 
Solvent 1 : 4.02 ± 0.01***  1 : 3.18 ± 0.74***  1 : 3.32 ± 0.88***  
10
-9
M E2 1 : 59.71 ± 4.70
###
    1 : 27.59 ± 2.47
###





M Genistein  1 : 18.28 ± 1.51**  1 : 8.43 ± 0.61** 1 : 8.90 ± 1.08**  
10
-9
M Luteolin 1 : 18.45 ± 5.01**  1 : 5.19 ± 0.95***  1 : 5.50 ± 1.29***  
10
-9
M Enterodiol  1 : 23.65 ± 9.36**  1 : 8.49 ± 3.40*** 1 : 9.01  ± 3.92** 
10
-9
M Coumestrol  1 : 25.19 ± 6.59**  1 : 8.52 ± 3.51*** 1 : 9.02 ± 3.96** 
9.8µg/ml P104  1 : 32.86 ± 2.45*
,#
 1 : 15.18 ± 1.29*
,#
 1 : 15.91 ± 0.57*
,#
 
9.8µg/ml Cup of Tea  1 : 46.81 ± 0.72
##
 1 : 21.61 ± 0.10
,##
 1 : 22.75 ± 1.23
,##
 
9.8µg/ml SM6Met  1 : 24.82 ± 8.01**  1 : 6.27 ± 1.58***  1 : 6.25 ± 1.60***  
 
 





We used not only the experimentally calculated Kd values but also literature Kd values to determine 
fmol expressed ER/mg protein.  Generally, as expected, the ERα:ERβ ratio calculated using fmol 
expressed ER/mg protein was higher than when calculated using ng transfected ER, however no 
significant difference was observed  between ratios of fmol expressed ER/mg protein calculated using 
experimental vs. literature Kd values (Table 1).  Treatment with 10
-9
M E2 significantly increased the 
amount of ERβ relative to ERα (Table 1A) and this may be attributed to the robust down-regulation of 
ERα protein levels by E2 without any significant effect on ERβ protein levels (Figs. 1A, B, & C).  The 
Cyclopia extracts, P104 and cup-of tea, also significantly up-regulated the levels of ERβ relative to 
ERα when compared to solvent treated cells, but not to the same extent as E2.  Furthermore, this 
elevated ratio of ERα:ERβ was obtained by down-regulating ERα and up-regulating ERβ, while E2 
only down-regulated ERα (Figs. 1A, B, & C).  SM6Met had no significant effect on the ERα:ERβ ratio 
when compared to solvent, although it was able to both down-regulate ERα protein levels and up-
regulate ERβ protein levels (Figs. 1A, B, & C). 
The same experimental approach was followed to evaluate the changes in the ERα:ERβ ratio exerted by 
treatment with the Cyclopia extracts in the presence of 10
-9
M E2 (Table 1B).  Although no significant 
changes in the ERα:ERβ ratio relative to E2 was observed, a trend towards higher ERβ relative to ERα 
protein levels is observed with the SM6Met extract and E2 co-treatment compared to E2 treatment 
alone.  Furthermore, when comparing effects of Cyclopia extracts alone with effects in the presence of 
E2 it is clear that E2 further reduces the ERα:ERβ ratio.   
To conclude, our findings suggest that although the phytoestrogenic Cyclopia extracts modulated the 
ERα:ERβ ratio in the same manner as E2 (Table 1), the mechanism whereby the ratio was modulated is 
different from that of E2 in that E2 only down-regulated ERα, while, the Cyclopia extracts both down-
regulated ERα and up-regulated ERβ protein levels (Fig. 1). 





4.3.4.  The methanolic extracts of Cyclopia induced increased nuclear localization of ERβ, but reduced 
nuclear localization of ERα, when compared to E2. 
Although the ER resides mostly in the nucleus of cells, the receptor does move between the nucleus 
and the cytoplasm [13-15].  Furthermore, findings that the pure ER antagonists, fulvestrant and ICI 
164,384, disrupt movement of the ER into the nucleus by either blocking re-uptake of the ER into the 
nucleus or by concentrating the ER in other cellular compartments, thereby contributing to the 
disruption of ER signalling [13], prompted us to evaluate how treatment with Cyclopia extracts would 
alter nuclear import rate and maximum nuclear localization of both ER subtypes.  COS-1 cells 
transfected with either yellow fluorescent protein tagged ERα (YFP-ERα) or YFP-ERβ were used to 
monitor nuclear translocation in real time in live cells. 
The YFP-ERα (Fig. 4A) as well as the YFP-ERβ (Fig. 5A) resided mostly in the nucleus of cells at 0 
minutes of treatment (Figs. 4A & 5A, top panel).  By selecting a region of interest (ROI) within each 
nucleus, shown in red in Figs. 4A & 5A for E2 treatment as an example, we could measure the change 
in fluorescent intensity between 0 and 30 minutes (Figs. 4A & 5A, bottom panel) of treatment.  
Changes in fluorescence intensity are indicative of changes in ER number and the changes between 0 
and 30 minutes are shown for ERα (Fig. 4B) and ERβ (Fig. 5B).  The nuclear localization may be 
plotted using exponential one phase association curves to determine maximal nuclear localization and 
the rate of nuclear localization as the time required to reach 50% of maximal nuclear localization (t1/2). 
For ERα (Fig. 4B&C), the calculated maximal nuclear localization of YFP-ERα after 30 minutes of 
treatment with 10
-9
M E2 was set as 100% import (Fig. 4C).  The Cyclopia extracts resulted in 
significantly lower localization of ERα (19%, 52%, and 35% for P104, cup-of-tea, and SM6Met, 
respectively).   






































































































































































































































































































































































































































































































Figure 4.  Treatment for 30 minutes with Cyclopia extracts induces faster nuclear import of ERα, 
compared to E2, but does not concentrate ERα in the nucleus to the same extent as E2.  COS-1 cell were 
transiently transfected with (A) YFP-ERα and fluorescent intensity was monitored for 30 minutes (A & B).  (A) 











coumestrol, 9.8μg/ml P104, 9.8μg/ml cup-of-tea, or 9.8μg/ml SM6Met.  YFP images were taken every 10 
seconds for 30 minutes and (A) is representative of a single cell at time point 0 (top panel) and 30 (bottom panel) 
minutes.  The red circle within the nucleus represents the region of interest (ROI). (B) Representative graph 
depicting changes in fluorescent intensity, within the ROI, over 30 minutes. Values for solvent control were 
baseline subtracted.  Representative graphs depicting calculated maximal nuclear localization (C), measured 
maximal nuclear localization (D) and t1/2 values (E) for this period.  The calculated maximal nuclear localization 
and t1/2 values were determined with the GraphPad Prism
®
 software fitting a one-phase association curve. 
Statistical analysis was done using One-way ANOVA with Dunnett’s post-test comparing all columns to the E2 
treated cells (*, P<0.05; **, P<0.01; ***, P<0.001).  Mean ± SEM is of two cells/treatment of two independent 
experiments.  r
2
 value depicts goodness of fit.  (C-E) Dotted line through graphs represents 10
-9
M E2 values. 
However, these calculated values were obtained using an exponential one-phase association curve fit 
and therefore, the accuracy of the obtained maximal nuclear localization values are dependent on the 
quality of curve fit as well as the plateauing of the curve indicating that an equilibrium between import 
and export has been obtained.  As the quality of the fit, depicted by r
2
 values in the figure legend (Fig. 
4B), was not good (r
2
 values should be as close to 1 as possible) and no distinguishable plateau was 
reached after 30 minutes for several treatments, the calculated theoretical maximal nuclear localization 
values do not always reflect what is observed in the graph.  Therefore, the measured values at the 30 
minute time point were also plotted for each of the treatments (Fig 4D).  At 30 minutes, the measured 
ERα nuclear localization values after treatment with the methanol extracts of Cyclopia still resulted in 
low ERα nuclear localization in comparison to E2, reflecting the calculated maximum localization 
values. However, treatment with the water extract, cup-of-tea, in contrast to the calculated findings, had 
a similar measured ERα nuclear localization value as E2.  Treatment with the polyphenols, like with the 
Cyclopia extracts, resulted in significantly lower calculated ERα nuclear localization when compared to 
E2 treatment.  Calculated values for enterodiol, however, could not be obtained as the exponential one-
phase association curve could not be accurately fitted.  Calculated maximal localization values of ERα 
for the polyphenols generally held when measured at 30 minutes with the exception of genistein and 
luteolin, which displayed increased nuclear localization relative to E2 when measured at 30 minutes. 



































































10-7M Coumestrol (does not fit)
9.8g/ml P104 (r2=0.31)
















































































































































































































































































































































Figure 5.  During a 30 minute period Cyclopia extracts, to a larger extent than E2, concentrates ERβ in the 
nucleus, but the rate of ERβ import into the nucleus is slower than that of E2.  COS-1 cell were transiently 
transfected with YFP-ERβ and fluorescent intensity was monitored for 30 minutes (A & B).  (A) Represents 










M coumestrol, 9.8μg/ml 
P104, 9.8μg/ml cup-of-tea, or 9.8μg/ml SM6Met.  YFP images were taken every 10 seconds for 30 minutes and 
(A) is representative of a single cell at time point 0 (top panel) and 30 (bottom panel) minutes.  The red circle 
within the nucleus represents the region of interest (ROI). (B) Representative graph depicting changes in 
fluorescent intensity, within the ROI, over 30 minutes. Values for solvent control were baseline subtracted.  
Representative graphs depicting calculated maximal nuclear localization (C), measured maximal nuclear 
localization (D) and t1/2 values (E) for this period.  The calculated maximal nuclear localization and t1/2 values 
were determined with the GraphPad Prism
®
 software fitting a one-phase association curve. Statistical analysis 
was done using One-way ANOVA with Dunnett’s post-test comparing all columns to the E2 treated cells (*, 
P<0.05; **, P<0.01; ***, P<0.001).  Mean ± SEM is of two cells/treatment of two independent experiments.  r
2
 
value depicts goodness of fit.  (C-E) Dotted line through graphs represents 10
-9
M E2 values. 
Exponential one-phase association curves, however, are useful as they allow us to determine t1/2 values 
(time to 50% maximal localization), but, as these values are dependent on the graph reaching a plateau 
(maximal localization) it could not be determined for treatments, like enterodiol, for which no plateau 
was reached.  The t1/2 values for ERα nuclear localization of the polyphenols and the Cyclopia extracts 
were significantly lower than that of E2, except for the SM6Met extract which was very similar to that 
of E2 (25.58 ± 6.75 vs. 29.94 ± 5.78 minutes, respectively) (Fig. 4E). 
With regards to ERβ (Fig. 5B), a plateau was not reached for most treatments after  30 minutes and 
thus maximum nuclear import values could either not be calculated or gave unrealistic values. The 
exceptions were the polyphenol, enterodiol, and the Cyclopia extracts, P104 and cup-of-tea (Fig. 5C).  
Therefore t1/2 values could only be calculated for enterodiol, P104 and cup-of-tea.  Although we are 
therefore not able to compare t1/2 values with that of E2 we can compare the t1/2 values for ERβ of these 
compounds with that of the t1/2 values for ERα.   With regards to P104 and cup-of-tea, the t1/2 values for 
ERβ were higher than those obtained for ERα (70.46 ± 51.52 vs. 6.27 ± 0.65 and 34.94 ± 14.31 vs. 6.24 
± 0.58 minutes, respectively).  Furthermore, with regards to the measured maximum nuclear 
localization values at 30 minutes, in contrast to ERα (Fig. 4), treatment with all of the polyphenols, 
except for coumestrol, and with the methanol extracts of Cyclopia resulted in higher measured maximal 
ERβ nuclear localization than with E2.  
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Figure 6.  Treatment for 10 minutes with Cyclopia extracts induces faster nuclear import of ERα, 
compared to E2, but the methanol extracts of Cyclopia does not concentrate ERα in the nucleus to the same 
extent as E2.  COS-1 cell were transiently transfected with YFP-ERα and fluorescent intensity was monitored 
for 10 minutes with YFP images taken every 10 seconds.  (A) Representative graph depicting changes in 
fluorescent intensity, within the ROI, over 10 minutes. Values for solvent control were baseline subtracted.  
Representative graphs depicting calculated maximal nuclear localization (B), measured maximal nuclear 
localization (C) and t1/2 values for this period (D).  The calculated maximal nuclear localization and t1/2 values 
were determined with the GraphPad Prism
®
 software fitting a one-phase association curve. Statistical analysis 
was done using One-way ANOVA with Dunnett’s post-test comparing all columns to the E2 treated cells (*, 
P<0.05; **, P<0.01; ***, P<0.001).  Mean ± SEM is of two cells/treatment of two independent experiments.  r
2
 
value depicts goodness of fit.  (B-D) Dotted line through graphs represents 10
-9
M E2 values. 
 





Upon closer inspection of the data obtained with the 30 minutes treatment of cells transfected with 
YFP-ERα (Fig. 4B) and YFP-ERβ (Fig. 5B) we observed an initial plateau of fluorescence intensity 
values before a second increase in fluorescence intensity.  This is most obvious for cup-of-tea via ERα 
(Fig. 4) and enterodiol and P104 via ERβ (Fig. 5).  To investigate this, we generated graphs using only 
the data points obtained within the first 10 minutes of treatment and determined the maximal 
localization (calculated and measured) and t1/2 values for both ERα (Fig. 6) and ERβ (Fig. 7) for this 
shorter time period.  Although generally the fit of the curves were not as good as for the 30 minute 
period we used the data to support conclusions reached concerning the Cyclopia extracts using the 30 
minute data sets. 
For ERα, measured maximum nuclear localization at 10 minutes confirmed (Fig. 6C) the fact that the 
methanol extracts of Cyclopia resulted in a lower maximal nuclear localization, while the water extract, 
cup-of-tea, resulted in a maximal nuclear localization either similar (30 minutes) or higher (10 minutes) 
than that achieved by E2.  Similarly, the absolute t1/2 values at 10 minutes suggest that the low values 
obtained at 30 minutes for P104 and cup-of-tea hold.  Although the t1/2 values for SM6Met appeared 
very different at the different time points (26 vs. 8 minutes), if we calculated the measured t1/2 values as 
a percentage of the total time (10 or 30 minutes) the proportional t1/2 values for the initial 10 minutes 
correlate well with the 30 minute values for all of the Cyclopia extracts.  For example, at 10 minutes 
SM6Met has a calculated t1/2 value of 8 minutes but a proportional t1/2 of 80% (8/10), while at 30 
minutes SM6Met has a calculated t1/2 value of 26 minutes but a proportional t1/2 of 86% (26/30).  
Similarly, the proportional t1/2 values for P104 are 20% at 30 minutes and 20% at10 minutes and for 
cup-of-tea they are 20% at 30 minutes and 40% at 10 minutes.   





























































































































































































































































































































































































































Figure 7.  During a 10 minute period Cyclopia extracts, to a larger extent than E2, concentrates ERβ in the 
nucleus, but the rate of ERβ import into the nucleus is slower than that of E2.  COS-1 cell were transiently 
transfected with YFP-ERβ and fluorescent intensity was monitored for 10 minutes with YFP images taken every 
10 seconds.  (A) Representative graph depicting changes in fluorescent intensity, within the ROI, over 10 
minutes. Values for solvent control were baseline subtracted.  Representative graphs depicting calculated 
maximal nuclear localization (B), measured maximal nuclear localization (C) and t1/2 values for this period (D).  
The calculated maximal nuclear localization and t1/2 values were determined with the GraphPad Prism
®
 software 
fitting a one-phase association curve. Statistical analysis was done using One-way ANOVA with Dunnett’s post-
test comparing all columns to the E2 treated cells (*, P<0.05; **, P<0.01; ***, P<0.001).  Mean ± SEM is of two 
cells/treatment of two independent experiments.  R
2
 value depicts goodness of fit.  (B-D) Dotted line through 
graphs represents 10
-9
M E2 values 
 





Therefore, our combined data suggests that P104 and cup-of-tea result in a significantly faster ERα 
nuclear import rate than SM6Met, which displays a nuclear import rate similar to that of E2.  For ERβ 
(Fig. 7), calculated and measured maximal nuclear localization values obtained within the first 10 
minutes of treatment were higher for all the Cyclopia extracts than for E2.  However, as similar results 
were only observed for P104 and SM6Met, but not cup-of-tea, at 30 minutes we can only definitively 
conclude that P104 and SM6Met treatment indeed resulted in greater ERβ maximal nuclear 
localization. 
In conclusion, within the limits of our system, the methanol extracts of Cyclopia did not concentrate 
ERα in the nucleus to the same extent as E2, however, ERβ was concentrated to a greater extent than 
for E2. Furthermore, P104 and cup-of-tea, but not SM6Met, displayed a faster import rate for ERα 
maximal nuclear localization than E2.  Together these results suggest that in terms of nuclear 
localization, the methanol extracts of Cyclopia display ERα antagonist behaviour and ERβ agonist 
behaviour [13,18].  However, as our conclusions are limited to two biological repeats, it would be 
advantageous to obtain a third biological repeat as it may provide more statistical power to the 
observed changes after treatments. 
4.3.5.  Treatment with Cyclopia extracts reduced ordered nuclear distribution of YFP-ERα, while 
increasing ordered nuclear distribution of YFP-ERβ in COS-1 cells. 
Upon ligand binding, nuclear receptors translocate to the nucleus and distributes in an orderly manner 
[18,50].  It has been shown, using green fluorescent protein tagged ER (GFP-ER), that upon agonist 
binding, the ER distributes in an ordered manner within the nucleus [18], while upon antagonist 
binding, a more random distribution of the ER is observed compared to agonist binding [18,19].  These 
studies, however, only evaluated the behaviour of the ERα subtype.   





To study the nuclear distribution of ERα and ERβ, we used the method of Schaaf et al. [50] and Htun et 
al. [18].  In brief, this method entails transiently transfecting COS-1 cells with YFP-ERα/β, inducing 
with ligand, obtaining YFP images of the nucleus at desired time points, and drawing a long as possible 
straight line through the nucleus of a cell avoiding nucleoli (Fig. 8A).  The coefficient of variation 
(CV) is then determined for the distribution of fluorescence intensity along this line (Fig. 8B).  A high 
CV value signifies an ordered nuclear distribution, whereas a low CV value points to random nuclear 
distribution of ER.  As this method is dependent on resolution, cells with a high as possible fluorescent 
resolution were chosen. 
In Fig. 8A representative micrographs of a cell with an increased CV value over time (10
-9
M E2, ERα) 
and a cell with decreased CV over time (9.8 μg/ml cup-of-tea, ERα) are shown. 
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Figure 8.  Cyclopia extracts reduced ordered nuclear distribution of YFP-ERα, whereas it increased 
ordered nuclear distribution of YFP-ERβ. COS-1 cells, transfected with either YFP-ERα or YFP-ERβ, were 
treated with E2, polyphenols or Cyclopia extracts for 30 minutes.  As long a line as possible (white line) was 
drawn within each nucleus, avoiding nucleoli and Cell
®
 software was used to quantify fluorescent changes along 
this line and GraphPad Prism
® 
software was used to calculate the CV of YFP fluorescent intensity.  (A) 
Representative images of E2 (high CV) and cup-of-tea (low CV) treated cells, transfected with YFP-ERα, at 0, 
15, and 30 minutes. (B) Representative graph of fluorescent intensity changes along the white line for E2 (23% 
CV) and cup-of-tea (7% CV) treated cells, transfected with YFP-ERα, at 30 minutes.  (C&D) Coefficient of 
variation (CV) of cells transfected with either YFP-ERα (C) or YFP-ERβ (D) treated with either E2, polyphenols, 
or Cyclopia extracts at 0, 15, and 30 minutes. Statistical analysis was done using One-way ANOVA with 
Dunnett’s post-test comparing all columns to the 0 minute column of each treatment (*, P<0.05; **, P<0.01; 






, p<0.001).  Mean ± SEM 
is of two cells/treatment of two independent experiments. 
The changes in fluorescent intensity along the white line drawn through cells (Fig. 9A) are shown in 
Fig. 8B (cells at 30 minutes).  For ERα (Fig. 8C), E2 and the polyphenol, genistein,  significantly 
increased the CV value along the line after 30 minutes of treatment, thus depicting a more ordered 
nuclear distribution of ERα, suggesting that genistein behaved like an ERα agonist.  In contrast, 30 
minutes of treatment with the Cyclopia extracts induced a nuclear distribution significantly less ordered 
(significantly lower CV) than that of E2, suggesting that the Cyclopia extracts act as ERα antagonists.  
No significant changes in CV values were obtained for ERβ (Fig. 8D).  However, when comparing the 
30 minute treatment values to the 30 minute value of the untreated control, a trend towards a higher CV 
value, and thus a more ordered nuclear distribution of ERβ, is observed for E2, the polyphenols and the 
methanol extracts of Cyclopia, P104 and SM6Met.  This ordered distribution is indicative of ERβ 
agonist activity [18,19].  In summary, the 30 minute treatment with Cyclopia extracts induced more 
random nuclear distribution of ERα than treatment with E2, indicating ERα antagonist activity, whereas 
a trend to a more ordered nuclear distribution of ERβ in cells treated with the Cyclopia extracts is 
observed, like for E2 treatment, indicating ERβ agonist activity. 
4.4.  Discussion 
In their lifetime approximately 1 out of 87 women in the United States will develop invasive breast 
cancer [59].  The sex hormone, estrogen, which can affect cell viability, cell proliferation, and gene 




expression [4,5], facilitates the development and growth of breast cancer [60,61].  Estrogens exert their 
function by binding to the ER [2,6,7], which exists as two subtypes, ERα and ERβ [8].  Furthermore, as 
ERβ has been shown to act as an inhibitor of ERα [20,23,26], which is associated with cell proliferation 
and breast cancer development [24], the modulation of the relative ER subtype protein levels, and thus 
also the biological processes under their control, has been identified as a molecular target in breast 
cancer and thus has become the focus of several strategies towards developing a treatment for the 
prevention and/or the treatment of breast cancer. 
With regards to the ER and its subtype protein levels, SERDs have been developed [34,38-40].  
Fulvestrant, a full ER antagonist, and GW5638/DPC974, a non-steroidal tamoxifen derivative [36,39], 
down-regulate ERα protein levels [34,35,39,40], while fulvestrant also stabilizes ERβ protein levels 
[34] and inhibits the growth of breast tumour xenografts [36,37].  In the current study we evaluated the 
effect of three phytoestrogenic extracts of Cyclopia on ER subtype protein levels, ERα:ERβ ratio, ER 
subtype nuclear localization and distribution. 
The extracts of Cyclopia, like E2, decreased the amount of ERα protein levels, while, unlike E2, 
significantly increasing the ERβ protein levels over a 24 hour period in MCF-7BUS cells (Fig. 1).  
Concerning E2 treatment, it is known that E2 treatment down-regulates ERα protein levels [34,62-64] 
by enhancing ERα ubiquination and consequent ubiquitin-proteasome pathway mediated degradation in 
rats and MCF-7, PR1 Lactotrope, and transiently transfected HeLa cells [64-67].  Furthermore, 
consistent with our findings, E2 slightly lowers ERβ protein levels in MCF-7 cells [34] and this 
decrease has also been shown to be mediated via the ubiquitin-proteasome pathway [68].  We may 
therefore postulate that the observed decrease in ERα protein levels by the methanol extracts of 
Cyclopia, P104 and SM6Met, is due to the ubiquination and consequent ubiquitin-proteasome pathway 
mediated degradation.  However, this should be verified by repeating our experiment in the presence of 
proteasome inhibitors such as MG132, lactacystin or proteasome inhibitor I (PI) as GW7604, the 




bioavailable metabolite of GW5638/DPC974, does not increase the ubiquination of ERα despite the 
fact that it down-regulates ERα [69]. 
To elucidate the mechanism whereby ERβ levels increased after treatment with Cyclopia extracts we 
look towards findings regarding fulvestrant, which stabilizes ERβ [34], and our results with 
polyphenols as we found that genistein, enterodiol, and coumestrol also significantly increased ERβ 
protein levels (Fig. 1).  With regards to fulvestrant, not much is known about how it stabilizes ERβ 
protein levels, except that the residue D489 in helix 12 (responsible for co-activator interaction [70]) is 
important for conveying stability to the fulvestrant-ERβ complex [34].  Furthermore, binding of the 
SERM, tamoxifen, to ERα conveys stability to the tamoxifen-ERα complex due to hypoubiquitination 
of ERα [69]. Therefore, we may speculate that binding of fulvestrant and the Cyclopia extracts to ERβ 
may induce a conformational change that inhibits ubiquination of the receptor.  This should be 
investigated.  However, we should also evaluate whether, or not, the increase in ERβ protein levels 
after treatment with the Cyclopia extracts is a consequence of increased mRNA levels by using 
cycloheximide, an inhibitor of protein synthesis. With regards to our findings concerning the effect of 
the polyphenols on ERα and ERβ, it has been shown that in porcine granulosa cells originating from 
medium follicles, genistein has no significant effect on ERα protein and mRNA levels, while 
increasing ERβ protein and mRNA levels [71] validating our findings. 
Although the most frequently occurring forms of breast cancer are both ERα and ERβ positive [27-29], 
during tumourigenesis the expression of ERβ is down-regulated, while ERα levels are up-regulated 
[72,73].  Therefore, the tempering effect ERβ on ERα [20,23,26,74] may be lost during breast cancer 
tumour progression when the ERα:ERβ ratio increases.  Therefore, by combining qualitative Western 
blotting with quantitative whole cell binding (Figs. 2&3), we evaluated how treatment with E2, 
polyphenols, or Cyclopia extracts changed the ERα:ERβ ratio (Table 1).  We found that treatment with 
E2 and the Cyclopia extracts decreased the ERα:ERβ ratio in comparison to solvent treatment.  




However, this favourable ratio was achieved by different mechanisms with the Cyclopia extracts down-
regulating ERα while also up-regulating ERβ, whereas E2 only robustly down-regulated ERα (Fig. 1). 
Although the observed decrease in the ERα:ERβ ratio with the Cyclopia extracts were promising, as 
increased ERβ relative to ERα would result in increased inhibition of ERα-induced cell proliferation 
[75,76], the fact that E2 resulted in a similar ratio, while associated with the promotion and growth of 
breast cancer [77], our result with E2, depicting a more favourable ERα:ERβ ratio, is confusing.  A 
possible scenario may involve effects of ER subtype levels on ER dimerization.  It is known that the 
ER can dimerize to from ERα/α or ERβ/β homodimers or ERα/β heterodimers [27,58] with the ERα/α 
homodimer accelerating and the ERβ/β homodimer, as well as the ERα/β heterodimer, inhibiting breast 
cancer cell proliferation [57].  With regards to our findings, the down-regulation of ERα may lead to 
the abolishment of ERα/α homodimers.  Furthermore, as ERα is the only heterodimeric partner capable 
of binding ligand to induce heterodimerization and relative similar amounts of both receptors are 
required for heterodimerization [27,57,58], we may postulate that the protective effect of the ERα/β 
heterodimer is abrogated with E2 treatment as ERα protein levels are down-regulated by 77% after a 24 
hour treatment period (Fig. 1).  Furthermore, although the ERβ/β homodimer inhibits cell proliferation, 
it does elicit an increase in the transactivation of an ERE-containing promoter-reporter construct and, 
although this is lower than the induction observed with the ERα/α homodimer, this increase in 
transactivataion is higher than that observed with the ERα/β heterodimer [27,58].  Furthermore, ERβ 
can assume the function of ERα if ERα is absent [78] and ERβ can drive proliferation of mammary 
epithelial cells upon induction with the ERβ selective ligand BAG [79].  Thus, the possibility exists 
that the ERβ/β homodimer may drive processes that induce cell proliferation in the absence of ERα.  
Therefore we may speculate that the changes in ERα:ERβ ratio after E2 treatment, abolishes 
heterodimerization, and that this loss drives E2-induced proliferation of MCF-7BUS cells.  In addition, 
we may also postulate that the ERα:ERβ ratio elicited by treatment with the Cyclopia extracts (all 




higher ERα:ERβ ratios than E2) may be more favourable for heterodimerization and that this may 
explain their lower potencies with regards to MCF-7BUS cell proliferation (Chapter 3).  For future 
studies this hypothesis could be tested by using the bioluminescent resonance energy transfer (BRET) 
assay which allows for the detection of ERα/α and ERβ/β homodimers as well as ERα/β heterodimers 
[27].  An alternative hypothesis may involve the modulation of growth factors by the ER.  It has been 
shown that ERα down-regulates growth factors, thus, ERα down-regulation by E2 is accompanied by an 
increase of growth factors and their receptors [77,80] and this could explain the increase in cell 
proliferation when ERα is down-regulated.  Furthermore, vascular endothelial growth factor (VEGF), a 
potent angiogenic factor in breast tumours, shown to be up-regulated by ERα and down-regulated by 
ERβ in MCF-7 cells [81], may be more significantly down-regulated in a scenario where both ERα is 
down-regulated and ERβ is up-regulated.  Thus conferring an advantage to the Cyclopia extracts in 
comparison to E2. 
Although the ER is mostly nuclear, movement between the cytoplasm and the nucleus of the cell does 
take place [13-15].  Furthermore, having shown that Cyclopia extracts differently modulate the ER 
subtype levels, thereby changing the ERα:ERβ ratio, we wanted to investigate whether the extracts 
would alter the nuclear localization of the ER subtypes or disrupt movement between the cytoplasm 
and the nucleus and if there were differences in the behaviour of the subtypes.  Using COS-1 cell 
transfected with either YFP-ERα or YFP-ERβ we found that the methanol extracts of Cyclopia, P104 
and SM6Met, did not concentrate the ERα in the nucleus to the same extent as E2 (Figs. 4&6).  
Furthermore the methanol extracts of Cyclopia also increased nuclear localization of ERβ to a greater 
extent than E2 (Fig. 5&7).  Furthermore, within the limitations of our test system, it does appear as if 
the Cyclopia extracts, specifically P104 and cup-of-tea, display a faster rate of ERα nuclear import than 
E2.  Therefore, in summary, our data suggests that the Cyclopia extracts are not as effective as E2 at 
inducing nuclear localization of ERα into the nucleus despite the fact that the rate of nuclear 




localization is faster, whereas the extracts are more efficient at inducing nuclear localization of ERβ 
into the nucleus.  Previous findings regarding nuclear import and localization of the ER [13], also 
showed that although the majority of ER was already nuclear, an increase in nuclear ER was observed 
in transfected COS-1 cells upon E2 treatment.  However, upon treatment with the pure antiestrogens, 
fulvestrant and ICI 164,384, a decrease in nuclear ER was observed.  Furthermore, Dauvois et al. [13] 
demonstrated that the pure antiestrogens disrupt shuttling of ER between the nucleus and cytoplasm.  
We may therefore speculate that the Cyclopia extracts, acting as ERα antagonists (Chapter 3), are not 
as effective as E2 regarding the shuttling of ERα into the nucleus or, like the antiestrogens, may be 
partially disrupting the shuttling of ERα into the nucleus.  In contrast, the Cyclopia extracts, acting as 
ERβ agonists (Chapter 3), may be increasing the movement of ERβ into the nucleus. 
Decreased nuclear localization of ERα may be due to either reduced nuclear import or increased 
nuclear export of ERα.  It has been proposed that heat shock protein (HSP) 70, associated with the ER 
[82], is involved in moving the ER across the nuclear membrane [13], therefore, it is possible that the 
Cyclopia extracts may be interfering with the HSP70-ERα interaction, thereby inhibiting nuclear 
uptake.  Furthermore, it has been shown for the glucocorticoid receptor that treatment with a protein 
phosphatase inhibitor inhibits the retention of the glucocorticoid receptor in the nucleus [83].  
Therefore, it may be possible binding of the Cyclopia extracts to ERα prevents the phosphorylation of 
ERα resulting in lower nuclear retention and increased export.  Genistein, for example, has been shown 
to inhibit the nuclear export of the Bach1 protein by inhibiting dephosphorylation of Bach1 [84], while, 
in contrast, luteolin has been shown to inhibit the accumulation of HIF-1α in the nucleus by impairing 
its phosphorylation [85].  Therefore, it may be possible that Cyclopia extracts alter the nuclear 
localization of the ER by differentially affecting the phosphorylation status of the ER subtypes.  
However, further research, using inhibitors of phosphorylation as well as dephosphorylation is 
required. 




Upon ligand binding and nuclear translocation the ER forms ordered clusters, indicative of areas of 
active transcription, within the cell nucleus [16-18].  While agonist binding results in an orderly 
distribution of nuclear receptors within the nucleus, antagonist binding, in contrast, induces a more 
random nuclear distribution [18,19,50].  We found that E2, both an ERα and ERβ agonist, induced a 
more ordered distribution of both ERα and ERβ (indicated by higher CV value [50]).  In contrast, the 
Cyclopia extracts, like fulvestrant, an ER antagonist [18], induced a more random nuclear distribution 
of ERα (lower CV value [50]), implying antagonism of ERα (Fig. 8).  Furthermore, the Cyclopia 
extracts induced a slightly more ordered nuclear distribution of ERβ suggesting ERβ agonism. 
To conclude, upon treatment with Cyclopia extracts, in MCF-7BUS cells, ERα protein levels were 
down-regulated while ERβ protein levels were up-regulated, resulting in an decreased ERα:ERβ ratio.  
Furthermore, treatment of COS-1 cells transfected with YFP-tagged ER with the Cyclopia extracts 
resulted in increased ERβ and decreased ERα nuclear localization.  Furthermore, the Cyclopia extracts 
induced a more random nuclear distribution of ERα while inducing a more ordered distribution of ERβ.  
Together, these results support our previous findings that the extracts of Cyclopia act as ERα 
antagonists and ERβ agonists (Chapter 3) and suggest that the Cyclopia extracts may be behaving as 
subtype specific SERDs in down-regulating ERα while stabilizing ERβ protein levels. 
Physiologically, considering the known roles of the ER subtypes in breast cancer development and 
progression [20-26,86,87], the down-regulation of ERα combined with the stabilization of ERβ may be 
considered a positive attribute of the Cyclopia extracts.  In addition, the disruption of ERα nuclear 
localization with increased ERβ nuclear localization provides an additional mechanism whereby the 
proliferative action of ERα may be inhibited.  Furthermore, the nuclear distribution of ERα and ERβ 
provides additional information regarding Cyclopia extracts as ERα antagonists and ERβ agonists, an 
attribute that may be beneficial for the development of an ideal drug for the treatment and/or prevention 
of breast cancer. 




To conclude, our findings provide valuable insights into the mechanism whereby the phytoestrogenic 
extracts of Cyclopia modulate the proliferation of a human breast cancer cell line and, furthermore, 
provide additional proof that the extracts behave as ERα antagonists and ERβ agonists.  Furthermore, 
these findings warrant further investigation that include, but is not limited to, in vivo breast cancer 
studies where we would not only monitor the development and progression of breast cancer tumours 
but also evaluate the levels and distribution of the ER subtypes present in the tumours and breast tissue. 
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Cyclopia extracts and estrogen elicit different responses 
relating to cancer promotion and progression in MCF-
7BUS breast cancer cells. 
 
  




5.1.  Introduction 
The development of breast cancer is not the result of one singular event, but rather the culmination of a 
series of events that may be divided into three steps namely, initiation, promotion, and progression [1-
4].  During initiation, genomic DNA damage may occur and if this damage remains unrepaired, or is 
repaired incorrectly, it may lead to gene mutations that change the characteristics of a cell [4,5].  These 
gene mutations may convey survival and growth advantages to the cell and during promotion this cell 
can divide to form an actively proliferating cell population [4,6], which, during progression, gives rise 
to the production of tumour cells with increased proliferative capacity, invasiveness, and metastatic 
potential [4]. 
The proliferative capacity of a cell is determined by the cell cycle, which is the period between the 
formation of a new cell by the division of a mother cell and the point where this cell in turn divides to 
form two new daughter cells [7].  The mammalian cell cycle consists of several phases, the G0/G1 
phase (gap phase), the S phase (synthesis phase), and the G2/M phase (gap and mitotic phase) [8-11].  
The G0/G1 phase is the post-mitotic phase where the genomic integrity of the mother cell is checked 
and is a phase of cell growth where RNA and proteins are synthesized [9,12,13].  Furthermore, during 
the G0/G1 phase, DNA prereplication complexes are assembled that remain dormant until the S phase 
commences [14].  In addition, the G0/G1 phase is the only mitogenic dependent phase and after the cell 
is committed to enter the S phase, proliferation will continue independently of exogenous signals [15].  
Furthermore, most of the cancer related defects that are initiated during the cell cycle occur during the 
G1 to S phase transition due to defective G1 phase control [16,17].  During the S phase, DNA is 
duplicated while protein and RNA synthesis continues [12,15].  The G2/M phase follows the S phase 
and during this phase DNA synthesis is halted, RNA and protein synthesis is reduced to a minimum, 
genomic stability is checked and the mother cell undergoes mitosis to generate two daughter cells 
[8,12,13].  Progression of cells through the cell cycle is coordinated at certain checkpoints and this 




coordination allows for the necessary regulation of cell growth [18,19].  The loss of cell cycle 
checkpoint control is a hallmark of breast cancer development [15,20]. 
Estrogen (E2), the natural female sex hormone [21-24], binds to the estrogen receptor (ER) and induces 
cell cycle progression via transcriptional up-regulation of cyclin D1 mRNA and protein levels [25].  
Furthermore, activation of membrane associated ERα can transactivate epidermal growth factor 
receptor (EGFR) in breast cancer cells [26].  Activation of EGFR, in response to either steroid 
hormones or growth factors, activates Akt and mitogen-activated protein kinases (MAPKs), which up-
regulate cyclin D1 thus promoting cell cycle progression [20,27].  Cyclin D1 binds and activates cell 
cycle dependent protein kinases and is important for cell cycle progression at the G1 to S phase 
checkpoint. Overexpression of cyclin D1 may lead to unrestricted cell proliferation and genomic 
instability [20,28], characteristics associated with cancer initiation and promotion.  Thus, by up-
regulating cyclin D1 levels, excessive estrogen signalling is associated with a cell acquiring these 
characteristics. 
Furthermore, once the initiated cell has acquired increased proliferative capacity, it will continue to 
grow and divide to generate new highly proliferative clones with invasive and metastatic potential [4]. 
Tumour invasion and metastasis is a process whereby cancer cells from a primary tumour invade 
surrounding tissues and migrate to distant sites, thereby spreading cancer through the body [29-31].   In 
addition, metastasis at distant organs is the most common form of cancer reoccurrence and the foremost 
cause of fatalities in breast cancer patients [32,33], however, patients with ER positive tumours have a 
more favourable prognosis than patients with ER negative tumours [32], suggesting that the ER may 
play a protective role in breast cancer invasion and metastasis. 
Previously we have shown that although phytoestrogenic extracts of Cyclopia (family: Fabaceae), an 
indigenous fynbos plant from the Western Cape province of South Africa [34,35], induced weak 
proliferation of the human breast cancer, MCF-7BUS cells, in the absence of E2, they antagonised E2-




induced proliferation of this cell line (Chapter 3).  Therefore, considering the role of E2 and its cognate 
receptor in the promotion and progression of breast cancer, as well as the effects of Cyclopia extracts 
on MCF-7BUS cell proliferation, we wanted to evaluate how the extracts of Cyclopia would affect the 
distribution of MCF-7BUS cells within the phases of the cell cycle.  In addition, we also evaluated the 
effect of these extracts on the invasive capabilities of this cell line.  Finally, as a key characteristic of 
cancer cells are growth independent of growth stimuli, due to either the modification, or 
overexpression, of growth factors or mutations of the components of the intracellular pathway 
transducing the stimulatory the signal [16,17,36,37], we also evaluated the effect of the Cyclopia 
extracts on the expression of genes involved in signal transduction, cell cycle, and apoptosis using the 
Human Breast Cancer RT
2
 Profiler™ PCR Array.  Furthermore, this array also allows for the 
evaluation of genes implicated in angiogenesis, adhesion, and proteolysis, which are all processes 
involved in cancer cell survival and invasion [30,31,38-41]. 
5.2.  Materials and methods 
5.2.1.  Test Compounds 
17β-Estradiol (E2), genistein, luteolin, enterodiol, and fulvestrant (ICI 182,780) were obtained from 
Sigma-Aldrich
®
, South Africa, and coumestrol was obtained from Fluka™ Analytical, Sigma-Aldrich
®
, 
South Africa.  The Cyclopia extracts, P104 [42], SM6Met [43] and cup-of-tea [43], were previously 
prepared.  E2, genistein, luteolin, enterodiol, coumestrol, ICI 182,780, and Cyclopia extract stock 
solutions were prepared in dimethylsulfoxide (DMSO).  The concentrations of E2 and the polyphenols 
used for experimental procedures in this chapter were chosen to reflect the concentrations that either 
displayed the highest efficacy in the absence of E2 (polyphenols) or the strongest antagonistic effect on 
E2 induction with the cell proliferation assay (Chapter 3). 




5.2.2.  Cell Culture 
MCF-7BUS human breast cancer cells [44] (a kind gift from A. Soto, Tufts University, Boston, 
Massachusetts, United States of America) were maintained in high glucose (4.5 g/L) Dulbecco’s 
modified eagle’s medium (DMEM) (Sigma-Aldrich
®
) supplemented with 10% FCS (Highveld 
Biologicals, South Africa), 100 IU/ml penicillin and 100 µg/ml streptomycin (Gibco, Invitrogen™, 
South Africa), 2mM glutamine (Merck), 44mM sodium-bicarbonate (Gibco), 1mM sodiumpyruvate 
(Gibco), and 0.1mM non-essential amino acids (Gibco).  All cells were maintained in a humidified cell 
incubator, set at 97% relative humidity and 5% CO2 at 37˚C.  Seven days prior to use, MCF-7BUS 
cells were withdrawn from 100 IU/ml penicillin and 100µg/ml streptomycin for seven days prior to 
use. 
5.2.3.  Cell cycle analysis 
MCF-7BUS cells were seeded into sterile 10 cm tissue culture plates at a concentration of 1 x 10
6
 
cells/plate and allowed 24 hours to settle.  After settling the cells were washed once with 10 ml pre-
warmed PBS/plate and the medium was changed to DMEM without phenol red supplemented with 5% 
charcoal treated FCS (Highveld Biologicals) and incubated for 24 hours.  Cells were then treated for 48 
hours with E2, polyphenols, and Cyclopia extracts where after nuclei were isolated and stained with 
propidium iodide (PI) with the CycleTEST™ PLUS DNA reagent kit (Becton Dickinson, South Africa) 
as described by the manufacturer.  For excitation of PI stained nuclei a 488 nm solid state sapphire 
laser was used and emission was measured in the PE Texas Red channel on a linear scale using a 
616/23 bandpass filter.  PI stained nuclei emit fluorescent light at wavelengths between 580 and 650 
nm.  Fluorescent histograms were generated with the BD FACS Aria Cell sorter from Becton 
Dickinson, manufactured in San Jose, California, USA, using FACS Diva 6.1.3. software.   To 
determine cell cycle phase distribution, fluorescence histograms were analysed using ModFit LTTM 
3.0 software (Verity Software House, Topsham, Maine, USA). 




5.2.4.  Cell invasion assay 
MCF-7BUS cells were seeded into sterile 10 cm tissue culture plates at a concentration of 1 x 10
6
 
cells/plate and allowed 24 hours to settle.  After settling the cells were washed once with 10 ml pre-
warmed PBS/per plate and the medium was changed to DMEM without phenol red supplemented with 
5% charcoal treated FCS and incubated for 24 hours.  The number of invasive cells was determined 
with the CytoSelect™ 96-Well cell invasion assay kit (Basement membrane, fluorometric format) (Cell 
Biolabs, Inc., BIOCOM biotech, South Africa) as described by the manufacturer.  After steroid 
withdrawal the cells were reseeded into a 96 membrane chamber plate at a concentration of 5 x 10
5
 
cells/chamber in DMEM without phenol red containing either E2, polyphenols, or Cyclopia extracts.  
The 96 membrane chamber plate was then placed in a feeder plate containing phenol red free DMEM 
supplemented with 10% charcoal treated FCS as chemoattractant.  After a 24 hour incubation period at 
37 °C, the 96 membrane chamber plate was removed from the tray containing the chemoattractant and 
placed in a tray containing the lysis buffer where cells, which had invaded the membrane, were 
dislodged from the bottom of the membrane, lysed and stained with CyQuant
®
 GR dye (Invitrogen).  
Invasive cells were quantified by measuring fluorescence with a Thermo Scientific
™ 
Varioskan plate 
reader at 480 nm/ 520 nm.  
5.2.5.  Microarray analysis 
Microarray analysis was carried out using the Human Breast Cancer RT
2
 Profiler™ PCR Array format 
E 384 (4 x 96) (Qiagen
®
, Whitehead Scientific (Pty) Ltd., South Africa, cat# PAHS-131Z).  To prepare 
RNA samples MCF-7BUS cell were seeded into sterile 12 well tissue culture plates at a concentration 
of 1 x 10
5
 cells/well.  After settling the cells were washed once with 1 ml pre-warmed PBS/per plate 
and the medium was changed to DMEM without phenol red supplemented with 5% charcoal treated 
FCS and incubated for 24 hours.  After incubation cells were treated with either E2, genistein, or 
Cyclopia extracts for 6 hours.  Total RNA was isolated from the treated MCF-7BUS cells using the 




RNeasy Protect Cell Mini Kit (Qiagen
®
), treated with the RNase-Free DNase Set (Qiagen
®
) to 
eliminate genomic DNA contamination.  cDNA was synthesised from 400 ng total RNA using the RT² 
First Strand Kit (Qiagen
®
).  Following synthesis, cDNA was amplified and quantified using the RT² 
qPCR SYBR Green/ROX MasterMix-8 with an Applied Biosystems model 7900HT (384-well block) 
real-time cycler using the following cycling conditions: 10 minutes at 95 °C and 40 cycles of 15 
seconds at 95 °C and 1 minute at 60 °C .  Data was analysed using the Excel
®
 SABiosciences PCR 
Array Data Analysis Template (www.SABiosciences.com/pcrarraydataanalysis.php).  All kits were 
used according to the manufacturer’s conditions. 
5.2.6.  Data manipulation and statistical analysis 
The GraphPad Prism
®
 version 5.10 for Windows (GraphPad Software) was used for graphical 
representations and statistical analysis.  One-way ANOVA and Dunnett’s post-test comparing all 
columns to either the solvent control or 10
-9
M E2 treatment were used for statistical analysis and 
significance is displayed on the graphs.  For all experiments the error bars represent the SEM of at least 
three independent experimental repeats, except for the cell invasion assay where only one experiment 
was performed. 
5.3.  Results 
5.3.1.  In the absence of E2 all Cyclopia extracts induce the accumulation of MCF-7BUS cells in the S 
phase of the cell cycle, whereas, in the presence of E2, SM6Met induces the accumulation of MCF-
7BUS cells in the G0/G1 phase of the cell cycle. 
Previously (Chapter 3) we showed that although Cyclopia extracts induce weak proliferation of the 
MCF-7BUS breast cancer cell line, they inhibit E2-induced cell proliferation.  Thus we were interested 
in investigating the effects of the Cyclopia extracts on the cell cycle.  Cell proliferation is dependent on 
the progression of cells through the cell cycle, which is coordinated at certain points, allowing for the 
necessary regulation of cell growth [18,19]. 





























































































































































































































































































































































Figure 1.  Extracts of Cyclopia induce the accumulation of MCF-7BUS cells in the S phase of the cell cycle 
in the absence of E2.  (A) Representative histograms of cell cycle distribution generated with FACS Diva 
6.1.3. software for solvent and 10
-9
M E2 treated cells. (B-I) Representative curves of MCF-7 BUS cell cycle 
distribution following treatment with E2 (B), polyphenols (C-F), or Cyclopia extracts (G-I) for 48 hours.  Values 
were normalised to solvent control value within each individual experiment.  Statistical analysis was done using 
One-way ANOVA with Dunnett’s post-test comparing all values to the solvent control of the particular phase of 
the cell cycle (*, P<0.05; **, P<0.01; ***, P<0.001).  The dotted line through the bars represents the values for 
solvent control.  Mean ± SEM is of four independent experiments. 
The mammalian cell cycle consists of several phases:  The G0/G1 phase, which precedes the S phase 
and serves as a checkpoint for any DNA damage in the mother cell, and allows for cell growth; the S 
phase, also known as the synthesis phase, where DNA, which passed the G0/G1 checkpoint, is 
synthesised resulting in chromosome duplication; and the G2/M phase, which follows the S phase, is 
where duplicated DNA, from the S-phase, is checked for damage where after the cells enter mitosis 
[8,9,12,13,15].  Mitosis is followed by nuclear division, which is followed by cell division [7]. 
Using the CycleTEST™ PLUS DNA reagent kit, as described in the materials and methods section of 
this chapter, we evaluated the effect of the Cyclopia extracts on the distribution of cells between the 
different phases of the cell cycle, both in the absence (Fig. 1) and presence (Fig. 2) of 10
-9
M E2.  
Representative histograms of solvent and E2 treated cells are shown (Fig. 1A) and phases of the cell 
cycle, as represented by the histogram, are indicated with arrows.  Using ModFit LTTM 3.0 software 
the percentage of apoptotic cells were also determined (Fig. 1A).  Treatment with E2 (Fig. 1B) 
significantly decreased the number of cells present in the G0/G1 phase and significantly increased the 
number of cells in the G2/M phase when compared to solvent treated cells (dashed line).  An increase 
in the number of cells present in the S phase as well as a small decrease in the number of apoptotic 
cells is seen, although these changes are not significantly different from the solvent values.  Treatment 
with the Cyclopia extracts (Figs. 1G, H, & I) extracts, like E2, significantly decreased the number cells 
in the G0/G1 phase and increased the number of cells in the S phase of the cell cycle.  However, unlike 
E2, the Cyclopia extracts decreased the number of cells in the G2/M phase of the cell cycle. 
 




Table 1.  The effect of E2, polyphenols, and Cyclopia extracts on the distribution of human breast cancer cells within the cell cycle.  MCF-7 BUS 
cells were treated with E2, polyphenols, or Cyclopia extracts for 48 hours.  After treatment the percentage of cells in each phase of the cell cycle was 
determined.  Statistical analysis was done using One-way ANOVA with Dunnett’s post-test comparing all values to the solvent control of the particular 
phase of the cell cycle.  Mean ± SEM is of four independent experiments. 
Percentage of cells in cell cycle phase 
 Apoptotic Change
a
 G0/G1 Change S Change G2/M Change 
Solvent 28.59 ± 1.52  48.50 ± 7.79  44.74 ± 9.15  2.67 ± 0.47  
10
-9
M E2 20.36 ± 2.22 -8.23
b
 39.97 ± 4.28 -8.53 51.19 ± 5.97 6.45 6.94 ± 1.72 4.27 
10
-9
M Genistein 36.14 ± 3.34 7.55 47.86 ± 9.92 -0.64 51.17 ± 17.41 6.43 2.33 ± 0.40 -0.34 
10
-8
M Luteolin 28.32 ± 2.34 -0.27 41.01 ± 11.09 -7.49 50.17 ± 10.88 5.43 1.29 ± 0.59 -1.38 
10
-9
M Enterodiol 29.34 ± 4.46 0.75 42.48 ± 13.45 -6.02 49.64 ± 11.73 4.90 1.56 ± 0.51 -1.11 
10
-7
M Coumestrol 21.80 ± 2.68 -6.79 48.00 ± 7.95 -0.50 47.00 ± 10.23 2.26 1.75 ± 0.74 -0.92 
9.8µg/ml P104 25.32 ± 4.04 -3.27 36.02 ± 9.78 -12.48 55.06 ± 10.88 10.32 1.27 ± 1.26 -1.40 
9.8µg/ml Cup-of-tea 22.54 ± 3.22 -6.05 34.58 ± 9.85 -13.92 55.72 ± 11.22 10.98 1.83 ± 1.62 -0.84 
9.8µg/ml SM6Met 24.65 ± 3.25 -3.94 36.52 ±10.63 -11.98 54.22 ± 11.19 9.48 2.44 ± 1.20 -0.23 
a
Change from solvent value. 
b
Negative value denotes a decrease in percentage cells. 
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The polyphenols, luteolin, enterodiol, and coumestrol (Figs. 1D-F), behaved like the Cyclopia extracts, 
while genistein (Fig. 1C) displayed a similar cell cycle distribution profile as E2.  Genistein, luteolin, 
and enterodiol, unlike E2 and the Cyclopia extracts, increased the number of apoptotic cells, although 
the values did not reach significance.  Whereas Figure 1 displayed the average normalized values 
relative to solvent control within each individual experiment Table 1 shows average values of the 
percentage MCF-7BUS cells in each phase of the cell cycle for all treatments in the absence of 10
-9
M 
E2.  Table 1 shows similar trends to that obtained with the normalized values, although the values did 
not reach significance. 
In the presence of 10
-9
M E2 (Fig. 2), no significant deviations from the E2-induced effect (dashed line) 
was observed, except for SM6Met (Fig. 2G), which significantly increased the number of cells in the 
G0/G1 phase.  All other treatments (Figs. 2A-F) increased the number of apoptotic cells, although the 
values did not reach significance.  Furthermore, upon comparison of the distribution patterns of MCF-
7BUS cells within the cell cycle following treatment with the Cyclopia extracts in the presence of E2 to 
the distribution patterns of solvent treated cells (Fig. 3, dashed line equals solvent), we observed a trend 
for SM6Met towards redistribution of the cells to the basal distribution (Fig 3H).  However, the P104 
and cup-of-tea extracts did not appear to alter the E2-induced MCF-7BUS cell distribution significantly 
(Figs. 3F&G).  The polyphenols, genistein (Fig. 2A) and enterodiol (Fig. 2C), increased the number of 
cells in the G2/M phase of the cell cycle, whereas luteolin (Fig. 2B), coumestrol (Fig. 2D), and the 
Cyclopia extracts, P104 (Fig. 2E) and SM6Met (Fig. 2F), decreased the number of cells in the G2/M 
phase when compared to E2, although none of the values reached significance.  In addition, none of the 
polyphenols altered the E2-induced MCF-7BUS cell distribution (Figs. 3B,D&E) although, luteolin did 
decrease the number of cells in the G2/M phase, however this value did not reach significance (Fig. 
3C).   
 































































































































































































































































Figure 2.  The Cyclopia extract, SM6Met, induces the accumulation of MCF-7BUS cells in the G0/G1 
phase of the cell cycle in the presence of E2.  Representative curves of MCF-7 BUS cell cycle distribution 
following treatment with polyphenols (A-D) or Cyclopia extracts (E-G) for 48 hours in the presence of 10
-9
M E2.  
Values were normalised to 10
-9
M E2 value within each individual experiment.  Statistical analysis was done 
using One-way ANOVA with Dunnett’s post-test comparing all values to 10
-9
M E2 treated value of the particular 
phase of the cell cycle (*, P<0.05; **, P<0.01; ***, P<0.001).  The dotted line through the bars represents the 
values for 10
-9
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Figure 3.  In the presence of E2, the Cyclopia extract, SM6Met, redistributes E2-induced MCF-7BUS cell 
cycle phase distribution towards basal levels.  Representative curves of MCF-7 BUS cell cycle distribution 
following treatment with E2 (A) or polyphenols (B-E) or Cyclopia extracts (F-H) for 48 hours in the presence of 
10
-9
M E2.  Values were normalized to solvent control values.  Statistical analysis was done using One-way 
ANOVA with Dunnett’s post-test comparing all values to solvent treated value of the particular phase of the cell 
cycle (*, P<0.05; **, P<0.01; ***, P<0.001).  The dotted line through the bars represents the values for solvent.  
Mean ± SEM is of four independent experiments. 
Whereas Figures 2 and 3 displayed the average normalized values relative to 10
-9
M E2 and solvent 
control values, respectively, within each individual experiment, Table 2 shows average values of the 
percentage MCF-7BUS cells in each phase of the cell cycle for all treatments in the presence of 10
-9
M 
E2.  Table 2 shows similar trends to that obtained with the normalized values, although the values did 
not reach significance. 
In conclusion, in the absence of 10
-9
M E2 (Fig. 1), the extracts of Cyclopia, like E2, induced 
redistribution of cells from the G0/G1 to the S phase of the cell cycle, but had an opposite effect to that 
of E2 in the distribution of cells in the G2/M phase, with the extracts decreasing rather than increasing 
the number of cells in the G2/M phase.  In the presence of E2, the SM6Met extract of Cyclopia 
significantly increased the number of cells in the G0/G1 phase of the cell cycle relative to E2 (Fig. 2) 
















Table 2.  The effect of polyphenols and Cyclopia extracts on the distribution of human breast cancer cells within the cell cycle in the presence of 
E2.  MCF-7 BUS cells were treated with polyphenols or Cyclopia extracts for 48 hours in the presence of 10
-9
M E2.  After treatment the percentage of 
cells in each phase of the cell cycle was determined.  Statistical analysis was done using One-way ANOVA with Dunnett’s post-test comparing all values 
to the 10
-9
M E2 values of the particular phase of the cell cycle (*, P<0.05; **, P<0.01; ***, P<0.001).  Mean ± SEM is of four independent experiments. 
Percentage of cells in cell cycle phase 
 Apoptotic Change
a
 G0/G1 Change S Change G2/M Change 
10
-9
M E2 20.36 ± 2.22  39.97 ± 4.28  51.19 ± 5.97  6.94 ± 1.72  
+ 10
-5
M Genistein 22.69 ± 4.12 2.33 39.85 ± 4.97 -0.12
b
 55.33 ± 6.30 4.14 10.24 ± 2.51 3.30 
+ 10
-5
M Luteolin 28.16 ± 2.56 7.80 38.33 ± 5.71 -1.64 58.30 ± 7.34 7.11 6.51 ± 3.11 -0.43 
+ 10
-5
M Enterodiol 27.66 ± 1.56 7.30 39.74 ± 6.57 -0.23 56.11 ± 8.26 4.92 6.81 ± 3.41 -0.13 
+ 10
-5
M Coumestrol 28.92 ± 0.27 8.56 38.92 ± 5.89 -1.05 57.67 ± 8.10 6.48 6.64 ± 4.80 -0.30 
+ 9.8µg/ml P104 29.84 ± 1.09 9.48 35.89 ± 5.58 -4.08 60.79 ± 7.56 9.60 6.53 ± 4.01 -0.41 
+ 9.8µg/ml Cup-of-tea 28.96 ± 1.95 8.60 36.04 ± 6.59 -3.93 60.30 ± 8.56 9.11 7.33 ± 3.95 0.39 
+ 9.8µg/ml SM6Met 18.12 ± 3.66 -2.24 43.76 ± 4.61 3.79 56.29 ± 6.40 5.10 5.08 ± 4.71 -1.86 
a
Change from solvent value. 
b
Negative value denotes a decrease in percentage cells. 
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5.3.2.  The methanol extracts of Cyclopia, P104 and SM6Met, like the ER antagonist ICI 182,780, 
increased the number of invasive MCF-7BUS cells in the presence of E2. 
Tumour invasion, a hallmark of cancer associated with progression [30], is a process whereby cancer 
cells from a primary tumour invade surrounding tissues and migrate to distant sites thereby spreading 
cancer through the body [29].  Therefore, we wanted to evaluate the effect the Cyclopia extracts on the 



























































































































































































Figure 4.  The number of invasive MCF-7BUS cells is increased by the Cyclopia extracts, P104 and 
SM6Met, in the presence of 10
-9
M E2.  The number of invasive MCF-7BUS cells was determined using the 
CytoSelect™ 96-Well cell invasion assay kit as described in the material and methods section. Figures represent 
(A) the effect of E2, polyphenols, or Cyclopia extracts in the absence of E2 and (B) in the presence of E2 on the 
number of invasive cells.  Statistical analysis was done using One-way ANOVA with Dunnett’s post-test 
comparing all values to the (A) solvent control or (B) 10
-9
M E2 treated cells.  Mean ± SEM is of one experiment 
with five replicates. 
No significant changes in the number of invasive cells were observed after treatment with E2, the 
polyphenols, or the Cyclopia extracts alone (Fig. 4A).  A slight decrease in the number of invasive cells 
was observed after E2 treatment, whereas the polyphenol, genistein, and the Cyclopia extracts, cup-of-
tea and SM6Met, slightly, but not significantly, increased the number of invasive cells. 




In the presence of 10
-9
M E2 (Fig. 4B), the Cyclopia extracts, P104 and SM6Met, like the full ER 
antagonist, fulvestrant (ICI 182,780), significantly increased the number of invasive cells when 
compared to cells treated with E2.  The polyphenols, luteolin, enterodiol, and coumestrol, also 
increased the number of invasive cells, however, not significantly when compared to E2 treated cells. 
To summarize, the Cyclopia extracts had no significant effect on the number of invasive MCF-7BUS 
cells in the absence of E2, but, like fulvestrant, P104 and SM6Met increased the number of invasive 
cells in the presence of 10
-9
M E2. 
5.3.3.  PCR array analysis of MCF-7BUS cells revealed that treatment with the Cyclopia extracts 
generate gene expression patterns that differ from that of E2 and furthermore, within the group of 
Cyclopia extracts, extracts from different species regulate genes in a different way. 
Hanahan et al. [30] refers to cancer cells as “masters of their own destinies” as they acquire the ability 
to grow without stimulation by modifying growth factors, their expression levels, or components of the 
intracellular signal transduction pathway [16,17,36,37].  Therefore, having evaluated the effect of the 
Cyclopia extracts on MCF-7BUS cell cycle distribution well as the effect on MCF-7BUS cell invasion, 
we evaluated the effect of the Cyclopia extracts on the expression of genes associated with signal 
transduction, the cell cycle, and apoptosis, as well as genes that may influence cancer cell survival and 
invasion via angiogenesis, epithelial to mesenchymal transition (EMT), adhesion and proteolysis, using 
the Human Breast Cancer RT
2
 Profiler™ PCR Array. 
Using this PCR array, which focuses on genes involved in signal transduction, cell cycle progression, 
apoptosis, angiogenesis, adhesion, and proteolysis in breast cancer, as described in the materials and 
methods section, we investigated how E2, genistein, and Cyclopia extracts modulated the transcription 
of genes associated with breast cancer (specific gene regulation results are shown in Table S1). 
 
 
















































































































































































































































































































































Figure 5.  Treatment of MCF-7BUS cells with Cyclopia extracts generate gene expression patterns that 





M genistein (B&C), 9.8μg/ml P104 (D&E), 9.8μg/ml cup-of-tea (F&G), and 9.8μg/ml SM6Met (H&I) 
relative to the gene expression pattern in both the solvent (A, B, D, F, & H) and E2 treated cells(C, E, G, & I).  
The pink lines represent ± two times fold change in gene expression levels and the black line represents no 
change from either solvent (A, B, D, F, & H)  or E2 treated (C, E, G, & I)  cells.  Figures are of log mean fold 
change in gene expression relative to housekeeping genes (ACTB, B2M, GAPDH, HPRT1, RPL13A) and are 
representative of three independent experiments, except for genistein, which represents only one experiment. 
An overview of the global gene expression pattern, compared to solvent (Figs. 5A, B, D, F, & H) or 10
-
9
M E2 (Figs. 5C, E, G, & I), may be achieved by generating log-log plots of average fold change in gene 
expression relative to the housekeeping genes, where the black line indicates no change in gene 
expression and the pink lines indicate ± two fold change in gene expression (generally accepted cut-off 
for significant changes in fold gene expression [45-47]).  Genes positioned above the pink line in the 
top left quadrant were up-regulated more than two fold relative to the treatment on the x-axis, while 
those below the pink line in the bottom right quadrant were down-regulated more than two fold.  
Treatment with 10
-9
M E2 (Fig. 5A) generated a global expression pattern where a similar number of 
genes were up-regulated and down-regulated relative to solvent (23.81% up-regulated vs. 19.05% 
down-regulated (Table 3)).  Upon treatment with the Cyclopia extract, P104 (Fig. 5D), the global gene 
expression pattern indicated that the majority of genes regulated by this extract were up-regulated 
relative to the solvent control (65.48% up-regulated vs. 10.71% down-regulated).  Treatment with the 
cup-of-tea (Fig. 5F) and SM6Met (Fig. 5H) Cyclopia extracts, however, unlike with E2 and P104, 
resulted in the majority of the genes being down-regulated (21.43% up-regulated vs. 45.24% down-
regulated and 16.67% up-regulated vs. 46.43% down-regulated, respectively) relative to solvent control 
(Table 3).  Treatment with the polyphenol, genistein (Fig. 5B), unlike with E2 and the Cyclopia 
extracts, resulted in the majority of genes not being regulated more than ± two fold relative to solvent 
(72.61%) and, of the regulated genes, similar numbers were up- and down-regulated (14.29% up-
regulated vs. 13.10% down-regulated) (Table 3), however caution should be exercised regarding 
genistein results as they represent only one experiment. 




Therefore, compared to the global gene expression pattern of the solvent control treated cells, the 
Cyclopia extracts affected more genes than either E2 or genistein (63-76% vs. 43% and 27%, 
respectively) (Table 3), which may reflect the fact that the extracts, in contrast to E2 and genistein, 
represent the contribution of several potential phytoestrogenic compounds (Chapter 3 and Addendum A 
[48]).  Furthermore, treatment with P104, a C. genistoides extract, generated a global gene expression 
pattern quite similar to that of E2 (Figs. 5A&D), whereas the extracts of C. subternata, cup-of-tea and 
SM6Met, generated global gene expression patterns that, although similar to each other (Figs. 5F&H), 
differ from that of E2 and P104.  Also, upon treatment with P104, the majority of the genes were up-
regulated, whereas with cup-of-tea and SM6Met, the majority were down-regulated (Table 3). 
In addition, we plotted the global gene expression values of genistein and the Cyclopia extracts against 
that of E2 (Figs. 5C, E, G, & I).   The global gene expression pattern for P104 became more condensed 
with the majority of genes falling on, or just above, the plus two fold change in fold gene expression 
line (Fig. 5E), supporting our previous suggestion that, relevant to solvent, P104 and E2 generate quite 
similar gene expression patterns, although more genes were up-regulated by P104 than by E2.  
Furthermore, for the cup-of-tea (Fig. 5G) and SM6Met (Fig. 5I) extracts, relative to E2, as for relative 
to solvent, a larger number of genes were found in the lower right hand quadrant of the graph, 
suggesting that, not only did treatment with the cup-of-tea and SM6Met extracts lower the expression 
levels of genes when compared to that of solvent, but also when compared to that of E2.   Furthermore, 
when the expression patterns of genistein regulated genes were compared to that of E2 regulated genes 
(Fig. 5C), the majority of genes were not regulated by more than ± two fold relative to E2, however, as 
mentioned previously, caution should be exercised regarding genistein results as they represent only 
one experiment 




Table 3.  Extracts of Cyclopia regulate both common and distinct genes within functional groups.  MCF-7BUS cells were treated with E2, genistein 
and Cyclopia extracts.  Genes were grouped according to their function in the development and progression of breast cancer.  Regulation was determined 




 M E2 10
-9
M Genistein 9.8 μg/ml P104 9.8 μg/ml Cup-of-tea 9.8 μg/ml SM6Met 
 ↑a ↓b ↑ ↓ ↑ ↓ ↑ ↓ ↑ ↓ 
Overall gene regulation [84]
c
 23.81d 19.05 14.29 13.10 65.48 10.71 21.43 45.24 16.67 46.43 
Functional grouping           
Angiogenesis [14] 7.14 35.71 21.43 0.00 64.29 21.43 14.29 50.00 14.29 64.29 
Epithelial to mesenchymal transition [5] 20.00 20.00 20.00 0.00 80.00 20.00 20.00 20.00 20.00 20.00 
Adhesion [13] 23.08 23.08 15.38 0.00 61.54 23.08 7.69 38.46 23.08 61.54 
Proteolysis [7] 14.29 0.00 28.57 14.29 71.43 14.29 14.29 71.43 14.29 85.71 
Apoptosis [20] 15.00 20.00 25.00 15.00 60.00 10.00 10.00 45.00 15.00 60.00 
Cell cycle [18] 27.78 27.78 5.56 5.56 66.67 16.67 22.22 44.44 16.67 55.56 
DNA damage [12] 25.00 8.33 8.33 0.00 91.67 8.33 8.33 8.33 16.67 25.00 
Xenobiotic transport [2] 0.00 0.00 0.00 50.00 50.00 0.00 0.00 50.00 0.00 50.00 
Transcription factors [17] 29.41 23.53 17.65 5.88 64.71 23.53 23.53 47.06 11.76 41.18 
a
Percentage of genes up-regulated relative to total number of genes within group. 
b
Percentage of genes down-regulated relative to total number of genes within group. 
c
Total number of genes in group. 
d
Percentage calculated:  [number of genes regulated (≥  ± 2 fold change)] / (total number of genes in group)*100
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Therefore, to summarise, the extracts of Cyclopia regulated the global gene expression levels of 
genes associated with signal transduction, cell cycle progression, apoptosis, angiogenesis, adhesion, 
and proteolysis in breast cancer.  Furthermore, the global gene regulation patterns were different for 
extracts of different Cyclopia species, with the extracts of C.genistoides increasing the expression 
levels of the majority of genes, whereas the extracts of C. subternata decreased the expression 
levels of the majority of the regulated genes. 
To evaluate the number of genes that are similarly or differentially regulated by different treatments 
we generated Venn diagrams depicting commonly or distinctly regulated genes between the 
Cyclopia extracts (Fig. 6A), P104, E2, and genistein (Fig. 6B), cup-of-tea, E2, and genistein (Fig. 
6C), and SM6Met, E2, and genistein (Fig. 6D).  Upon comparison of the three Cyclopia extracts 
(Fig. 6A) 27 of the 84 genes were commonly regulated with 59% of these genes regulated in the 
same direction (all treatments either up- or down-regulated gene expression) by all three extracts, 
while 41% were regulated in different directions (the same gene up-regulated by one extract but 
down-regulated by the other two extracts, or vice versa).  P104 was the outlier responsible for 82% 
of the differentially regulated genes, again illustrating afore mentioned differences in behaviour of 
the extracts from the different species of Cyclopia.  Out of the 84 genes P104, cup-of-tea, and 
SM6Met distinctly regulated 16, 4, and 1 gene, respectively, within this comparison.  Of the 84 
genes, 10 genes were regulated by both P104 and cup-of-tea, but not SM6Met, 90% of which were 
regulated in the same direction and 10% in different directions.  Furthermore, 11 genes were 
regulated by P104 and SM6Met, but not cup-of-tea, and 36% were regulated in the same and 64% 
in different directions.  The cup-of-tea and SM6Met extracts both regulated 15 genes that were not 
regulated by P104, 93% were regulated in the same direction and only 7% in different directions, 
again reinforcing the similarity between the C. subternata extracts.   
 

















Figure 6.  Relative to the group of Cyclopia extracts, E2, and genistein, individual Cyclopia extracts 
regulate distinct and common genes.  Venn diagrams, illustrating common and distinct gene regulation, 
were generated for (A) P104, cup-of-tea, and SM6Met, (B) P104, E2, and genistein, (C) cup-of-tea, E2, and 
genistein, and (D) SM6Met, E2, and genistein, from fold regulation data obtained from the human breast 
cancer RT
2
 Profiler PCR array (Table S1).  Regulation was determined as ± 2 fold change from solvent 
control. Figures are representative of three independent experiments, except for genistein, which represents 
one experiment. 
Upon comparing gene regulation patterns of P104, E2, and genistein we found 30, 12, and 8 genes, 
respectively, to be distinctly regulated within this comparison (Fig 6B).  Within this grouping, only 
5 genes were commonly regulated by E2, genistein and P104.  Of the 19 genes regulated by P104 
and E2 but not genistein, 89% were regulated in the same direction and 11% in different directions, 






reflecting the gene expression patterns observed in Fig. 5.  P104 and genistein commonly regulated 
10 genes that were not regulated by E2, of which 80% were regulated in the same direction and 20% 
in different directions.  No genes were regulated by E2 and genistein but not P104.  Of the 5 genes 
commonly regulated by all three treatments, 60% were regulated in the same direction. 
Treatment of MCF-7BUS cells with the cup-of-tea extract, E2, and genistein (Fig. 6C)  resulted in 
four of the genes being regulated by all three of the treatments of which 50% were regulated in the 
same direction, with E2 being the outlier in all of the genes regulated in different directions.  Of the 
26 genes regulated by the cup-of-tea extract and E2, but not genistein, only 23% were regulated in 
different directions.  The cup-of-tea extract and genistein, but not E2, regulated 13 genes, 62% of 
which were regulated in the same direction and 38% in different directions.  Within this comparison 
only one gene was jointly regulated by E2 and genistein, but not by cup-of-tea.  This gene was 
regulated in the same direction. 
SM6Met, E2, and genistein commonly regulated 5 genes within this comparison group (Fig. 6D) of 
which 60% were regulated in the same direction and 40% in different directions.  Of the 20 genes 
co-regulated by SM6Met and E2, but not genistein, 86% were regulated in the same direction and 
14% in different directions.  SM6Met and genistein, but not E2, jointly regulated 17 genes within 
this group of which 59% were in the same direction and 41% in a different direction.  No genes 
were uniquely shared between genistein and E2 within this group. 
Therefore, when comparing commonly regulated genes, the Cyclopia extracts regulated more genes 
in common with each other than with either E2 or genistein (Fig. 6A).  Specifically, P104 regulated 
37 and 38 genes commonly with cup-of-tea and SM6Met, respectively, but only 24 and 15 genes 
commonly with E2 and genistein, respectively, while cup-of-tea regulated 42 genes commonly with 
SM6Met, but only 30 and 17 commonly with E2 and genistein, respectively, and SM6Met only 
regulated 26 and 22 genes commonly with E2 and genistein, respectively.  P104 uniquely regulated 






the largest number of genes (16 vs. 4 and 1, in Fig. 6A, and 30 vs. 12 and 8, in Fig. 6B) and even 
within the commonly regulated genes of the group of Cyclopia extracts (27 genes) P104 regulated 
82% of the jointly regulated genes in the opposite direction to that of cup-of-tea and SM6Met.  
Furthermore, in only one of the groupings E2 and genistein jointly regulated a gene that was not 
regulated by a Cyclopia extract and they generally shared more regulated genes with the Cyclopia 
extracts than with each other.  Therefore, our results indicate that although the extracts are more 
similar to each other than to either E2 or genistein, the extracts from different species regulated 
genes in different ways and P104 specifically may be considered an outlier within the Cyclopia 
grouping.  Furthermore, E2 and genistein behave more like the Cyclopia extracts than each other 
within the context of the PCR array data. 
In addition, to better understand how these changes in gene regulation may impact breast cancer 
survival and progression, we grouped the genes according to function (Table 3 and Table S2).  
Concerning survival, growing cancer cells, like normal cells, require nutrients and oxygen and 
furthermore, they require a system to remove carbon dioxide and metabolic waste [30,38].  The 
formation of new blood vessels, angiogenesis, is employed by tumours to provide for these 
requirements [30,38,39].  The extracts of Cyclopia regulated more angiogenesis related genes than 
either E2 or genistein, however, P104 up-regulated the highest percentage of regulated genes, whilst 
cup-of-tea and SM6Met, down-regulated a greater percentage of regulated genes. Furthermore, of 
the 64% angiogenesis related genes up-regulated by P104, 78% promote angiogenesis whereas 22% 
inhibit angiogenesis and of the 21% down-regulated genes, 67% promote angiogenesis and 33% 
inhibit angiogenesis.  In addition, 50% of the genes up-regulated by cup-of-tea promote 
angiogenesis, while 50% inhibits angiogenesis and 86% of the genes down-regulated by this extract 
promotes angiogenesis, while 14% inhibits angiogenesis.  All of the genes up-regulated by SM6Met 
inhibit angiogenesis, while 89% of the down-regulated genes promote angiogenesis and 11% inhibit 






angiogenesis.  Therefore, not only is there a difference in the gene regulation pattern of the extracts 
from different species of Cyclopia, the extract from C. genistoides, P104, seems to be more 
markedly pro-angiogenic than the extracts from C. subternata, cup-of-tea and SM6Met.  
Furthermore, of the E2 regulated angiogenic genes, 83% of the total genes regulated were down-
regulated of which 80% promote angiogenesis and 20% inhibit angiogenesis and all of the up-
regulated genes (17%) inhibit angiogenesis.  Therefore, with regards to the promotion of 
angiogenesis, the P104 extract regulated the majority of the regulated genes towards angiogenesis 
(67%), whereas E2, cup-of-tea and SM6Met only regulated 17%, 22%, and 8%, respectively, of the 
regulated genes towards angiogenesis. 
Furthermore, regarding cancer cell invasion, not only is angiogenesis an important contributing 
factor, but also adhesion, the EMT transition, and proteolysis.  Adhesion, specifically, plays an 
important role in the motility and invasiveness of cells with invasive cells being less adhesive and 
thus more mobile [49].  Adhesion related genes were regulated similarly by the extracts as for 
angiogenesis related genes, with P104 up-regulating the majority of regulated genes, while cup-of-
tea and SM6Met down-regulated the majority of the regulated genes.  During EMT a cell loses its 
epithelial phenotype, and assumes a mesenchymal phenotype, which allows the cell to migrate from 
the parent tissue and invade adjacent tissues [50].  The most notable regulator of EMT related genes 
was the P104 extract, which regulated all of the EMT related genes.  A pattern of regulation, similar 
to that of angiogenesis and adhesion, was also observed regarding proteolysis, a process whereby 
proteolytic enzymes degrade the extracellular matrix thus increasing cell motility and invasion [40].  
Therefore, concerning our results for genes implicated in cancer cell invasion, specifically adhesion, 
EMT transition, and proteolysis, the P104 extract of Cyclopia generally up-regulated a larger 
number of genes, while cup-of-tea and SM6Met down-regulated a larger number of genes.  
Specifically, of the cancer invasion genes regulated by each extract, P104 up-regulated 79% of the 






regulated genes of which 67% promote invasion whereas 33% inhibit invasion, while down-
regulating 21% of the regulated genes of which 75% promote invasion and 25% inhibit invasion.  
Furthermore, the cup-of-tea extract up-regulated 27% of the regulated genes of which 67% promote 
invasion and 33% inhibit invasion, while down-regulating 73% of the regulated of which 63% 
promote invasion and 37% inhibit invasion, while SM6Met up-regulated 24% of the regulated 
genes of which 50% promote invasion and 50% inhibit invasion, while down-regulating 76% of the 
regulated genes of which 54% promote invasion and 46% inhibit invasion.  Estrogen regulated 32% 
of the genes that regulate cancer invasion. Of the E2 regulated genes 71% are up-regulated of which 
60% promote invasion and 40% inhibit invasion, while of the 29% down-regulated genes, 50% 
promote invasion and 50% inhibit invasion.  To summarise, when all the genes involved in cancer 
invasion are considered, whether up- or down-regulated, P104, an extract of C. genistoides, 
regulated 58% of the regulated genes towards promoting cancer invasion, while the cup-of-tea and 
SM6Met extracts, C. subternata extracts, regulated 46% and 47%, respectively, towards promoting 
invasion.  E2 regulates 57% of the genes towards promoting invasion.  Therefore, by evaluating the 
regulation of invasion associated genes by the Cyclopia extracts, although an accurate prediction 
cannot be made of whether the Cyclopia extracts would inhibit or promote cancer cell invasion, it 
does appear as if P104, like E2, tends slightly more towards the promotion of cancer invasion. 
Damaged DNA can be pro-mutagenic and contribute to cancer development [51].  The basis of 
cancer development and progression is abnormal cell growth [52], where the normal tightly 
controlled cycle of growth, division, and apoptosis is disrupted [30,53,54].  Therefore, concerning 
abnormal cell growth, we will evaluate the regulation by the Cyclopia extracts of genes involved in 
DNA damage, the cell cycle, and apoptosis together. 
The previously observed pattern of gene regulation, P104 up-regulated the majority of regulated 
genes, while cup-of-tea and SM6Met down-regulated the majority of the regulated genes, was also 






observed for genes involved in cell growth.  P104 up-regulated 86% of the regulated genes with 
56% of the up-regulated genes promoting cell growth, while 44% inhibit cell growth and of the 
14% down-regulated genes, 25% promote growth and 75% inhibit growth.  The cup-of-tea extract, 
in contrast, only up-regulated 29% of the regulated genes of which 67% promote growth and 33% 
inhibit growth and furthermore, the extract down-regulated 71% of the regulated genes of which 
47% promote growth and 53% inhibit growth.  In addition, of the regulated genes, SM6Met up-
regulated 29% of which 57% promote growth and 43% inhibit growth, while of the 71% down-
regulated genes, 41% promote growth and 59% inhibit growth.  Estrogen up-regulated 50% of the 
regulated genes of which 71% promote growth and 29% inhibit growth and furthermore, of the 50% 
down-regulated genes, 14% promote growth and 86% inhibit growth.  To summarise, when all the 
genes involved in cancer cell growth are considered, whether up- or down-regulated, E2, P104, cup-
of-tea, and SM6Met, all regulated genes towards cell growth (79%, 59%, 57%, and 58%, 
respectively), although the extracts of Cyclopia did not regulate genes towards cell growth to the 
same extent as E2. 
Furthermore, the PCR array also allows for the evaluation of genes involved in xenobiotic transport 
as up-regulation of xenobiotic transport proteins may convey resistance to breast cancer drug 
treatment [55]) as well as genes of transcription factors, such as the ER subtypes and the 
progesterone receptor (PR), that may contribute to the development and progression of breast 
cancer [45,56-59].  Within these functional groups the Cyclopia extracts generally regulated a larger 
number of genes than E2 and genistein, with P104 up-regulating the majority of regulated genes and 
the cup-of-tea and SM6Met extracts down-regulating the majority of regulated genes. 
To conclude, the Cyclopia extracts regulated the expression of genes that are known to play a role 
in breast cancer.  Furthermore, not only did the extracts regulate distinct as well as common genes, 
when compared to E2 and genistein, the extracts also regulated distinct and common genes when 






compared to each other.  Also, of the genes that are commonly regulated by the Cyclopia extracts, 
P104, a C. genistoides extract, generally regulated these genes in a different direction from that of 
SM6Met and cup-of-tea, C. subternata extracts. 
5.4.4.  Discussion  
Upon cancer initiation a cell acquires capabilities, referred to as hallmark capabilities, which may 
allow the initiated cancer cell to sustain proliferative signalling, evade growth suppressors, resist 
cell death, enable replicative immortality, induce angiogenesis, and activate invasion and metastasis 
[30].  In this chapter we focussed on hallmark capabilities that allow for the growth, by sustaining 
proliferative signalling and resisting cell death, and survival, by promoting angiogenesis, of the 
cancer cell, as well as those that promote invasion and metastasis. 
During initiation genomic DNA damage may occur and this may lead to gene mutations that change 
the characteristics of a cell  Some of these gene mutations may convey survival and growth 
advantages to the cancer cell by altering the expression levels of genes coding for the proteins 
associated with these processes and furthermore, during progression, gene mutations may increase 
the invasive and metastatic potential of the cells [4-6,16,17,36,37].  Furthermore, exogenous 
signals, such as E2 in breast cancer, may exacerbate these processes by also activating mutagenic, 
growth promoting or proliferation factors.  Therefore, using the Human Breast Cancer RT
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Profiler™ PCR Array, we evaluated the effect of the Cyclopia extracts on the expression of genes 
associated with the cell cycle and apoptosis, as well as genes that may influence cancer cell survival 
and invasion via angiogenesis, EMT, adhesion and proteolysis.  We found that the Cyclopia extracts 
generated global gene expression profiles that were different from that of E2 although, the extract 
from C. genistoides, P104, like E2, generally increased the expression levels of the regulated genes, 
whereas, cup-of-tea and SM6Met, C. subternata extracts, unlike E2 and P104, generally decreased 
the expression levels of regulated genes (Fig. 5).  Upon comparison of the regulation patterns of the 






Cyclopia extracts we found that all of the extracts regulated both common and distinct genes (Fig. 
6A), with 32% of the genes regulated by all three extracts. Furthermore, closer inspection of these 
commonly regulated genes revealed that P104 regulated 82% of these genes in a different direction 
than cup-of-tea and SM6Met, implying interspecies differences in the modulation of breast cancer 
associated genes by Cyclopia extracts.  Furthermore, upon comparison of the regulation patterns of 
each of the individual extracts grouped with E2 and genistein (Figs. 6B-D), we found that, generally 
all of the extracts regulated more genes  in common with E2 than with genistein, suggesting that, 
concerning the global number of genes regulated, the extracts behaved more like E2 than genistein.  
In addition, we functionally grouped all of the genes to evaluate how afore mentioned changes in 
gene expression would affect the cell phenotype (Table 3).  Concerning genes that affect 
angiogenesis, we found that P104 generally regulated genes towards the promotion of angiogenesis 
whereas E2, cup-of-tea, and SM6Met regulated genes towards the inhibition of angiogenesis.  Our 
results for angiogenesis with the cup-of-tea and SM6Met extracts are promising as inhibition of 
angiogenesis would inhibit the growth and survival of cancer tumours, but as our results for E2 are 
in conflict with the known role of E2 in angiogenesis [60], further research, using both in vitro [61] 
as well as in vivo [62] angiogenesis models, into these findings is warranted. 
In addition, the array allows for the evaluation of the expression levels of genes that would alter the 
growth of cells.  We found that E2 regulated genes towards cell growth and that the extracts, like E2, 
also regulated the majority of genes towards cell growth, although the number of genes regulated 
towards growth was lower than that of E2.  These findings suggest that the extracts of Cyclopia, like 
E2, may promote cell growth although not to the same extent.  Previously (Chapter 3), using the 
MCF-7BUS cell proliferation assay we found that although the Cyclopia extracts did indeed induce 
cell proliferation it was not to the same extent as E2, in accordance with our PCR array findings 
concerning the number of genes regulated towards growth promotion.  Furthermore, the 






proliferation marker Ki-67 was more robustly up-regulated by E2 than by any of the Cyclopia 
extracts.  In addition, we also found that in the presence of E2, the Cyclopia extracts antagonised E2-
induced cell proliferation.  This prompted us to evaluate changes in MCF-7BUS cell distribution 
between the phases of the cell cycle after treatment with Cyclopia extracts, as progression of cells 
through the cell cycle is a coordinated process consisting of several phases that allows for the 
regulation of cell growth [8,9,18,19] and thus, perturbation of cell distribution between the phases 
of the cycle may provide insight into how the Cyclopia extracts modulate MCF-7BUS cell 
proliferation.  Upon E2 induction the number of cells in the G0/G1 phase (checkpoint for DNA 
damage) decreased and the number of cells in the S phase (DNA synthesis) and G2/M phase 
(duplicated DNA checked for damage and cells progress to mitosis) increased.  Similar distribution 
patterns after E2 treatment have previously been reported and this distribution pattern is assigned to 
E2 induced proliferation [63-65].  A similar distribution pattern was observed for genistein, albeit 
less pronounced, and this phase distribution following genistein treatment has also been previously 
shown for low concentrations (0.1- 10μM) of genistein [66].  Interestingly, treatment of cells with 
luteolin, enterodiol, coumestrol, and Cyclopia extracts uniformly increased the number of cells in 
the S phase, while decreasing the number of cells in the G0/G1 and G2/M phases.  This distribution 
has previously been shown for coumestrol [66] and the increase in the S phase, also seen for E2 and 
genistein, is suggested to be the result of the stimulation of S phase activity with resultant 
proliferation.  However, the cell cycle may also be disrupted by arresting cells in the S phase due to 
DNA not being replicated [67].  As a possible scenario, this arrest may be achieved by the 
inhibition of cyclin-dependent kinase 2 (CDK2) as CDK2 inhibition prevents the initiation of DNA 
synthesis [9].  The cup-of-tea and SM6Met extracts both down-regulated CDK2 expression levels, 
while P104 up-regulated the levels of ataxia telangiectasia mutated (ATM), an inhibitor of CDK2 
[9] (Table S1 & S2).  Therefore, we may postulate that the extracts of Cyclopia could be disrupting 






the cell cycle by arresting cells in the S phase through either down-regulating CDK2 or by up-
regulating the inhibitor of CDK2, ATM.  However, further experiments are required to confirm 
whether this is indeed an S phase arrest or whether the cells were analysed at a stage where they 
were on the brink of G2/M phase entry.  To resolve this issue, for future studies the cell cycle 
distribution assays should be repeated with the added modification of synchronizing the cells in the 
G0/G1 phase via serum starvation before induction [68,69].  Furthermore, the PCR array findings 
for CDK2 and ATM gene expression levels should be validated as well as the effect of Cyclopia 
extracts on CDK2 and ATM protein levels.  Furthermore, treatment of MCF-7BUS cell with E2 and 
Cyclopia extracts resulted in the up-regulation of the mRNA levels (Table S1) of promoters of 
G0/G1 to S phase progression (cyclins D1, D2, & especially E1) [67] and the down-regulation of 
cyclin dependent kinase inhibitor 2A (CDKN2A), a negative regulator of G1/S transition cyclins, as 
well as cell proliferation [70,71].   Therefore, in conclusion, we suggest that in the absence of E2, 
cell proliferation is induced by the Cyclopia extracts, as well as E2, by the stimulation of G1 phase 
to S phase progression after which the cell is committed to complete the cycle [15], but that in the 
case of the Cyclopia extracts, unlike E2, DNA synthesis is not fully completed and thus a S phase 
arrest results. 
Furthermore, in an attempt to elucidate the mechanism whereby Cyclopia extracts inhibited E2-
induced MCF-7BUS cell proliferation (Chapter 3), we evaluated changes in cell cycle phase 
distribution after treatment of MCF-7BUS cells with Cyclopia extracts in the presence of E2.  We 
found no significant deviation from E2-induced phase distribution with the polyphenols, luteolin, 
coumestrol, and the Cyclopia extracts, P104 and cup-of-tea, except for slight increases in the 
percentage apoptotic cells.  The polyphenols, genistein and enterodiol, however, increased the 
percentage of cells in the G2/M phase of the cell cycle.  For genistein, it has been shown that after a 
72 hour treatment of MCF-7 cells with 20 μg/ml genistein, proliferation was inhibited by inducing a 






G2/M arrest [72], therefore, in the presence of E2, we may assume that cell proliferation is inhibited 
by genistein and enterodiol by inducing a G2/M phase arrest.  Interestingly, the Cyclopia extract, 
SM6Met, induced a significant G0/G1 phase arrest in the presence E2, similar to the SERM, 
tamoxifen [73], which has protective properties in breast tissue.  Therefore we postulate that MCF-
7BUS cell proliferation, in the presence of E2, is inhibited by the polyphenols, genistein and 
enterodiol, by inducing cell cycle arrest in the G2/M phase and by the Cyclopia extract, SM6Met, 
by inducing a G0/G1 phase arrest in the cell cycle, thus disrupting the cell cycle distribution pattern 
assigned to E2-induced proliferation.  For future studies, as for in the absence of E2, the cell cycle 
distribution assays may be repeated with the added modification of synchronizing the cells in the 
G0/G1 phase via serum starvation before induction [68,69].  This modification may provide more 
significant distribution changes and potentially provide helpful information on the modulation of 
MCF-7BUS cell proliferation by the Cyclopia extracts, P104 and cup-of-tea, in the presence of E2.  
In addition, the PCR array may be repeated with MCF-7BUS cells treated with the Cyclopia 
extracts in the presence of E2 to evaluate how this would modulate the expression levels of genes 
associated with cell growth to establish whether differences in gene expression may explain the 
antagonism of E2-induced cell proliferation by the Cyclopia extracts, specifically evaluating 
apoptosis associated gene expression as well as genes of proteins that regulate progression from the 
G0/G1 phase to the S phase of the cell cycle. 
Furthermore, using the PCR array, we evaluated genes that have been linked to cancer cell invasion 
and found that all of the extracts, as well as E2, regulated genes in such a way that it is difficult to 
predict how these treatments would affect the invasive phenotype of the MCF-7BUS cells.  
However, these findings may help to interpret our findings with the MCF-7BUS cell invasion assay 
(Fig. 4).  Using this assay we found that E2 did not affect the number of invasive MCF-7BUS cells 
and that none of the polyphenols or Cyclopia extracts significantly affected the number of invasive 






cells.  Therefore, we may postulate that, treatment with E2 and the Cyclopia extracts do not increase 
the invasive capabilities of the MCF-7BUS cells and that the invasion associated genes were 
regulated in such a way that the net regulation of all the genes did not result in a phenotypic shift to 
either increased or decreased invasive capabilities.  Interestingly, although having no effect in the 
absence of E2, we found that in the presence of E2, like cells treated with the ER antagonist, ICI 
182,780, the number of invasive cells was significantly increased by the Cyclopia extracts, P104 
and SM6Met.  Previously, Goto et al. [74] also reported an increase in the number of invasive cells 
following treatment with ICI 182,780.  As we did not evaluate the effect of the Cyclopia extracts on 
gene expression in the presence of E2, we cannot ascribe changes in gene expression levels to our 
invasion assay findings in the presence of E2.  Therefore, for future studies, it may be beneficial to 
evaluate the modulation of gene expression by the Cyclopia extracts in the presence of E2 and 
furthermore, not only to evaluate gene expression and invasive capabilities of the MCF-7BUS cells, 
but also that of a highly invasive cell line such as the MCF-7-M5 cell line [74]. 
To conclude, our findings provide insight into how Cyclopia extracts regulate processes involved in 
the promotion and progression of breast cancer.  The Cyclopia extracts may sustain proliferative 
signalling by up-regulating genes that promote cell growth, although not to the same extent than E2.  
Furthermore, the extracts of C. subternata, cup-of-tea and SM6Met, up-regulated genes that inhibit 
angiogenesis, which is beneficial as it may inhibit the survival of cancer tumours.  In addition, our 
findings concerning cell invasion, showing that the ER antagonist increased the number of invasive 
cells, supports the finding that the ER may have protective properties during the later stages of 
tumour progression [74].  Furthermore, our MCF-7BUS cell cycle assay results provide insight into 
the mechanism whereby the Cyclopia extracts modulate MCF-7BUS cell proliferation.  Finally, our 
findings show that although all of the extracts of Cyclopia may promote cell growth, the extracts 
from different species have different mechanisms of doing so.  For future studies, the PCR array 






may be repeated to evaluate gene regulation by the Cyclopia extracts in the presence of E2 to obtain 
further insight into the mechanism whereby the extracts antagonises E2-induced MCF-7BUS cell 
proliferation.  In addition, the PCR array results should be validated using quantitative-PCR and 
furthermore, the findings regarding angiogenesis associated genes should be followed up by both in 
vitro as well as in vivo angiogenesis test models. 
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5.6.  Supporting information 
Table S1.  Alphabetical list of proteins, involved in breast cancer development and progression, regulated by E2, genistein, and the Cyclopia extracts.   
  
  














 ATP-binding cassette, sub-family B (MDR/TAP), member 1 1.67 -3.15
a
 1.45 -3.23 -2.59 
 ATP-binding cassette, sub-family G (WHITE), member 2 1.43 -1.36 3.05
b
 -1.09 -1.83 
 ADAM metallopeptidase domain 23 1.39 1.15 2.55 -4.61 -12.46 
 V-akt murine thymoma viral oncogene homolog 1 -46.38 -1.21 -1.48 -2.17 -45.42 
 Adenomatous polyposis coli 1.57 1.13 3.77 -1.19 -3.80 
 Androgen receptor 1.33 -1.34 3.14 1.60 1.12 
 Ataxia telangiectasia mutated 1.71 1.86 4.31 -1.89 -1.43 
 BCL2-associated agonist of cell death 1.29 1.25 2.79 1.59 -1.21 
 B-cell CLL/lymphoma 2 1.53 -1.11 30.99 1.92 1.18 
 Baculoviral IAP repeat containing 5 6.27 100.01 14.73 6.13 2.97 
 Breast cancer 1, early onset 1.34 -1.13 2.99 1.74 -1.33 
 Breast cancer 2, early onset 1.36 -1.44 3.11 1.40 -1.47 
 Cyclin A1 1.25 1.43 5.13 -1.35 -2.54 
 Cyclin D1 1.77 1.73 123.57 4.49 1.64 
 Cyclin D2 1.20 -1.59 2.53 -14.37 -12.97 
 Cyclin E1 74.72 1.26 10.51 10.84 2.29 
 Cadherin 1, type 1, E-cadherin (epithelial) -2.42 1.16 -1.02 1.04 87.52 
 Cadherin 13, H-cadherin (heart) -1.24 -1.64 2.45 -1.05 -5.03 
 Cyclin-dependent kinase 2 1.44 1.10 4.95 -3.69 -5.17 
 Cyclin-dependent kinase inhibitor 1A (p21, Cip1) 4.20 -1.05 2.58 2.85 1.96 
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 Cyclin-dependent kinase inhibitor 1C (p57, Kip2) -3.02 -5.38 -9.20 -89.85 -668.50 
 Cyclin-dependent kinase inhibitor 2A  
(melanoma, p16, inhibits CDK4) 1.20 21.22 1.57 -16.59 -22.68 
 Colony stimulating factor 1 (macrophage) 3.14 1.33 -191.79 -968.30 -1695.11 
 Cystatin E/M 1.29 3.53 3.21 -6.55 -3.92 
 Catenin (cadherin-associated protein), beta 1, 88kDa -8.50 1.16 -2.60 -5.09 -9.69 
 Cathepsin D 63.22 1.22 3.18 5.04 107.59 
 Epidermal growth factor -2.40 -1.09 -1.11 -2.87 -9.61 
 Epidermal growth factor receptor 1.84 2.69 6.70 -1.85 -2.29 
 V-erb-b2 erythroblastic leukemia viral oncogene homolog 2,  
neuro/glioblastoma derived oncogene homolog (avian) 1.27 -1.03 2.54 -1.01 -1.75 
 Estrogen receptor 1 11.57 -1.02 7.44 1.93 1.22 
 Estrogen receptor 2 (ER beta) 1.81 11.36 40.67 -3.26 2.79 
 Forkhead box A1 1.26 -1.20 1080.73 1.88 1.27 
 GATA binding protein 3 273.41 -1.86 41.47 41.64 1.24 
 GLI family zinc finger 1 1.03 -5.38 1.34 -18.61 -2.94 
 Growth factor receptor-bound protein 7 -2.37 -1.24 -1.26 -4.02 -1.90 
 Glutathione S-transferase pi 1 -1.47 -29.09 -1.12 -8.88 -30.85 
 Hypermethylated in cancer 1 2.89 -5.38 5.87 -2.40 -2.90 
 Inhibitor of DNA binding 1,  
 dominant negative helix-loop-helix protein -3.97 1.16 -1.71 2.01 -4.03 
 Insulin-like growth factor 1 (somatomedin C) 1.20 -5.38 1.57 -16.59 -22.68 
 Insulin-like growth factor 1 receptor 12.91 1.34 3.58 2.42 1.56 
 Insulin-like growth factor binding protein 3 4.30 -2.58 2.61 -2.30 -2.97 
 Interleukin 6 (interferon, beta 2) 1.60 2.39 -1.94 -15.82 -2.95 
 Jun proto-oncogene -7.35 -1.01 9.31 1.52 -3.51 
 Keratin 18 -2.43 -1.01 -1.35 3.13 2.29 
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 Keratin 19 -2.63 1.55 -1.01 -3.58 -2.63 
 Keratin 5 1.20 -5.38 11.62 -16.59 -22.68 
 Keratin 8 1.35 1.54 3.47 9.08 22.13 
 Mitogen-activated protein kinase 1 1.30 -1.49 2.81 2.42 1.59 
 Mitogen-activated protein kinase 3 9.37 1.38 22.06 -1.37 1.79 
 Mitogen-activated protein kinase 8 1.36 -1.13 2.72 1.38 -1.18 
 O-6-methylguanine-DNA methyltransferase 22.01 1.17 2.66 2.34 1.46 
 Antigen identified by monoclonal antibody Ki-67 15.31 -1.15 2.29 1.28 1.91 
 MutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli) 1.44 1.09 101.41 1.63 15.41 
 Matrix metallopeptidase 2  
 (gelatinase A, 72kDa gelatinase, 72kDa type IV  collagenase) 1.20 -5.38 1.57 -16.59 -22.68 
 Matrix metallopeptidase 9  
 (gelatinase B, 92kDa gelatinase, 92kDa type IV  collagenase) 1.23 13.36 2.84 -1.52 -6.51 
 Mucin 1, cell surface associated 10.14 8.71 4.36 1.37 5.00 
 V-myc myelocytomatosis viral oncogene homolog (avian) 1.95 1.67 1.10 -5.23 1.70 
 Non-metastatic cells 1, protein (NM23A) expressed in -2.12 -1.02 -1.48 -2.11 -1.30 
 Notch 1 1.41 6.90 4.69 -1.08 2.47 
 Nuclear receptor subfamily 3, group C, member 1 
 (glucocorticoid receptor) -44.13 -1.05 -14.01 -55.10 -86.23 
 Progesterone receptor 1.91 1.77 -1.17 -4.27 -1.27 
 Plasminogen activator, urokinase 1.13 -1.23 7.47 -3.20 -5.68 
 PR domain containing 2, with ZNF domain 1.35 1.02 3.16 2.98 -1.53 
 Phosphatase and tensin homolog -5.37 -1.26 -2.50 -2.64 -3.50 
 Prostaglandin-endoperoxide synthase 2  
 (prostaglandin G/H synthase and cyclooxygenase) 1.20 -5.38 1.57 -16.59 -13.50 
 PYD and CARD domain containing 1.24 1.42 -7.23 -4.29 -14.71 
 Retinoic acid receptor, beta 1.04 3.39 3.58 -2.33 -7.04 
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 Ras association (RalGDS/AF-6) domain family member 1 -3.88 1.08 -1.69 -5.78 -12.00 
 Retinoblastoma 1 1.33 1.18 3.27 1.63 1.17 
 Serpin peptidase inhibitor, clade E  
 (nexin, plasminogen activator inhibitor type 1), member 1 1.36 1.83 3.11 -2.20 -2.94 
 Stratifin 3.27 1.40 2.99 3.12 1.72 
 Secreted frizzled-related protein 1 1.20 -5.38 1.57 -16.59 -22.68 
 Solute carrier family 39 (zinc transporter), member 6 2.34 -1.10 2.23 -5.14 2.07 
 Slit homolog 2 (Drosophila) 1.16 -1.54 3.62 -2.91 1.09 
 Snail homolog 2 (Drosophila) -2.95 1.13 -1.08 -13.05 -21.61 
 V-src sarcoma (Schmidt-Ruppin A-2)  
 viral oncogene homolog (avian) 1.25 -1.08 30.87 6.17 -1.68 
 Trefoil factor 3 (intestinal) 1.82 1.37 3.14 1.65 -1.05 
 Transforming growth factor, beta 1 23.10 -1.09 2.89 1.35 -1.08 
 Thrombospondin 1 31.34 1.85 4.65 4.65 90.60 
 Tumor protein p53 -137.15 -1.00 -63.16 -57.88 -175.28 
 Tumor protein p73 1.16 9.70 3.39 -1.50 -2.96 
 Twist homolog 1 (Drosophila) 1.14 1.04 2.44 1.00 -1.68 
 Vascular endothelial growth factor A 1.53 2.39 3.76 1.27 1.08 
 X-box binding protein 1 1.60 1.49 3.81 6.66 3.91 
a
Green denotes > 2 fold down-regulation compared to solvent treated cells. 
b
Red denotes >2 fold up-regulation compared to solvent treated cells. 
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Table S2.  Functional grouping of proteins, involved in breast cancer development and progression regulated, by E2, genistein, and the Cyclopia extracts.   
  
Fold change from solvent control treated cells 
Functional 





















Catenin (cadherin-associated protein), beta 1, 88kDa -8.50 1.16 -2.60 -5.09 -9.69 
 
Epidermal growth factor -2.40 -1.09 -1.11 -2.87 -9.61 
 
V-erb-b2 erythroblastic leukemia viral oncogene homolog 2, 
neuro/glioblastoma derived oncogene homolog (avian) 
1.27 -1.03 2.54 -1.01 -1.75 
 
Inhibitor of DNA binding 1, dominant negative helix-loop-helix 
protein 
-3.97 1.16 -1.71 2.01 -4.03 
 
Interleukin 6 (interferon, beta 2) 1.60 2.39 -1.94 -15.82 -2.95 
 
Jun proto-oncogene -7.35 -1.01 9.31 1.52 -3.51 
 
Notch 1 1.41 6.90 4.69 -1.08 2.47 
 
Plasminogen activator, urokinase 1.13 -1.23 7.47 -3.20 -5.68 
 
Phosphatase and tensin homolog -5.37 -1.26 -2.50 -2.64 -3.50 
 
Serpin peptidase inhibitor, clade E (nexin, plasminogen activator 
inhibitor type 1), member 1 
1.36 1.83 3.11 -2.20 -2.94 
 
Slit homolog 2 (Drosophila) 1.16 -1.54 3.62 -2.91 1.09 
 
Thrombospondin 1 31.34 1.85 4.65 4.65 90.60 
 




Catenin (cadherin-associated protein), beta 1, 88kDa -8.50 1.16 -2.60 -5.09 -9.69 
 
Notch 1 1.41 6.90 4.69 -1.08 2.47 
 
V-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian) 1.25 -1.08 30.87 6.17 -1.68 
 
Transforming growth factor, beta 1 23.10 -1.09 2.89 1.35 -1.08 
 
Twist homolog 1 (Drosophila) 1.14 1.04 2.44 1.00 -1.68 
Adhesion ADAM metallopeptidase domain 23 1.39 1.15 2.55 -4.61 -12.46 
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Adenomatous polyposis coli 1.57 1.13 3.77 -1.19 -3.80 
 
B-cell CLL/lymphoma 2 1.53 -1.11 30.99 1.92 1.18 
 
Cadherin 1, type 1, E-cadherin (epithelial) -2.42 1.16 -1.02 1.04 87.52 
 
Cadherin 13, H-cadherin (heart) -1.24 -1.64 2.45 -1.05 -5.03 
 
Cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) 1.20 21.22 1.57 -16.59 -22.68 
 
Colony stimulating factor 1 (macrophage) 3.14 1.33 -191.79 -968.30 -1695.11 
 
Catenin (cadherin-associated protein), beta 1, 88kDa -8.50 1.16 -2.60 -5.09 -9.69 
 
Epidermal growth factor receptor 1.84 2.69 6.70 -1.85 -2.29 
 
V-erb-b2 erythroblastic leukemia viral oncogene homolog 2, 
neuro/glioblastoma derived oncogene homolog (avian) 
1.27 -1.03 2.54 -1.01 -1.75 
 
Phosphatase and tensin homolog -5.37 -1.26 -2.50 -2.64 -3.50 
 
Transforming growth factor, beta 1 23.10 -1.09 2.89 1.35 -1.08 
 
Thrombospondin 1 31.34 1.85 4.65 4.65 90.60 
Proteolysis ADAM metallopeptidase domain 23 1.39 1.15 2.55 -4.61 -12.46 
 
Cystatin E/M 1.29 3.53 3.21 -6.55 -3.92 
 
Cathepsin D 63.22 1.22 3.18 5.04 107.59 
 
Matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa 
type IV collagenase) 
1.20 -5.38 1.57 -16.59 -22.68 
 
Matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type 
IV collagenase) 
1.23 13.36 2.84 -1.52 -6.51 
 
Plasminogen activator, urokinase 1.13 -1.23 7.47 -3.20 -5.68 
 
PYD and CARD domain containing 1.24 1.42 -7.23 -4.29 -14.71 
Apoptosis V-akt murine thymoma viral oncogene homolog 1 1.39 1.15 2.55 -4.61 -12.46 
 
Adenomatous polyposis coli 1.57 1.13 3.77 -1.19 -3.80 
 
BCL2-associated agonist of cell death 1.29 1.25 2.79 1.59 -1.21 
 
B-cell CLL/lymphoma 2 1.53 -1.11 30.99 1.92 1.18 
 
Cadherin 1, type 1, E-cadherin (epithelial) -2.42 1.16 -1.02 1.04 87.52 
 
Cadherin 13, H-cadherin (heart) -1.24 -1.64 2.45 -1.05 -5.03 
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Cyclin-dependent kinase inhibitor 1A (p21, Cip1) 4.20 -1.05 2.58 2.85 1.96 
 
Cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) 1.20 21.22 1.57 -16.59 -22.68 
 
Glutathione S-transferase pi 1 -1.47 -29.09 -1.12 -8.88 -30.85 
 
Insulin-like growth factor 1 (somatomedin C) 1.20 -5.38 1.57 -16.59 -22.68 
 
Interleukin 6 (interferon, beta 2) 1.60 2.39 -1.94 -15.82 -2.95 
 
Jun proto-oncogene -7.35 -1.01 9.31 1.52 -3.51 
 
Mucin 1, cell surface associated 10.14 8.71 4.36 1.37 5.00 
 
Non-metastatic cells 1, protein (NM23A) expressed in -2.12 -1.02 -1.48 -2.11 -1.30 
 
Retinoic acid receptor, beta 1.04 3.39 3.58 -2.33 -7.04 
 
Stratifin 3.27 1.40 2.99 3.12 1.72 
 
Secreted frizzled-related protein 1 1.20 -5.38 1.57 -16.59 -22.68 
 
Tumor protein p53 -137.15 -1.00 -63.16 -57.88 -175.28 
 
Tumor protein p73 1.16 9.70 3.39 -1.50 -2.96 
 
Twist homolog 1 (Drosophila) 1.14 1.04 2.44 1.00 -1.68 
Cell cycle Adenomatous polyposis coli 1.57 1.13 3.77 -1.19 -3.80 
 
B-cell CLL/lymphoma 2 1.53 -1.11 30.99 1.92 1.18 
 
Cyclin A1 1.25 1.43 5.13 -1.35 -2.54 
 
Cyclin D1 1.77 1.73 123.57 4.49 1.64 
 
Cyclin D2 1.20 -1.59 2.53 -14.37 -12.97 
 
Cyclin E1 74.72 1.26 10.51 10.84 2.29 
 
Cyclin-dependent kinase 2 1.44 1.10 4.95 -3.69 -5.17 
 
Cyclin-dependent kinase inhibitor 1A (p21, Cip1) 4.20 -1.05 2.58 2.85 1.96 
 
Cyclin-dependent kinase inhibitor 1C (p57, Kip2) -3.02 -5.38 -9.20 -89.85 -668.50 
 
Cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) 1.20 21.22 1.57 -16.59 -22.68 
 
Jun proto-oncogene -7.35 -1.01 9.31 1.52 -3.51 
 
Antigen identified by monoclonal antibody Ki-67 15.31 -1.15 2.29 1.28 1.91 
 
V-myc myelocytomatosis viral oncogene homolog (avian) 1.95 1.67 1.10 -5.23 1.70 
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Phosphatase and tensin homolog -5.37 -1.26 -2.50 -2.64 -3.50 
 
Ras association (RalGDS/AF-6) domain family member 1 -3.88 1.08 -1.69 -5.78 -12.00 
 
Retinoblastoma 1 1.33 1.18 3.27 1.63 1.17 
 
Stratifin 3.27 1.40 2.99 3.12 1.72 
 
Tumor protein p53 -137.15 -1.00 -63.16 -57.88 -175.28 
DNA damage Adenomatous polyposis coli 1.57 1.13 3.77 -1.19 -3.80 
 
Ataxia telangiectasia mutated 1.71 1.86 4.31 -1.89 -1.43 
 
Breast cancer 1, early onset 1.34 -1.13 2.99 1.74 -1.33 
 
Breast cancer 2, early onset 1.36 -1.44 3.11 1.40 -1.47 
 
Cyclin D1 1.77 1.73 123.57 4.49 1.64 
 
Cyclin-dependent kinase inhibitor 1A (p21, Cip1) 4.20 -1.05 2.58 2.85 1.96 
 
Mitogen-activated protein kinase 1 1.30 -1.49 2.81 2.42 1.59 
 
O-6-methylguanine-DNA methyltransferase 22.01 1.17 2.66 2.34 1.46 
 
MutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli) 1.44 1.09 101.41 1.63 15.41 
 
Stratifin 3.27 1.40 2.99 3.12 1.72 
 
Tumor protein p53 -137.15 -1.00 -63.16 -57.88 -175.28 
 
Tumor protein p73 1.16 9.70 3.39 -1.50 -2.96 
Xenobiotic transport ATP-binding cassette, sub-family B (MDR/TAP), member 1 1.67 -3.15 1.45 -3.23 -2.59 
 
ATP-binding cassette, sub-family G (WHITE), member 2 1.43 -1.36 3.05 -1.09 -1.83 
Transcription  factors Androgen receptor 1.33 -1.34 3.14 1.60 1.12 
 
Catenin (cadherin-associated protein), beta 1, 88kDa -8.50 1.16 -2.60 -5.09 -9.69 
 
Estrogen receptor 1 11.57 -1.02 7.44 1.93 1.22 
 
Estrogen receptor 2 (ER beta) 1.81 11.36 40.67 -3.26 2.79 
 
Forkhead box A1 1.26 -1.20 1080.73 1.88 1.27 
 
GATA binding protein 3 273.41 -1.86 41.47 41.64 1.24 
 
Hypermethylated in cancer 1 2.89 -5.38 5.87 -2.40 -2.90 
 
Jun proto-oncogene -7.35 -1.01 9.31 1.52 -3.51 
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V-myc myelocytomatosis viral oncogene homolog (avian) 1.95 1.67 1.10 -5.23 1.70 
 
Nuclear receptor subfamily 3, group C, member 1 (glucocorticoid 
receptor) 
-44.13 -1.05 -14.01 -55.10 -86.23 
 
Progesterone receptor 1.91 1.77 -1.17 -4.27 -1.27 
 
PR domain containing 2, with ZNF domain 1.35 1.02 3.16 2.98 -1.53 
 
Retinoic acid receptor, beta 1.04 3.39 3.58 -2.33 -7.04 
 
Retinoblastoma 1 1.33 1.18 3.27 1.63 1.17 
 
Tumor protein p53 -137.15 -1.00 -63.16 -57.88 -175.28 
 
Tumor protein p73 1.16 9.70 3.39 -1.50 -2.96 
 
X-box binding protein 1 1.60 1.49 3.81 6.66 3.91 
a
Red denotes > 2 fold up-regulation compared to solvent treated cells. 
b
Green denotes >2 fold down-regulation compared to solvent treated cells. 
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Final discussion and conclusions  






Excessive levels of estrogens can give rise to abnormal cell growth, the basis of cancer development 
and progression, in estrogen sensitive tissues like the breast [1].  High levels of estrogen not only 
induce cell hyper-proliferation [2,3], which itself provides an opportunity for DNA damage, but can 
serve as the chemical carcinogen inflicting DNA damage [4-11].  Furthermore, damaged DNA may 
initiate the process of cancer development [12,13]. 
Breast cancer is a global problem [14-16] and there is a need to find effective treatments to either 
prevent the initiation of cancer or inhibit the progression thereof.  Current treatments, at the 
molecular level, target estrogen production via AIs or ovarian function suppressors [17-22], or 
estrogen signalling through its cognate receptors via SERMs and SERDs [23-27].  However, 
although excessive estrogen signalling can be detrimental to an individual’s health, abolishment of 
its function can also have severe consequences.  Blocking of estrogen signalling can induce 
menopause associated side-effects [28-31] as well as a surge in inflammatory diseases [32,33] and 
an increase in the occurrence of osteoporosis [17,28,34].  Therefore, although current treatments are 
effective, there is a need for therapeutics with a reduced side-effect profile.  As the ER has two 
subtypes, ERα and ERβ [35,36], and, physiologically, ERα is associated with the promotion of cell 
proliferation that contributes to the occurrence of breast and endometrial cancer, whereas several 
studies have shown that ERβ inhibits ERα-dependent cell proliferation and could prevent cancer 
development [37-45], it has been suggested that SERSMs may offer a safer alternative in breast 
cancer treatment.  Specifically, it has been postulated that finding a treatment that would antagonize 
ERα [46], while being an ERβ agonist [32,44,45,47], would be an effective treatment to either 
prevent the initiation of cancer or inhibit the progression thereof at a molecular level, while 
producing fewer side-effects.  The R, R enantiomer of 5,11-cis-diethyl-5,6,11,12-
tetrahydrochrysene-2,8-diol (THC) is an ERα agonist and potently antagonizes E2 function via ERβ 
[48], which provides a proof of concept that ER subtype specific agonist and antagonist activity 






may be found within one compound and thus supports the possibility of finding a compound that 
behaves inversely.  Furthermore, as breast cancer occurs more frequently in postmenopausal women 
[49,50], a group that often requires HRT, it has been suggested that an ideal HRT would offer a 
treatment effectively addressing menopausal symptoms, while as a side-effect, preventing breast 
cancer [51,52].  For this too, SERSMs may present a worthwhile avenue to pursue. 
Cyclopia, an indigenous South African plant used to prepare honeybush tea, contains 
phytoestrogens [53] and is being considered for the preparation of an estrogenic nutraceutical for 
the treatment of menopausal symptoms.  The current work is part of this larger project, but has 
focussed on evaluating the modulation of molecular targets involved in the prevention and 
treatment of breast cancer.  Specifically, we looked towards Cyclopia extracts for finding the 
elusive ideal SERSM.  Previously it has been shown that Cyclopia extracts can bind to both ER 
subtypes [53-55], but can only activate transcription through the ERβ subtype [54,56].  This raised 
the question that if Cyclopia extracts can bind to ERα, but not act as an agonist, can it antagonize E2 
function via ERα?  To answer this question we evaluated the SERSM behaviour of Cyclopia 
extracts in COS-1 cells transfected with either ERα or ERβ (Chapter 3) and found that, like 
previous findings, the methanol extracts of Cyclopia acted as ERβ agonists [54,56].  In addition, for 
the first time we showed that all of the tested Cyclopia extracts (P104 [54,55] and SM6Met [56], 
methanol extracts of C. genistoides and C. subternata, respectively, and cup-of-tea [56], a water 
extract of C. subternata) antagonized E2-induced activation of an ERE-containing promoter reporter 
construct via ERα.  In addition, we evaluated the SERSM behaviour of the Cyclopia extracts in a 
breast carcinoma cell line, MCF-7BUS, not only because the breast carcinoma cell line would be 
relevant to a study of molecular targets involved in breast cancer, but also because it represents a 
more complex environment where both of the ER subtypes are co-expressed.  In this test system we 
found that all of the Cyclopia extracts behaved as agonists by activating transcription of an ERE-






containing promoter reporter construct and concluded that this activation is probably being 
mediated via ERβ, as we had established, in the model where the subtypes were expressed 
separately, that the extracts are ERα antagonists and ERβ agonists.  In a transrepression model, 
however, we found that when the ER subtypes were expressed separately, P104, a C. genistoides 
extract, behaved as an ER agonist whereas SM6Met, a methanol extract of C. subternata, displayed 
antagonism towards ERα, in the absence of E2, and towards ERβ, in the presence of E2, while the 
water extract of C. subternata, cup-of-tea, displayed ERβ antagonism.  Furthermore, in the more 
complex milieu where both subtypes are co-expressed (MCF-7BUS cells) all of the Cyclopia 
extracts acted as agonists while the water extract of C. subternata also displayed ER antagonism.  
Although these findings do not uniformly support our previous findings in a transactivation model 
showing ERα antagonism and ERβ agonism, they do show that in a system where the ER subtypes 
are co-expressed (MCF-7BUS cells), as for our transactivation model, the Cyclopia extracts display 
ER agonist behaviour.   
Having shown that Cyclopia extracts display SERSM activity on a transcriptional level we 
investigated whether effects on ER subtype protein levels could offer additional explanations for the 
observed SERSM activity.  We found that, in MCF-7BUS cells, the methanol extracts, like E2, 
significantly down-regulated ERα protein levels while, unlike E2, all extracts significantly increased 
ERβ protein levels (Chapter 4).  Furthermore, in the presence of E2, the extracts of Cyclopia down-
regulated ERα protein levels even further than E2 alone.  These findings, in addition to 
strengthening our argument that the transcriptional effects (transactivation and transrepression) 
observed in MCF-7BUS cells is probably being mediated via ERβ, also supports a postulate that the 
observed ERα antagonist behaviour of the Cyclopia extracts in the transactivation model, in COS-1 
cells, may be due to the down-regulation of ERα levels, as fulvestrant, an ER antagonist, inhibits E2 
signalling through the ER by accelerating the degradation of the ER protein [57-59].  However, as 






E2, an ERα agonist, also down-regulates ERα protein levels [60,61], as a part of the endocrine 
feedback loop [60], it must be stressed that this is mere speculation and that other avenues must be 
explored to elucidate how the extracts of Cyclopia antagonize E2-induced activation of an ERE-
containing promoter reporter construct via ERα. 
The localization to and distribution of ER in the nucleus of a cell may be one of these avenues.  
Upon ligand activation, both of the ER subtypes localize to the nucleus, associate with 
transcriptional machinery, and regulate ER-dependent signalling [62-65], however, treatment with 
the pure antiestrogens, fulvestrant and ICI 164,384, disrupts nuclear localization of the ER and 
shuttling of the ER between the cytoplasm and the nucleus [66].  Furthermore, ER agonists induce 
an ordered distribution of ER within the nucleus, whereas ER antagonists result in a nuclear 
distribution that is more random than that of an agonist [64,67].  We indeed found that the Cyclopia 
extracts were more efficient at inducing nuclear localization of ERβ (Chapter 4), but not as effective 
as E2 at inducing nuclear localization of ERα, and induced a less ordered nuclear distribution of 
ERα than E2, while, like E2, inducing a more ordered nuclear distribution of ERβ.  These findings 
could thus indeed provide an additional explanation for the SERSM mechanism of action of the 
Cyclopia extracts and specifically, supports the ERα antagonist and ERβ agonist behaviour in our 
transactivation model. 
The ER subtypes stimulate the transcription of both common and distinct subsets of E2 target genes 
[39,41,44,68-70] and therefore, to further support our SERSM findings, we look towards results 
from our PCR array to identify genes previously found to be distinctly regulated by either the ERβ 
or ERα subtype (Chapter 5).  Unfortunately, the previous tested arrays [39,41,44,45] differed  from 
the one that we used and thus we could only identify one gene, the cyclin A1 gene (CCNA1), as a 
distinctly ERβ regulated gene.  However, reports differ on how this gene is regulated by E2 via ERβ 
with Chang et al. [39] reporting up-regulation of CCNA1, whereas Paruthiyil et al. [41] reports 






down-regulation.  In accordance with Chang et al. [39], P104 up-regulated CCNA1 expression, 
while SM6Met down-regulated CCNA1 expression, in accordance with Paruthiyil et al. [41].  
However, in vivo the Cyclopia extracts did display ERα antagonism (Chapter 3) by retarding uterine 
growth [71,72], which supports our ERα antagonism findings. 
In conclusion, we have found that the Cyclopia extracts display SERSM behaviour.  The 
predominantly ERβ agonism and ERα antagonism of the extracts was illustrated in the 
transactivation, and to a lesser extent in the transrepression models, was reflected in the differential 
regulation of ER subtype protein levels as well as nuclear localization and distribution, and was 
reiterated in the regulation of ERβ regulated genes and the retardation of uterine growth. 
The subtype specific effect of the Cyclopia extracts on ER protein levels (Chapter 4) also highlights 
the possibility of SERD development from the Cyclopia extracts.  All of the Cyclopia extracts 
decreased the ERα:ERβ ratio when compared to that of solvent treated cells, although the values for 
SM6Met did not reach significance.  Treatment with E2 had a similar effect on the ERα:ERβ ratio, 
however, this end-point was obtained by robustly down-regulating ERα protein levels while having 
no significant effect on ERβ levels, while the Cyclopia extracts, not only down-regulated ERα, but 
also increased ERβ protein levels.  Co-treatment with E2 and the Cyclopia extracts did not result in 
additional significant changes in the ERα:ERβ ratio, although it does appear as if co-treatment with 
SM6Met does further decrease the ERα:ERβ  ratio.  The effect of E2 and the Cyclopia extracts on 
ERα protein levels was, however, not reflected in mRNA levels (Chapter 5), a finding supported by 
other studies [25,73], however, ERβ mRNA expression levels after treatment with P104 and 
SM6Met, but not cup-of-tea, do reflect effects on ERβ protein levels.  These results obtained with 
the Cyclopia extracts reflect those obtained with fulvestrant, a SERD and full ER antagonist, which 
has been shown to promote the degradation of ERα while stabilizing ERβ protein levels [25,74].   In 
addition, higher ERα levels are associated with malignant tumours, while higher ERβ levels are 






associated with benign tumours [42,75] and lower ERα:ERβ ratios can reduce ERα mediated cell 
proliferation [76-78], which suggests that the Cyclopia extracts may have an inhibiting effect on 
breast cancer cell proliferation. 
Cell proliferation is a hallmark of cancer and in MCF-7BUS cells cell proliferation constitutes an 
integrated model where not only are the ER subtypes co-expressed, but both transactivation and 
transrepression of endogenous genes contribute towards the final phenotype, whether it is 
proliferative or anti-proliferative [39,79-81].  All of the Cyclopia extracts, like E2, induced the 
proliferation of MCF-7BUS cells, but with lower potencies and efficacies than E2 (Chapter 3).  
These results are supported by results obtained with the PCR array of MCF-7BUS cells (Chapter 5) 
where evaluation of the functional grouping of genes that influence cell growth showed that E2 
regulated 79% of the E2 regulated genes towards the promotion of cell growth, whereas the 
Cyclopia extracts regulated only 57-59% of the extract regulated genes towards the promotion of 
cell growth.  Furthermore, Ki-67, a proliferation marker [82], is up-regulated to a lesser extent by 
the Cyclopia extracts than by E2.  In addition, we found that, although in the absence of E2 the 
Cyclopia extracts induced MCF-7BUS cell proliferation, in the presence of E2, they antagonised E2-
induced cell proliferation (Chapter 3).  A possible explanation for this observed antagonism may be 
found in the SERSM behaviour of the Cyclopia extracts.  It is known that ERα is associated with 
the promotion of cell proliferation whereas ERβ inhibits ERα-dependent cell proliferation [37-45].  
Thus we are presented with some possible explanations for the observed antagonism.  Firstly, the 
Cyclopia extracts may be behaving as ERα antagonists, antagonising E2-induced cell proliferation.  
Secondly, the Cyclopia extracts may be behaving as ERβ agonists, ameliorating the proliferative 
effect of ERα.  Lastly, the Cyclopia extracts may be inhibiting the proliferative effect of ERα by 
degrading ERα protein levels and enhancing the ameliorative effect of ERβ by stabilizing ERβ 






protein levels.  Furthermore, the possibility that all of these effects contribute to the inhibition of 
MCF-7BUS cell proliferation cannot be excluded. 
The MTT assay used to evaluate cell proliferation relies on the metabolic activity of proliferating 
cells and may produce false positive signals due to a test substance inducing metabolic changes in 
the cell and not due to an increase in proliferation [83].  Cell cycle analysis, in contrast, is a more 
accurate test system that, in addition, provides new information concerning the phase of cell cycle 
arrest [83].  For the benefit of the reader, cell proliferation is dependent on the progression of cells 
through the cell cycle, which is coordinated at certain points, allowing for the necessary regulation 
of cell growth [84,85].  The Cyclopia extracts, like E2, induced cell proliferation by promoting the 
movement of cells from the G0/G1 phase to the S phase, but decreased the rate of proliferation by, 
unlike E2, either arresting cells in the S phase of the cell cycle or by decreasing the rate whereby 
cells move from the S phase to the G2/M phase.  These findings are supported by our PCR array 
results (Chapter 5).  Specifically, concerning the movement of cells from the G0/G1 to the S phase, 
all of the Cyclopia extracts up-regulated cyclin E1 mRNA levels, a regulator of G0/G1 to S phase 
transition [86], although not to the same extent as E2.  In addition, the Cyclopia extracts, unlike E2, 
down-regulated CDKN2A mRNA levels, a negative regulator of G1/S transition cyclins as well as 
cell proliferation [87],  Furthermore, in Chapter 5, we postulated that, concerning the accumulation 
of cells in the S phase of the cell cycle, the extracts of Cyclopia may be disrupting the cell cycle by 
arresting cells in the S phase by either down-regulating CDK2 (CDK2 inhibition prevents the 
initiation of DNA synthesis [88]) or by up-regulating ATM mRNA levels (inhibitor of CDK2 
[88,89]).  Furthermore, upon co-treatment of the cells with the Cyclopia extracts and E2, we found 
no significant deviation from E2-induced phase distribution with P104 and cup-of-tea except for a 
slight increase in the percentage apoptotic cells.  However, SM6Met, like the SERM, tamoxifen 
[90], induced a significant G0/G1 cell cycle phase arrest.  We may therefore postulate that in the 






presence of E2, P104 and cup-of-tea attenuates E2-induced MCF-7BUS cell proliferation by 
inducing cell death via apoptosis, whereas SM6Met disrupts the cell cycle by arresting cells in the 
G0/G1 phase of the cell cycle.   
Inflammation is considered as an enabling characteristic in cancer development and progression as 
it contributes to the acquisition of hallmark capabilities in cancer development [81] and, in addition, 
NFκB, a pro-inflammatory transcription factor, is involved in the development of breast cancer [91-
93].  In MCF-7BUS cells, all of the Cyclopia extracts displayed anti-inflammatory behaviour in 
transrepressing an NFκB-containing promoter reporter construct derived from the NFκB element in 
the promoter of the IL6 gene [94] (Chapter 3).  In addition, all of the extracts also down-regulated 
IL-6 mRNA levels (Chapter 5).  Together these results showing that the Cyclopia extracts possess 
anti-inflammatory properties in an environment where both ER subtypes are co-expressed, as in 
approximately 60% of breast cancer tumours [95-97], may be seen as a positive attribute, as 
inflammation is considered to be an enabling characteristic for cancer development [81].  In 
addition, with regards to the postmenopausal surge in inflammatory disorders, the fact that the 
Cyclopia extracts displayed anti-inflammatory behaviour may also be considered a positive 
attribute, while, in addition, this attribute may also decrease the occurrence of osteoporosis.   
Tumour invasion, a hallmark of cancer progression [81], is a process whereby cancer cells from a 
primary tumour invade surrounding tissues and migrate to distant sites and thereby spread cancer 
through the body [98].  Furthermore, angiogenesis is employed by tumours to provide nutrients and 
oxygen and remove carbon dioxide and metabolic waste [81,99].  We found that although one of the 
Cyclopia extracts, P104, regulated the majority of the regulated genes towards angiogenesis (67%), 
the other two extracts, cup-of-tea and SM6Met, only regulated 22% and 8%, respectively, of the 
regulated genes towards angiogenesis (Chapter 5).  Furthermore, neither E2, nor the Cyclopia 
extracts, regulated the expression of invasion associated genes in a way that allowed us to 






conclusively predict the outcome of Cyclopia extract treatment on MCF-7BUS cell invasion 
(Chapter 5).  This is supported by our findings that neither E2, nor the Cyclopia extracts, affected 
the number of invasive MCF-7BUS cells in a cell invasion assay (Chapter 5).  However, we did 
find that in the presence of E2, similarly to ICI 182,780 (an ER antagonist) treated cells, the number 
of invasive cells were increased by the Cyclopia extracts.  As Goto et al. [100] proposed that ERα 
protects against breast cancer cell invasion and reported an increase in the number of invasive cells 
by treatment with ICI 182,780, which he ascribed to ERα antagonism, we may speculate that the 
protective effect of ERα is abrogated by the Cyclopia extracts acting as ERα antagonists or by 
down-regulating ERα.  This finding may thus further support our findings that the Cyclopia extracts 
behaved as ERα antagonists (Chapter 3).  However, although the observed ERα antagonism may be 
beneficial for the treatment and prevention of breast cancer during initiation and promotion, it may 
have a negative effect on breast cancer progression and, therefore, it would be of benefit to evaluate 
the effect of the Cyclopia extracts on breast cancer during different stages of breast cancer 
development. 
For the preparation of an orally administered nutraceutical, such as proposed for the 
phytoestrogenic Cyclopia extracts, a pre-requisite would be intestinal absorption, biological activity 
in vivo, and little to no toxicity at biologically active concentrations.  Using the immature rat 
uterotrophic assay, we for the first time showed that the phytoestrogenic extracts of C. subternata 
are not toxic at the administered doses, are absorbed when administered orally and elicit a 
biological effect in vivo (Chapter 3).  Specifically, Cyclopia extracts, like E2, had no effect on liver 
weights (a surrogate measurement for toxicity), however, in contrast to E2, the Cyclopia extracts 
delayed vaginal opening, did not induce uterine growth and antagonized E2-induced uterine growth.  
These results suggest that the Cyclopia extracts are absorbed, are not toxic, and display biological 






activity in vivo by retarding uterine growth, which supports our previous ERα antagonism findings 
[71,72]. 
To conclude, our study expands our current knowledge concerning the behaviour and the molecular 
mechanism of the phytoestrogenic extracts of Cyclopia and identifies the ER subtypes as important 
molecular targets involved in the development and progression of breast cancer.  Specifically, 
highlights of this study include that these extracts antagonize E2-induced cell proliferation both in 
vitro and in vivo, behave as ERα antagonists and ERβ agonists, and act as SERDs by down-
regulating ERα protein levels while stabilizing ERβ protein levels.  Therefore, with respect to the 
known roles of the ER subtypes in breast cancer [37-45], the Cyclopia extracts, by behaving as 
SERSMs, may be beneficial for the prevention or treatment of breast cancer. 
Cyclopia extracts have previously been shown to be anti-mutagenic by inhibiting tumour promotion 
in mouse skin [101], inhibiting aflatoxin B1- [102] and fumonisin B1-induced cancer in rat livers 
[103], and inhibiting esophageal cancer development in rats [104].  However, none of these studies 
investigated the molecular targets involved in cancer initiation, promotion, and progression and thus 
the current study is the first to do so.  Therefore, although we do believe that the Cyclopia extracts 
show potential to be developed as SERSMs for the treatment or prevention of breast cancer or as a 
nutraceutical for the alleviation of menopausal symptoms, future work is needed to further establish 
their molecular mechanism of action.  This includes, but is not limited to, directly comparing the 
Cyclopia extracts with known SERMs and SERDs, such as tamoxifen and fulvestrant, investigating 
the effect of Cyclopia extracts on ER homo- or heterodimerization using the BRET assay [95], 
investigating whether the Cyclopia extracts regulate ERα and ERβ specific genes, and evaluating 
the modulation of cancer development and progression by the Cyclopia extracts in a rat breast 
cancer model such as the MNU-induced mammary gland carcinogenesis model [105].  In addition, 
further work is needed to identify the polyphenol(s) present in these Cyclopia extracts responsible 






for eliciting the observed effects, while the possibility that a combination of polyphenols present in 
Cyclopia, rather than an individual polyphenol, may be causing the observed ERα agonism and ERβ 
antagonism cannot be excluded. 
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